<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ther Adv Musculoskelet Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ther Adv Musculoskelet Dis</journal-id>
      <journal-id journal-id-type="publisher-id">TAB</journal-id>
      <journal-id journal-id-type="hwp">sptab</journal-id>
      <journal-title-group>
        <journal-title>Therapeutic Advances in Musculoskeletal Disease</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1759-720X</issn>
      <issn pub-type="epub">1759-7218</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage UK: London, England</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35186126</article-id>
      <article-id pub-id-type="pmc">8848057</article-id>
      <article-id pub-id-type="doi">10.1177/1759720X211073001</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1759720X211073001</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8743-3236</contrib-id>
          <name>
            <surname>Dima</surname>
            <given-names>Alina</given-names>
          </name>
          <aff id="aff1-1759720X211073001">Department of Rheumatology, Colentina Clinical Hospital, Bucharest, Romania</aff>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jurcut</surname>
            <given-names>Ciprian</given-names>
          </name>
          <aff id="aff2-1759720X211073001">Department of Internal Medicine, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania</aff>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chasset</surname>
            <given-names>Fran&#xE7;ois</given-names>
          </name>
          <aff id="aff3-1759720X211073001">Department of Dermatology and Allergology, H&#xF4;pital Tenon, Paris, France; Facult&#xE9; de M&#xE9;decine, Sorbonne Universit&#xE9;, Paris, France</aff>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4951-4032</contrib-id>
          <name>
            <surname>Felten</surname>
            <given-names>Renaud</given-names>
          </name>
          <aff id="aff4-1759720X211073001">National Reference Center for Rare Auto-immune and Systemic Diseases Est Sud-Est (RESO), Strasbourg, France</aff>
          <aff id="aff5-1759720X211073001">Department of Rheumatology, Les H&#xF4;pitaux Universitaires de Strasbourg, Strasbourg, France</aff>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8077-8394</contrib-id>
          <name>
            <surname>Arnaud</surname>
            <given-names>Laurent</given-names>
          </name>
          <xref rid="corresp1-1759720X211073001" ref-type="corresp"/>
          <aff id="aff6-1759720X211073001">National Reference Center for Rare Auto-immune and Systemic Diseases Est Sud-Est (RESO), Strasbourg, France</aff>
          <aff id="aff7-1759720X211073001">Department of Rheumatology, Les H&#xF4;pitaux Universitaires de Strasbourg, Strasbourg, France</aff>
          <aff id="aff8-1759720X211073001">Universit&#xE9; de Strasbourg, Inserm UMR-S 1109, Strasbourg, France</aff>
          <aff id="aff9-1759720X211073001">Service de Rhumatologie, H&#xF4;pital de Hautepierre, 1, avenue Moli&#xE8;re BP 83049, 67098 Strasbourg Cedex, France</aff>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Supervision">Supervision</role>
          <role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="corresp1-1759720X211073001">
<email>laurent.arnaud@chru-strasbourg</email>
</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>2</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2022</year>
      </pub-date>
      <volume>14</volume>
      <elocation-id>1759720X211073001</elocation-id>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>8</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>12</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s), 2022</copyright-statement>
        <copyright-year>2022</copyright-year>
        <copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
          <license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ pharmacologic features, detailed its mechanism of action, and summarized the existing guidelines and recommendations for HCQ use in rheumatology with a systematic literature search for the randomized controlled trials focused on lupus. HCQ has been shown to decrease SLE activity, especially in mild and moderate disease, to prevent disease flare and to lower the long-term glucocorticoid need. The numerous benefits of HCQ are extended to pregnancy and breastfeeding period. Based on cohort studies, antithrombotic and metabolic HCQ&#x2019;s effects were shown, including lipid-lowering properties, which might contribute to an improved cardiovascular risk. Moreover, early HCQ use in antinuclear antibodies positive individuals might delay the progression to SLE. Finally, HCQ has a significant favorable impact on long-term outcomes such as damage accrual and mortality in SLE. Based on these multiple benefits, HCQ is now the mainstay long-term treatment in SLE, recommended by current guidelines in all patients unless contraindications or side effects. The daily dose associated with the best compromise between efficacy and safety is matter of debate. The concern regarding retinal toxicity rather than proper efficacy data is the one that dictated the daily dosage of &#x2A7D;5&#x2009;mg/kg/day actual body weight currently agreed upon.</p>
      </abstract>
      <kwd-group>
        <kwd>antimalarials</kwd>
        <kwd>cutaneous lupus erythematosus</kwd>
        <kwd>hydroxychloroquine</kwd>
        <kwd>immunomodulatory</kwd>
        <kwd>lupus nephritis</kwd>
        <kwd>systemic lupus erythematosus</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January-December 2022</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>typesetter</meta-name>
          <meta-value>ts1</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="section1-1759720X211073001">
      <title>Background</title>
      <p>Hydroxychloroquine (HCQ) is an antimalarial drug used initially for the treatment of <italic toggle="yes">Plasmodium</italic> parasitic infection, from where the name of the drug class came from. Beyond its initial indication as antimalarial, HCQ has been used in autoimmune and infectious diseases, as well as in metabolic or neoplastic disorders.<sup>
<xref rid="bibr1-1759720X211073001" ref-type="bibr">1</xref>
</sup> But, as recently reviewed,<sup>
<xref rid="bibr2-1759720X211073001" ref-type="bibr">2</xref>
</sup> clear benefits were reported mainly in systemic lupus erythematosus (SLE).</p>
      <p>Thus, HCQ is now one of the most valuable therapies in SLE, showing multiple benefits over several outcomes associated with the disease itself, but also to its related comorbidities. HCQ is an inexpensive, generally available, well-tolerated immunomodulator.<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup> For more than a decade, different authors emphasized that all patients with SLE should be given HCQ<sup><xref rid="bibr4-1759720X211073001" ref-type="bibr">4</xref><xref rid="bibr5-1759720X211073001" ref-type="bibr"/><xref rid="bibr6-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr7-1759720X211073001" ref-type="bibr">7</xref></sup> and the latest guidelines&#x2019; recommendations also stated the HCQ importance in SLE unless there are contraindications or side effects.<sup><xref rid="bibr8-1759720X211073001" ref-type="bibr">8</xref><xref rid="bibr9-1759720X211073001" ref-type="bibr"/><xref rid="bibr10-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr11-1759720X211073001" ref-type="bibr">11</xref></sup></p>
      <p>The history of HCQ is supposed to start <italic toggle="yes">circa</italic> 1600 with the Incas in Chile, from whom the cinchona bark properties were learned by the Jesuits. The main alkaloids of quinine and cinchonine were isolated in 1820 and subsequently chloroquine (CQ) was obtained much later in 1934.<sup>
<xref rid="bibr12-1759720X211073001" ref-type="bibr">12</xref>
</sup> HCQ sulfate is the hydroxylated analogue of CQ, synthesized in 1946. Due to a better safety profile, HCQ was given since 1955 as an alternative to CQ.<sup><xref rid="bibr12-1759720X211073001" ref-type="bibr">12</xref>,<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref></sup></p>
      <p>For SLE, the first report of the antimalarials use dates back to 1894, regarding the improvement of cutaneous lupus lesions with quinine.<sup><xref rid="bibr14-1759720X211073001" ref-type="bibr">14</xref>,<xref rid="bibr15-1759720X211073001" ref-type="bibr">15</xref></sup> In the United States, HCQ was approved for SLE in 1955 for symptoms like fatigue, rashes, joint pain, and mouth sores<sup>
<xref rid="bibr16-1759720X211073001" ref-type="bibr">16</xref>
</sup> and, with specific approval and license characteristics for each country, is now among the main drugs used for SLE treatment worldwide.</p>
    </sec>
    <sec id="section2-1759720X211073001">
      <title>Pharmacology of hydroxychloroquine</title>
      <sec id="section3-1759720X211073001">
        <title>Molecular structure</title>
        <p>The knowledge about the pharmacokinetics of antimalarials is not completely understood and still debated. These pharmacokinetic characteristics are complex<sup><xref rid="bibr17-1759720X211073001" ref-type="bibr">17</xref><xref rid="bibr18-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref></sup> due to the large volume of distribution,<sup><xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>,<xref rid="bibr20-1759720X211073001" ref-type="bibr">20</xref></sup> significant tissue binding,<sup><xref rid="bibr20-1759720X211073001" ref-type="bibr">20</xref><xref rid="bibr21-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr22-1759720X211073001" ref-type="bibr">22</xref></sup> and long terminal elimination half-life.<sup><xref rid="bibr18-1759720X211073001" ref-type="bibr">18</xref>,<xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>,<xref rid="bibr23-1759720X211073001" ref-type="bibr">23</xref>,<xref rid="bibr24-1759720X211073001" ref-type="bibr">24</xref></sup> Indeed, important differences have been observed between HCQ pharmacokinetic parameters as evidenced recently by its use in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19).<sup>
<xref rid="bibr25-1759720X211073001" ref-type="bibr">25</xref>
</sup> Historically, terminal elimination half-lives were considered very long, 40&#x2013;50&#x2009;days for HCQ<sup><xref rid="bibr18-1759720X211073001" ref-type="bibr">18</xref>,<xref rid="bibr23-1759720X211073001" ref-type="bibr">23</xref></sup> and up to 60&#x2009;days for CQ.<sup><xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>,<xref rid="bibr24-1759720X211073001" ref-type="bibr">24</xref></sup> More recent studies suggest a shorter half-life of about 5&#x2009;days.<sup><xref rid="bibr25-1759720X211073001" ref-type="bibr">25</xref>,<xref rid="bibr26-1759720X211073001" ref-type="bibr">26</xref></sup> A long HCQ half-life can be attributed to extensive tissue uptake rather than to an intrinsic inability to clear the drug. The expected delay in the attainment of steady-state concentrations (3&#x2013;4&#x2009;months) may be in part responsible for the slow therapeutic response observed with HCQ.<sup>
<xref rid="bibr27-1759720X211073001" ref-type="bibr">27</xref>
</sup> Renal clearance is an important consideration for both drugs as reduced clearance increases the bioavailability<sup>
<xref rid="bibr28-1759720X211073001" ref-type="bibr">28</xref>
</sup> and subsequently the related side effects.<sup><xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>,<xref rid="bibr20-1759720X211073001" ref-type="bibr">20</xref>,<xref rid="bibr24-1759720X211073001" ref-type="bibr">24</xref></sup> Finally, dose&#x2013;response relationships and toxicity thresholds have not yet been fully defined. The main pharmacodynamic properties of antimalarials are shown in <xref rid="table1-1759720X211073001" ref-type="table">Table 1</xref>.</p>
        <table-wrap position="float" id="table1-1759720X211073001">
          <label>Table 1.</label>
          <caption>
            <p>Main pharmacodynamic properties of antimalarials.</p>
          </caption>
          <alternatives>
            <graphic xlink:href="10.1177_1759720X211073001-table1" position="float"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th rowspan="1" colspan="1"/>
                  <th align="left" rowspan="1" colspan="1">Hydroxychloroquine (HCQ)</th>
                  <th align="left" rowspan="1" colspan="1">Chloroquine (CQ)</th>
                  <th align="left" rowspan="1" colspan="1">Quinacrine</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">Chemical structure</td>
                  <td rowspan="1" colspan="1">
<inline-graphic xlink:href="10.1177_1759720X211073001-img1.jpg"/>
</td>
                  <td rowspan="1" colspan="1">
<inline-graphic xlink:href="10.1177_1759720X211073001-img2.jpg"/>
</td>
                  <td rowspan="1" colspan="1">
<inline-graphic xlink:href="10.1177_1759720X211073001-img3.jpg"/>
</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Chemical formula</td>
                  <td rowspan="1" colspan="1">C<sub>18</sub>H<sub>26</sub>ClN<sub>3</sub>O</td>
                  <td rowspan="1" colspan="1">C<sub>18</sub>H<sub>26</sub>ClN<sub>3</sub></td>
                  <td rowspan="1" colspan="1">C<sub>23</sub>H<sub>30</sub>ClN<sub>3</sub>O</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Way of administration</td>
                  <td colspan="3" rowspan="1">Oral intake</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Absorption</td>
                  <td rowspan="1" colspan="1">In upper intestinal tract<break/>after a 200&#x2009;mg oral dose, HCQ reached a <italic toggle="yes">C</italic><sub>max</sub> of 129.6&#x2009;ng/ml with a <italic toggle="yes">T</italic><sub>max</sub> of 3.26&#x2009;h in the blood<sup>
<xref rid="bibr18-1759720X211073001" ref-type="bibr">18</xref>
</sup></td>
                  <td rowspan="1" colspan="1">In upper intestinal tract<break/>oral CQ reaches a <italic toggle="yes">C</italic><sub>max</sub> of 65&#x2013;128&#x2009;&#xB5;g/L with a <italic toggle="yes">T</italic><sub>max</sub> of 0.5&#x2009;h<sup>
<xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>
</sup></td>
                  <td rowspan="1" colspan="1">In upper intestinal tract<break/>more details not available</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Bioavailability</td>
                  <td rowspan="1" colspan="1">67&#x2013;74%<sup>
<xref rid="bibr20-1759720X211073001" ref-type="bibr">20</xref>
</sup></td>
                  <td rowspan="1" colspan="1">67&#x2013;100%<sup>
<xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Not available</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Volume of distribution</td>
                  <td rowspan="1" colspan="1">5522&#x2009;liters from blood and 44,257&#x2009;liters from plasma<sup>
<xref rid="bibr20-1759720X211073001" ref-type="bibr">20</xref>
</sup></td>
                  <td rowspan="1" colspan="1">200&#x2013;800&#x2009;L/kg<sup>
<xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Not available</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Protein binding</td>
                  <td rowspan="1" colspan="1">50%<sup>
<xref rid="bibr20-1759720X211073001" ref-type="bibr">20</xref>
</sup></td>
                  <td rowspan="1" colspan="1">46&#x2013;74%<sup>
<xref rid="bibr21-1759720X211073001" ref-type="bibr">21</xref>
</sup></td>
                  <td rowspan="1" colspan="1">80&#x2013;90%<sup>
<xref rid="bibr22-1759720X211073001" ref-type="bibr">22</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Metabolism</td>
                  <td rowspan="1" colspan="1">In the liver, N-dealkylated by CYP3A4 to the active metabolite desethylhydroxychloroquine, as well as the inactive metabolites desethylchloroquine and bidesethylchloroquine<sup><xref rid="bibr17-1759720X211073001" ref-type="bibr">17</xref>,<xref rid="bibr18-1759720X211073001" ref-type="bibr">18</xref></sup></td>
                  <td rowspan="1" colspan="1">In the liver, N-dealkylated primarily by CYP2 C8 and CYP3A4 to <italic toggle="yes">N</italic>-desethylchloroquine<break/>N-dealkylated to a lesser extent by CYP3A5, CYP2D6, and to an ever lesser extent by CYP1A1<sup>19</sup></td>
                  <td rowspan="1" colspan="1">Not available</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Elimination</td>
                  <td rowspan="1" colspan="1">40&#x2013;50% of HCQ is excreted renally, while only 16&#x2013;21% of a dose is excreted in the urine as unchanged drug<break/>5% of a dose is sloughed off in skin and 24&#x2013;25% is eliminated through the feces<sup><xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>,<xref rid="bibr20-1759720X211073001" ref-type="bibr">20</xref></sup></td>
                  <td rowspan="1" colspan="1">Predominantly eliminated in the urine, renal excretion: 65&#x2013;70%.<sup>
<xref rid="bibr24-1759720X211073001" ref-type="bibr">24</xref>
</sup>
<break/>50% of a dose is recovered in the urine as unchanged CQ, with 10% of the dose recovered in the urine as desethylchloroquine<sup>
<xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Less than 11% is eliminated in the urine daily<sup>
<xref rid="bibr28-1759720X211073001" ref-type="bibr">28</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Elimination half-life</td>
                  <td rowspan="1" colspan="1">Historically, 40&#x2013;50&#x2009;days (chronic use)<break/>A 200&#x2009;mg oral dose of HCQ: 537&#x2009;h to 50&#x2009;days (blood) or 32&#x2009;days or 123&#x2009;days in plasma<sup><xref rid="bibr18-1759720X211073001" ref-type="bibr">18</xref>,<xref rid="bibr23-1759720X211073001" ref-type="bibr">23</xref></sup>
<break/>Maybe shorter, about 5&#x2009;days, according to more recent studies<sup><xref rid="bibr25-1759720X211073001" ref-type="bibr">25</xref>,<xref rid="bibr26-1759720X211073001" ref-type="bibr">26</xref></sup></td>
                  <td rowspan="1" colspan="1">6&#x2013;60&#x2009;days (mean of 20&#x2009;days)<sup><xref rid="bibr19-1759720X211073001" ref-type="bibr">19</xref>,<xref rid="bibr24-1759720X211073001" ref-type="bibr">24</xref></sup></td>
                  <td rowspan="1" colspan="1">5&#x2013;14&#x2009;days</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
        </table-wrap>
      </sec>
      <sec id="section4-1759720X211073001">
        <title>Galenic and commercial presentations</title>
        <p>HCQ is commercialized as 200&#x2009;mg HCQ sulfate tablets corresponding to 155&#x2009;mg HCQ base for each tablet.<sup>
<xref rid="bibr29-1759720X211073001" ref-type="bibr">29</xref>
</sup> The daily dosage of HCQ varies accordingly to its indication,<sup>
<xref rid="bibr29-1759720X211073001" ref-type="bibr">29</xref>
</sup> with the American Academy of Ophthalmology (2016-AAO) recommending no more than 5&#x2009;mg/kg/day of real body weight in SLE to decrease retinopathy occurrence,<sup>
<xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>
</sup> recommendation that has been recently reinforced by agreement of four medical societies.<sup>
<xref rid="bibr31-1759720X211073001" ref-type="bibr">31</xref>
</sup> The indication is based on an ophthalmological study by Melles and Marmor<sup>
<xref rid="bibr32-1759720X211073001" ref-type="bibr">32</xref>
</sup> of nearly 2500 patients in whom daily HCQ intake below 5&#x2009;mg/kg/day of regular body weight was associated with a low risk of toxicity, &lt;2% within the first 10&#x2009;years of use. However, some authors highlighted that in that study, the dose of HCQ was based on pharmacy refill information and not on prescribed dose.<sup>
<xref rid="bibr33-1759720X211073001" ref-type="bibr">33</xref>
</sup></p>
        <p>Dose adjustments with 50% reduction of posology are needed for patients with renal impairment and lower than 30&#x2009;ml/min filtration rate.<sup>
<xref rid="bibr34-1759720X211073001" ref-type="bibr">34</xref>
</sup> For patients weighting more than 80&#x2009;kg, a maximum daily dose of 400&#x2009;mg is recommended in SLE. Doses for CQ were established only from extrapolation of HCQ and those lower than 2.3&#x2009;mg/kg/day were considered safe.<sup><xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>,<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref></sup></p>
        <p>As the terminal elimination half time is not short,<sup>
<xref rid="bibr36-1759720X211073001" ref-type="bibr">36</xref>
</sup> dosing can be adjusted by alternate day regimens, such as 200&#x2009;mg on the first day and 400&#x2009;mg on the second day, yielding a mean dose equivalent to 300&#x2009;mg per day.<sup>
<xref rid="bibr32-1759720X211073001" ref-type="bibr">32</xref>
</sup> Based on recent surveys, the most common daily dosage for HCQ is 400&#x2009;mg daily.<sup><xref rid="bibr37-1759720X211073001" ref-type="bibr">37</xref>,<xref rid="bibr38-1759720X211073001" ref-type="bibr">38</xref></sup></p>
      </sec>
      <sec id="section5-1759720X211073001">
        <title>Mechanism of action</title>
        <p>The mechanisms of action for HCQ are complex and still not completely understood (see <xref rid="table2-1759720X211073001" ref-type="table">Table 2</xref> and <xref rid="fig1-1759720X211073001" ref-type="fig">Figure 1</xref>). Because of its high lipophilicity, lysosomotropism, and pH,<sup><xref rid="bibr39-1759720X211073001" ref-type="bibr">39</xref>,<xref rid="bibr40-1759720X211073001" ref-type="bibr">40</xref></sup> HCQ can pass through cell membranes and accumulate into lysosomes<sup>
<xref rid="bibr40-1759720X211073001" ref-type="bibr">40</xref>
</sup> where it disrupts key important cellular functions via the inhibition of the Toll-like receptors (TLRs)<sup><xref rid="bibr41-1759720X211073001" ref-type="bibr">41</xref><xref rid="bibr42-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr43-1759720X211073001" ref-type="bibr">43</xref></sup> and of the Cyclic GMP-AMP synthase&#x2013;Stimulator of Interferon Genes (cGAS-STING) pathway.<sup>
<xref rid="bibr44-1759720X211073001" ref-type="bibr">44</xref>
</sup> The main effects include the inhibition of enzyme and cytokine release,<sup><xref rid="bibr45-1759720X211073001" ref-type="bibr">45</xref><xref rid="bibr46-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr47-1759720X211073001" ref-type="bibr">47</xref></sup> receptor recycling, plasma membrane repair, cell signaling, apoptosis,<sup><xref rid="bibr48-1759720X211073001" ref-type="bibr">48</xref><xref rid="bibr49-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr50-1759720X211073001" ref-type="bibr">50</xref></sup> autophagy,<sup><xref rid="bibr39-1759720X211073001" ref-type="bibr">39</xref>,<xref rid="bibr51-1759720X211073001" ref-type="bibr">51</xref></sup> antigen presentation,<sup>
<xref rid="bibr52-1759720X211073001" ref-type="bibr">52</xref>
</sup> T-cell polarization,<sup><xref rid="bibr53-1759720X211073001" ref-type="bibr">53</xref><xref rid="bibr54-1759720X211073001" ref-type="bibr"/><xref rid="bibr55-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr56-1759720X211073001" ref-type="bibr">56</xref></sup> inhibition of the natural killer (NK) cells,<sup><xref rid="bibr57-1759720X211073001" ref-type="bibr">57</xref>,<xref rid="bibr58-1759720X211073001" ref-type="bibr">58</xref></sup> energy metabolism,<sup>
<xref rid="bibr40-1759720X211073001" ref-type="bibr">40</xref>
</sup> and increases photoprotection against ultraviolet (UV)-A and B.<sup><xref rid="bibr59-1759720X211073001" ref-type="bibr">59</xref><xref rid="bibr60-1759720X211073001" ref-type="bibr"/><xref rid="bibr61-1759720X211073001" ref-type="bibr"/><xref rid="bibr62-1759720X211073001" ref-type="bibr"/><xref rid="bibr63-1759720X211073001" ref-type="bibr"/><xref rid="bibr64-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr65-1759720X211073001" ref-type="bibr">65</xref></sup></p>
        <table-wrap position="float" id="table2-1759720X211073001">
          <label>Table 2.</label>
          <caption>
            <p>Mechanisms of action of hydroxychloroquine.</p>
          </caption>
          <alternatives>
            <graphic xlink:href="10.1177_1759720X211073001-table2" position="float"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">HCQ/CQ Mechanisms of action</th>
                  <th align="left" rowspan="1" colspan="1">Molecular mechanism(s) demonstrated</th>
                  <th align="left" rowspan="1" colspan="1">Potential consequence(s) in SLE pathogenesis</th>
                  <th align="left" rowspan="1" colspan="1">References</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">Inhibition of TLR-7 and TLR-9</td>
                  <td rowspan="1" colspan="1">Suppression of endosomal TLR activation direct binding of antimalarials to nucleic acids rather than inhibition of endosomal acidification</td>
                  <td rowspan="1" colspan="1">Inhibition of IFN-I production by pDC</td>
                  <td rowspan="1" colspan="1">Lamphier <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr41-1759720X211073001" ref-type="bibr">41</xref>
</sup>
<break/>Ku&#x17E;nik <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr42-1759720X211073001" ref-type="bibr">42</xref>
</sup>
<break/>Gardet <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr43-1759720X211073001" ref-type="bibr">43</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Inhibition of cyclic GMP-AMP synthase (cGAS) activity</td>
                  <td rowspan="1" colspan="1">Inhibition of (cGAS)-STING pathway</td>
                  <td rowspan="1" colspan="1">Inhibition of IFN-I production</td>
                  <td rowspan="1" colspan="1">An <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr44-1759720X211073001" ref-type="bibr">44</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Inhibition of autophagy</td>
                  <td rowspan="1" colspan="1">Blockade of autophagosome fusion with the lysosome</td>
                  <td rowspan="1" colspan="1">Inhibition of MHC class II-mediated autoantigen presentation by antigen-presenting cells to CD4+ T cells</td>
                  <td rowspan="1" colspan="1">Levy <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr51-1759720X211073001" ref-type="bibr">51</xref>
</sup>
<break/>Schrezenmeier and D&#xF6;rner<sup>
<xref rid="bibr39-1759720X211073001" ref-type="bibr">39</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Inhibition of antigen presentation</td>
                  <td rowspan="1" colspan="1">CQ has been shown to inhibit presentation of antigen <italic toggle="yes">in vitro</italic> by affecting invariant chain dissociation from MHC class II</td>
                  <td rowspan="1" colspan="1">Inhibition of MHC class II-mediated autoantigen presentation by antigen-presenting cells to CD4+ T cells</td>
                  <td rowspan="1" colspan="1">Humbert <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr52-1759720X211073001" ref-type="bibr">52</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Inhibition of inflammatory cytokine production and angiogenesis</td>
                  <td rowspan="1" colspan="1">Decrease mRNA expression of IL-1&#x3B2;, IL-6, and TNF-&#x3B1; in CLE skin lesions<break/>Decrease VEGF expression in CLE skin lesion</td>
                  <td rowspan="1" colspan="1">Decrease of local inflammation<break/>Decrease of mononuclear cellular infiltrate in the skin<break/>Inhibition of angiogenesis</td>
                  <td rowspan="1" colspan="1">Wozniacka <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr45-1759720X211073001" ref-type="bibr">45</xref>
</sup>
<break/>Lesiak <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr46-1759720X211073001" ref-type="bibr">46</xref>
</sup>
<break/>Zeidi <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr47-1759720X211073001" ref-type="bibr">47</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Photoprotection against UVA and UVB</td>
                  <td rowspan="1" colspan="1">Increase of c-Jun mRNA expression<break/>Decrease mRNA expression of IL-1&#x3B2;, IL-6, and TNF-&#x3B1; in CLE skin lesions<break/>Decrease UV-induced ICAM-1 expression in keratinocytes<break/>CQ inhibits lipid peroxidation and decrease UVB and induces phospholipase A2 activity in skin<break/>Decrease of the number of cutaneous HLA-DR+ and CD1a+ cells after UVB irradiation</td>
                  <td rowspan="1" colspan="1">Decrease of local inflammation, apoptosis, and necrosis of keratinocytes<break/>Decrease of the release of skin nucleic acids<break/>Decrease of the mononuclear cellular infiltrate in the skin</td>
                  <td rowspan="1" colspan="1">Nguyen <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr65-1759720X211073001" ref-type="bibr">65</xref>
</sup>
<break/>Sjolin-Forsberg <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr59-1759720X211073001" ref-type="bibr">59</xref>
</sup>
<break/>Wozniacka <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr64-1759720X211073001" ref-type="bibr">64</xref>
</sup>
<break/>Wozniacka <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr60-1759720X211073001" ref-type="bibr">60</xref>
</sup>
<break/>Bondeson and Sundler<sup>
<xref rid="bibr61-1759720X211073001" ref-type="bibr">61</xref>
</sup>
<break/>el Tahir <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr62-1759720X211073001" ref-type="bibr">62</xref>
</sup>
<break/>Segal-Eiras <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr63-1759720X211073001" ref-type="bibr">63</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Decrease NET formation and circulating DNA</td>
                  <td rowspan="1" colspan="1">HCQ inhibits NETs formation <italic toggle="yes">in vitro</italic>
<break/>Circulating DNA significantly decreases after CQ treatment</td>
                  <td rowspan="1" colspan="1">Decrease of circulating nucleic acids<break/>Inhibition of IFN-I production<break/>Decrease of LL37 formation and inflammasome activation<break/>Decrease of MMP-9 and reduced endothelial cell death</td>
                  <td rowspan="1" colspan="1">Smith <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr48-1759720X211073001" ref-type="bibr">48</xref>
</sup>
<break/>Smith and Kaplan<sup>
<xref rid="bibr49-1759720X211073001" ref-type="bibr">49</xref>
</sup>
<break/>Cepika <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr50-1759720X211073001" ref-type="bibr">50</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Change in T-cell polarization</td>
                  <td rowspan="1" colspan="1">HCQ decreases Th17-related cytokines<break/>HCQ decreases Th22-related cytokines<break/>HCQ blood concentrations correlate negatively with the percentage of CD45RO+ CD4+ cells</td>
                  <td rowspan="1" colspan="1">Decrease of mononuclear cellular infiltrate in the skin<break/>Decrease of survival and proliferation of human B cells as well as the differentiation of B cells into antibody-producing cells<break/>Recruitment and activation of inflammatory cells with tissue damage<break/>Inhibition of angiogenesis</td>
                  <td rowspan="1" colspan="1">Silva <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr53-1759720X211073001" ref-type="bibr">53</xref>
</sup>
<break/>Zhao <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr54-1759720X211073001" ref-type="bibr">54</xref>
</sup>
<break/>Shin <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr55-1759720X211073001" ref-type="bibr">55</xref>
</sup>
<break/>Sailler <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr56-1759720X211073001" ref-type="bibr">56</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Inhibition of NK cells</td>
                  <td rowspan="1" colspan="1">Decrease proliferation, cytotoxicity, and cytokine production of NK cells</td>
                  <td rowspan="1" colspan="1">Possible deleterious effects of NK cells in SLE: tissue infiltration, proinflammatory cytokine production: IFN&#x3B3;, IL-15</td>
                  <td rowspan="1" colspan="1">Spada <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr57-1759720X211073001" ref-type="bibr">57</xref>
</sup>
<break/>Fox<sup>
<xref rid="bibr58-1759720X211073001" ref-type="bibr">58</xref>
</sup></td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="table-fn1-1759720X211073001">
              <p>cGAS, cyclic GMP-AMP synthase; CLE, cutaneous lupus erythematosus; CQ, chloroquine; DC, dendritic cells; HCQ, hydroxychloroquine; ICAM, intercellular adhesion molecule-1; IFN, interferon; IL, interleukin; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; NETs, neutrophil extracellular traps; NK, natural killer; SLE, systemic lupus erythematosus; STING, stimulator of interferon genes; Th, T helper; TLRs, Toll-like receptors; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <fig position="float" id="fig1-1759720X211073001">
          <label>Figure 1.</label>
          <caption>
            <p>Hydroxychloroquine&#x2019;s mechanisms of action.</p>
          </caption>
          <graphic xlink:href="10.1177_1759720X211073001-fig1" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec id="section6-1759720X211073001">
      <title>Efficacy in systemic lupus erythematosus</title>
      <sec id="section7-1759720X211073001">
        <title>Systematic search of randomized controlled trials regarding hydroxychloroquine in systemic lupus erythematosus</title>
        <p>A systematic search for randomized controlled trials (RCTs) regarding HCQ treatment in SLE was performed using the medical subject headings (MeSH) terms &#x2018;Hydroxychloroquine&#x2019; AND &#x2018;Lupus Erythematosus, Systemic&#x2019; AND &#x2018;Clinical Trials, Randomized&#x2019;. The search was performed on Excerpta Medica/EMBASE, MEDLINE via PubMed, Cochrane Library, and Thomson Reuters&#x2019; Web of Science Core Collection using the same combination of relevant keywords (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental File 1</ext-link>). The four databases were systematically searched from inception to 1 February 2021, without any language, geographic, or type of article restrictions. The references and citations of the articles identified were also screened.</p>
        <p>Reports not referring to HCQ or CQ use in SLE, not involving human subjects, not including adult cases, and presenting other types of studies than RCTs were excluded. A total of eight RCTs were identified in the initial search with one more identified after the references and citations screen (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental Figure 1</ext-link>&#x2013;Flowchart Diagram, <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental Table 1</ext-link>). For each RCT included, the following information was extracted: study design, drug posology, time of follow-up, study&#x2019;s endpoints, proven efficacy, and side effects noted (as presented in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental Table 2a, 2b</ext-link>).</p>
        <p>To the best of our knowledge, the first RCT involving antimalarial therapy in SLE was published in 1991 by Canadian Hydroxychloroquine Study Group<sup>
<xref rid="bibr66-1759720X211073001" ref-type="bibr">66</xref>
</sup> and reported a 2.5-fold increase in the risk of mild flare after HCQ withdrawal in the placebo group.<sup>
<xref rid="bibr66-1759720X211073001" ref-type="bibr">66</xref>
</sup> In 1998, Tsakonas <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr67-1759720X211073001" ref-type="bibr">67</xref>
</sup> presented an extension phase in 1991 and evaluated the risk of major flare after HCQ withdrawal.<sup>
<xref rid="bibr67-1759720X211073001" ref-type="bibr">67</xref>
</sup> The endpoint considered, namely flare, subtype of flare, and hospitalization, were all improved under long-term HCQ therapy; however, the results did not reach statistical significance most probably due to the small sample size.<sup>
<xref rid="bibr67-1759720X211073001" ref-type="bibr">67</xref>
</sup></p>
        <p>Other RCTs have also demonstrated improvement of arthralgia<sup>
<xref rid="bibr14-1759720X211073001" ref-type="bibr">14</xref>
</sup> even if without a significant impact over arthritis,<sup>
<xref rid="bibr68-1759720X211073001" ref-type="bibr">68</xref>
</sup> prevention of SLE flares and reduction of the corticosteroids dose,<sup>
<xref rid="bibr14-1759720X211073001" ref-type="bibr">14</xref>
</sup> improvement of lipid metabolism<sup>
<xref rid="bibr69-1759720X211073001" ref-type="bibr">69</xref>
</sup> with decrease in total cholesterol and triglycerides, while increase in HDL-cholesterol,<sup>
<xref rid="bibr70-1759720X211073001" ref-type="bibr">70</xref>
</sup> and a safety profile of administration during pregnancy.<sup>
<xref rid="bibr71-1759720X211073001" ref-type="bibr">71</xref>
</sup> Also, the PLUS (Plaquenil LUpus Systemic) failed to demonstrate that adjusted HCQ dosing schedules targeting [HCQ] &#x2A7E;1000&#x2009;ng/ml might reduce the occurrence of SLE flares.<sup>
<xref rid="bibr72-1759720X211073001" ref-type="bibr">72</xref>
</sup> Most recently, Zanetti <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr73-1759720X211073001" ref-type="bibr">73</xref>
</sup> tested the efficacy of lower HCQ doses (2&#x2013;3&#x2009;mg/kg/day)<sup>
<xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>
</sup> and found similar 6- and 12-month flare rates between groups.<sup>
<xref rid="bibr73-1759720X211073001" ref-type="bibr">73</xref>
</sup></p>
        <p>For cutaneous lupus erythematosus (CLE), the first RCT by Kraak <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr74-1759720X211073001" ref-type="bibr">74</xref>
</sup> in 1965 tested HCQ up to a maximum posology of 1200&#x2009;mg daily. Furthermore, the efficacy of antimalarials has been tested in RCTs against placebo,<sup>
<xref rid="bibr75-1759720X211073001" ref-type="bibr">75</xref>
</sup> acitrecin,<sup>
<xref rid="bibr76-1759720X211073001" ref-type="bibr">76</xref>
</sup> or clofazimine<sup>
<xref rid="bibr77-1759720X211073001" ref-type="bibr">77</xref>
</sup> in RCTs showing proven efficacy in RCT with better safety profile than clofazimine or acitrecin.</p>
      </sec>
      <sec id="section8-1759720X211073001">
        <title>Observational data for hydroxychloroquine in systemic lupus erythematosus</title>
        <p>Currently published RCTs do not cover the whole spectrum of SLE features. Many of the data regarding HCQ benefits are from prospective SLE cohorts, such as the Hopkins Lupus Cohort,<sup><xref rid="bibr78-1759720X211073001" ref-type="bibr">78</xref><xref rid="bibr79-1759720X211073001" ref-type="bibr"/><xref rid="bibr80-1759720X211073001" ref-type="bibr"/><xref rid="bibr81-1759720X211073001" ref-type="bibr"/><xref rid="bibr82-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr83-1759720X211073001" ref-type="bibr">83</xref></sup> LUMINA (Lupus in Minorities: Nature <italic toggle="yes">versus</italic> Nurture) Cohort,<sup><xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref><xref rid="bibr85-1759720X211073001" ref-type="bibr"/><xref rid="bibr86-1759720X211073001" ref-type="bibr"/><xref rid="bibr87-1759720X211073001" ref-type="bibr"/><xref rid="bibr88-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr89-1759720X211073001" ref-type="bibr">89</xref></sup> Toronto Lupus Cohort,<sup><xref rid="bibr90-1759720X211073001" ref-type="bibr">90</xref>,<xref rid="bibr91-1759720X211073001" ref-type="bibr">91</xref></sup> or GLADEL (multinational Latin American lupus) Cohort<sup><xref rid="bibr92-1759720X211073001" ref-type="bibr">92</xref><xref rid="bibr93-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr94-1759720X211073001" ref-type="bibr">94</xref></sup> (see <xref rid="table3-1759720X211073001" ref-type="table">Table 3</xref>; <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental Table 3</ext-link>).</p>
        <table-wrap position="float" id="table3-1759720X211073001">
          <label>Table 3.</label>
          <caption>
            <p>Research for antimalarials in systemic lupus erythematosus.</p>
          </caption>
          <alternatives>
            <graphic xlink:href="10.1177_1759720X211073001-table3" position="float"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">Effects</th>
                  <th align="left" rowspan="1" colspan="1">Randomized controlled trials</th>
                  <th align="left" rowspan="1" colspan="1">Observational studies</th>
                  <th align="left" rowspan="1" colspan="1">Systematic reviews</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">Decrease of disease severity</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Prospective study, 25 patients<sup>
<xref rid="bibr95-1759720X211073001" ref-type="bibr">95</xref>
</sup>
<break/>Prospective LUMINA Cohort, 256 patients<sup>
<xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref>
</sup>
<break/>Cross-sectional study, 57 patients<sup>
<xref rid="bibr96-1759720X211073001" ref-type="bibr">96</xref>
</sup>
<break/>Longitudinal study, LUMINA cohort, 35 patients<sup>
<xref rid="bibr85-1759720X211073001" ref-type="bibr">85</xref>
</sup>
<break/>Prospective study, 41 SLE patients<sup>
<xref rid="bibr97-1759720X211073001" ref-type="bibr">97</xref>
</sup>
<break/>Observational study, 28 SLE pregnant women<sup>
<xref rid="bibr98-1759720X211073001" ref-type="bibr">98</xref>
</sup>
<break/>Retrospective study, 165 SLE patients<sup>
<xref rid="bibr99-1759720X211073001" ref-type="bibr">99</xref>
</sup>
<break/>Retrospective study, 101 SLE patients<sup>
<xref rid="bibr100-1759720X211073001" ref-type="bibr">100</xref>
</sup>
<break/>Prospective Hopkins Lupus Cohort, 916 patients<sup>
<xref rid="bibr101-1759720X211073001" ref-type="bibr">101</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Prevent of disease flare</td>
                  <td rowspan="1" colspan="1">RCT, NCT03122431: 73 stable LN patients<sup>
<xref rid="bibr73-1759720X211073001" ref-type="bibr">73</xref>
</sup>
<break/>RCT, NCT00413361: 573 patients<sup>
<xref rid="bibr72-1759720X211073001" ref-type="bibr">72</xref>
</sup>
<break/>RCT, 24 SLE patients stable disease<sup>
<xref rid="bibr14-1759720X211073001" ref-type="bibr">14</xref>
</sup>
<break/>RCT, 47 clinically stable SLE patients<sup>
<xref rid="bibr66-1759720X211073001" ref-type="bibr">66</xref>
</sup>
<break/>RCT, 20 patients lupus pregnancy<sup>
<xref rid="bibr71-1759720X211073001" ref-type="bibr">71</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Retrospective, matched with themselves, 43/209 patients<sup>
<xref rid="bibr102-1759720X211073001" ref-type="bibr">102</xref>
</sup>
<break/>Retrospective, matched with themselves, 43 patients, 76 matched years<sup>
<xref rid="bibr103-1759720X211073001" ref-type="bibr">103</xref>
</sup>
<break/>Prospective, Padua Lupus Cohort, 319 SLE patients<sup>
<xref rid="bibr104-1759720X211073001" ref-type="bibr">104</xref>
</sup>
<break/>Retrospective study, 101 SLE patients<sup>
<xref rid="bibr100-1759720X211073001" ref-type="bibr">100</xref>
</sup>
<break/>Prospective, Hopkins Lupus Cohort, 2512 patients<sup>
<xref rid="bibr78-1759720X211073001" ref-type="bibr">78</xref>
</sup>
<break/>Longitudinal, 143 SLE patients<sup>
<xref rid="bibr105-1759720X211073001" ref-type="bibr">105</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Cutaneous lupus</td>
                  <td rowspan="1" colspan="1">RCT, NCT01551069: 103 patients Cutaneous Lupus<sup>
<xref rid="bibr75-1759720X211073001" ref-type="bibr">75</xref>
</sup>
<break/>RCT, 20 patients lupus pregnancy<sup>
<xref rid="bibr71-1759720X211073001" ref-type="bibr">71</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Retrospective, matched with themselves, 43/209 patients<sup>
<xref rid="bibr102-1759720X211073001" ref-type="bibr">102</xref>
</sup>
<break/>Prospective, 17/27 patients SLE<sup>
<xref rid="bibr106-1759720X211073001" ref-type="bibr">106</xref>
</sup>
<break/>Prospective, 300 patients subacute or chronic CLE<sup>
<xref rid="bibr107-1759720X211073001" ref-type="bibr">107</xref>
</sup>
<break/>Retrospective cohort, 200 patients DLE<sup>
<xref rid="bibr108-1759720X211073001" ref-type="bibr">108</xref>
</sup>
<break/>Cross-sectional study, 1002 patients CLE<sup>
<xref rid="bibr109-1759720X211073001" ref-type="bibr">109</xref>
</sup>
<break/>Prospective cohort, 218 CLE and SLE patients<sup>
<xref rid="bibr110-1759720X211073001" ref-type="bibr">110</xref>
</sup>
<break/>Retrospective, 36 LE tumidus<sup>
<xref rid="bibr111-1759720X211073001" ref-type="bibr">111</xref>
</sup>
<break/>Retrospective, 61 DLE and SCLE patients<sup>
<xref rid="bibr112-1759720X211073001" ref-type="bibr">112</xref>
</sup>
<break/>Prospective, 34 CLE patients<sup>
<xref rid="bibr113-1759720X211073001" ref-type="bibr">113</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline, Embase, Scopus, Cochrane<sup>
<xref rid="bibr114-1759720X211073001" ref-type="bibr">114</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Adjuvant for lupus nephritis remission</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Prospective, Hopkins Lupus Cohort, 29 patients<sup>
<xref rid="bibr79-1759720X211073001" ref-type="bibr">79</xref>
</sup>
<break/>Retrospective study, 35 patients<sup>
<xref rid="bibr115-1759720X211073001" ref-type="bibr">115</xref>
</sup>
<break/>Retrospective study, 206 patients lupus nephritis<sup>
<xref rid="bibr116-1759720X211073001" ref-type="bibr">116</xref>
</sup>
<break/>Prospective LUMINA Cohort, 256 patients<sup>
<xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref>
</sup>
<break/>Retrospective study, 90 patients with lupus nephritis<sup>
<xref rid="bibr117-1759720X211073001" ref-type="bibr">117</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Improvement of articular complaints</td>
                  <td rowspan="1" colspan="1">RCT, 71 SLE patients mild SLE<sup>
<xref rid="bibr68-1759720X211073001" ref-type="bibr">68</xref>
</sup>
<break/>RCT, 24 SLE patients stable disease<sup>
<xref rid="bibr14-1759720X211073001" ref-type="bibr">14</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Decrease disease activity/prevent flare during pregnancy</td>
                  <td rowspan="1" colspan="1">RCT, 20 patients lupus pregnancy<sup>
<xref rid="bibr71-1759720X211073001" ref-type="bibr">71</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Prospective study, 60 patients &#x2013; 103 pregnancies<sup>
<xref rid="bibr118-1759720X211073001" ref-type="bibr">118</xref>
</sup>
<break/>Prospective, Hopkins Lupus Pregnancy Cohort, 282 (163&#x2004;+&#x2004;56&#x2004;+&#x2004;68) pregnancies<sup>
<xref rid="bibr80-1759720X211073001" ref-type="bibr">80</xref>
</sup>
<break/>Retrospective study, 176 patients &#x2013; 396 pregnancies<sup>
<xref rid="bibr119-1759720X211073001" ref-type="bibr">119</xref>
</sup>
<break/>Retrospective study, 179 pregnancies<sup>
<xref rid="bibr120-1759720X211073001" ref-type="bibr">120</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup>
<break/>Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Protection against preeclampsia</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Retrospective cohort, 151 pregnancies<sup>
<xref rid="bibr121-1759720X211073001" ref-type="bibr">121</xref>
</sup>
<break/>Prospective cohort, 316 pregnancies<sup>
<xref rid="bibr122-1759720X211073001" ref-type="bibr">122</xref>
</sup>
<break/>114 HCQ-exposed pregnancies<sup>
<xref rid="bibr123-1759720X211073001" ref-type="bibr">123</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Prevention of fetal growth restriction and prematurity</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Observational study, 28 SLE pregnant women<sup>
<xref rid="bibr98-1759720X211073001" ref-type="bibr">98</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Reducing antiphospholipid antibodies persistence</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Retrospective study, 90 patients &#x2013; 17 patients with persistent LA<sup>
<xref rid="bibr124-1759720X211073001" ref-type="bibr">124</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Reduce the risk of thrombosis</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Prospective cohort, 92 patients<sup>
<xref rid="bibr125-1759720X211073001" ref-type="bibr">125</xref>
</sup>
<break/>Retrospective study, 272 patients<sup>
<xref rid="bibr126-1759720X211073001" ref-type="bibr">126</xref>
</sup>
<break/>Prospective cohort, 232 patients<sup>
<xref rid="bibr127-1759720X211073001" ref-type="bibr">127</xref>
</sup>
<break/>Prospective cohort, 67 SLE-aPL patients<sup>
<xref rid="bibr128-1759720X211073001" ref-type="bibr">128</xref>
</sup>
<break/>Retrospective study, 206 patients lupus nephritis<sup>
<xref rid="bibr116-1759720X211073001" ref-type="bibr">116</xref>
</sup>
<break/>Longitudinal, cross-sectional, 144 patients<sup>
<xref rid="bibr129-1759720X211073001" ref-type="bibr">129</xref>
</sup>
<break/>Prospective, Tromso Lupus cohort, 158 patients<sup>
<xref rid="bibr130-1759720X211073001" ref-type="bibr">130</xref>
</sup>
<break/>Retrospective study, 1930 patients<sup>
<xref rid="bibr131-1759720X211073001" ref-type="bibr">131</xref>
</sup>
<break/>Nested case&#x2013;control study, 54 SLE cases <italic toggle="yes">versus</italic> 108 controls<sup>
<xref rid="bibr132-1759720X211073001" ref-type="bibr">132</xref>
</sup>
<break/>Prospective Hopkins Cohort, 1795 SLE patients, 193 thrombotic events, 10,508&#x2009;person-years<sup>
<xref rid="bibr133-1759720X211073001" ref-type="bibr">133</xref>
</sup>
<break/>Prospective study, 189 SLE patients<sup>
<xref rid="bibr134-1759720X211073001" ref-type="bibr">134</xref>
</sup>
<break/>Prospective Hopkins Cohort, 739 patients<sup>
<xref rid="bibr135-1759720X211073001" ref-type="bibr">135</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup>
<break/>Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Lower fasting glucose/diabetes mellitus protection</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Cross-sectional study, 149 SLE patients<sup>
<xref rid="bibr136-1759720X211073001" ref-type="bibr">136</xref>
</sup>
<break/>Population-based cohort study, 221 with diabetes mellitus out of 8628 SLE patients<sup>
<xref rid="bibr137-1759720X211073001" ref-type="bibr">137</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Improving lipidic profile</td>
                  <td rowspan="1" colspan="1">RCT, 72 SLE patients<sup>
<xref rid="bibr69-1759720X211073001" ref-type="bibr">69</xref>
</sup>
<break/>RCT, 17/19 SLE female patients<sup>
<xref rid="bibr70-1759720X211073001" ref-type="bibr">70</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Cross-sectional, 155 patients (SLE&#x2004;+&#x2004;AR)<sup>
<xref rid="bibr138-1759720X211073001" ref-type="bibr">138</xref>
</sup>
<break/>Case-control, 18 SLE patients<sup>
<xref rid="bibr139-1759720X211073001" ref-type="bibr">139</xref>
</sup>
<break/>Longitudinal Cohort &#x2013; John Hopkins, 264 patients<sup>
<xref rid="bibr81-1759720X211073001" ref-type="bibr">81</xref>
</sup>
<break/>Retrospective study, 382 patients<sup>
<xref rid="bibr140-1759720X211073001" ref-type="bibr">140</xref>
</sup>
<break/>Cross-sectional study, 123 patients<sup>
<xref rid="bibr141-1759720X211073001" ref-type="bibr">141</xref>
</sup>
<break/>Cross-sectional study, 90 subjects &#x2013; 60 SLE patients<sup>
<xref rid="bibr142-1759720X211073001" ref-type="bibr">142</xref>
</sup>
<break/>Cross-sectional study, 86 patients<sup>
<xref rid="bibr143-1759720X211073001" ref-type="bibr">143</xref>
</sup>
<break/>Prospective study, 30 subjects &#x2013; 20 SLE patients<sup>
<xref rid="bibr144-1759720X211073001" ref-type="bibr">144</xref>
</sup>
<break/>Cross-sectional study, 185 outpatients<sup>
<xref rid="bibr145-1759720X211073001" ref-type="bibr">145</xref>
</sup>
<break/>Prospective &#x2013; Toronto Lupus Cohort &#x2013; 1260 patients<sup>
<xref rid="bibr90-1759720X211073001" ref-type="bibr">90</xref>
</sup>
<break/>Case-control, 100 lupus nephritis patients<sup>
<xref rid="bibr146-1759720X211073001" ref-type="bibr">146</xref>
</sup>
<break/>Cross-sectional study, 24 patients<sup>
<xref rid="bibr147-1759720X211073001" ref-type="bibr">147</xref>
</sup>
<break/>Prospective Hopkins Cohort, 51 patients, over 229 visits<sup>
<xref rid="bibr82-1759720X211073001" ref-type="bibr">82</xref>
</sup>
<break/>Cross-sectional study, 48 patients<sup>
<xref rid="bibr148-1759720X211073001" ref-type="bibr">148</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: PubMed, Embase, Cochrane<sup>
<xref rid="bibr149-1759720X211073001" ref-type="bibr">149</xref>
</sup>
<break/>Databases: PubMed, Embase, Web of Science, Medline/Ovid, Google Scholar, CINAHL, Cochrane<sup>
<xref rid="bibr150-1759720X211073001" ref-type="bibr">150</xref>
</sup>
<break/>Databases: Medline and Embase<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup>
<break/>Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Reduction of atherosclerosis</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Pittsburgh Lupus Registry, 220 women<sup>
<xref rid="bibr151-1759720X211073001" ref-type="bibr">151</xref>
</sup>
<break/>Prospective study, 41 SLE patients and 96 controls<sup>
<xref rid="bibr152-1759720X211073001" ref-type="bibr">152</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr153-1759720X211073001" ref-type="bibr">153</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Decrease the risk of infections</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Retrospective study, 206 patients lupus nephritis<sup>
<xref rid="bibr116-1759720X211073001" ref-type="bibr">116</xref>
</sup>
<break/>A nested case&#x2013;control study, Lupus-Cruces cohort, 83/166 patients<sup>
<xref rid="bibr154-1759720X211073001" ref-type="bibr">154</xref>
</sup>
<break/>Prospective cohort, Northern California, 3030 patients<sup>
<xref rid="bibr155-1759720X211073001" ref-type="bibr">155</xref>
</sup>
<break/>Retrospective study, Spanish Rheumatology Society Lupus Registry (RELESSER), 3658 patients<sup>
<xref rid="bibr156-1759720X211073001" ref-type="bibr">156</xref>
</sup>
<break/>Case&#x2013;control study, 65 SLE patients <italic toggle="yes">versus</italic> 130 controls<sup>
<xref rid="bibr157-1759720X211073001" ref-type="bibr">157</xref>
</sup>
<break/>Prospective RELES Cohort, 282 SLE patients<sup>
<xref rid="bibr158-1759720X211073001" ref-type="bibr">158</xref>
</sup>
<break/>Retrospective study, 339 patients<sup>
<xref rid="bibr159-1759720X211073001" ref-type="bibr">159</xref>
</sup>
<break/>Inception cohort study GLADEL, 1243 patients<sup>
<xref rid="bibr92-1759720X211073001" ref-type="bibr">92</xref>
</sup>
<break/>Population-based study, 24343 SLE patients<sup>
<xref rid="bibr160-1759720X211073001" ref-type="bibr">160</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: PubMed, Embase, Cochrane<sup>
<xref rid="bibr161-1759720X211073001" ref-type="bibr">161</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Improvement of bone mineral density</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Prospective study, 92 patients<sup>
<xref rid="bibr162-1759720X211073001" ref-type="bibr">162</xref>
</sup>
<break/>Prospective study, 34 SLE patients<sup>
<xref rid="bibr163-1759720X211073001" ref-type="bibr">163</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Protection against osteonecrosis</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Nested matched case&#x2013;control study, LUMINA cohort<sup>
<xref rid="bibr86-1759720X211073001" ref-type="bibr">86</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Decrease the corticosteroids need</td>
                  <td rowspan="1" colspan="1">RCT, 20 patients lupus pregnancy<sup>
<xref rid="bibr71-1759720X211073001" ref-type="bibr">71</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Retrospective, matched with themselves, 43 patients, 76 matched years<sup>
<xref rid="bibr103-1759720X211073001" ref-type="bibr">103</xref>
</sup>
<break/>Prospective LUMINA Cohort, 256 patients<sup>
<xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref>
</sup>
<break/>Prospective study, 257 pregnancies<sup>
<xref rid="bibr80-1759720X211073001" ref-type="bibr">80</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Protection against accrual damage</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Prospective Israeli Cohort, 151 patients<sup>
<xref rid="bibr164-1759720X211073001" ref-type="bibr">164</xref>
</sup>
<break/>Prospective LUMINA Cohort, 632 patients<sup>
<xref rid="bibr88-1759720X211073001" ref-type="bibr">88</xref>
</sup>
<break/>Prospective LUMINA Cohort, 256 lupus nephritis<sup>
<xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref>
</sup>
<break/>Prospective LUMINA Cohort, 580 patients<sup>
<xref rid="bibr89-1759720X211073001" ref-type="bibr">89</xref>
</sup>
<break/>Prospective Hopkins Cohort, 2054 patients<sup>
<xref rid="bibr83-1759720X211073001" ref-type="bibr">83</xref>
</sup>
<break/>Nested case-control, Inception cohort &#x2013; Toronto Lupus Cohort, 685 patients: 174/307 patients<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup>
<break/>SLICC Inception Cohort Study, 1722 patients<sup>
<xref rid="bibr165-1759720X211073001" ref-type="bibr">165</xref>
</sup>
<break/>Retrospective inception cohort, 476 subjects, 26&#x2009;years<sup>
<xref rid="bibr166-1759720X211073001" ref-type="bibr">166</xref>
</sup>
<break/>Early Lupus Project, Prospective Inception Cohort, 230 patients<sup>
<xref rid="bibr167-1759720X211073001" ref-type="bibr">167</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Protection against neoplasia</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Prospective cohort, 235 patients<sup>
<xref rid="bibr168-1759720X211073001" ref-type="bibr">168</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Reducing SLE-related hospitalization</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Retrospective study, 339 patients<sup>
<xref rid="bibr159-1759720X211073001" ref-type="bibr">159</xref>
</sup>
<break/>Retrospective study, 526 patients<sup>
<xref rid="bibr169-1759720X211073001" ref-type="bibr">169</xref>
</sup>
<break/>Retrospective registry-based, 40,381 patients<sup>
<xref rid="bibr170-1759720X211073001" ref-type="bibr">170</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Improvement of survival</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Case-control, 76 matched pairs<sup>
<xref rid="bibr171-1759720X211073001" ref-type="bibr">171</xref>
</sup>
<break/>Prospective cohort, 232 patients<sup>
<xref rid="bibr127-1759720X211073001" ref-type="bibr">127</xref>
</sup>
<break/>Case-control study &#x2013; LUMINA L cohort, 608 patients<sup>
<xref rid="bibr87-1759720X211073001" ref-type="bibr">87</xref>
</sup>
<break/>Retrospective study, 206 patients lupus nephritis<sup>
<xref rid="bibr116-1759720X211073001" ref-type="bibr">116</xref>
</sup>
<break/>Prospective University of Toronto Lupus Clinic, 1241 patients<sup>
<xref rid="bibr91-1759720X211073001" ref-type="bibr">91</xref>
</sup>
<break/>Prospective GLADEL cohort, 1480 patients<sup>
<xref rid="bibr93-1759720X211073001" ref-type="bibr">93</xref>
</sup>
<break/>Retrospective, 1956 SLE inpatients<sup>
<xref rid="bibr172-1759720X211073001" ref-type="bibr">172</xref>
</sup>
<break/>Retrospective, 42 patients lupus nephritis<sup>
<xref rid="bibr173-1759720X211073001" ref-type="bibr">173</xref>
</sup>
<break/>Retrospective study, 491 patients with lupus nephritis<sup>
<xref rid="bibr174-1759720X211073001" ref-type="bibr">174</xref>
</sup>
<break/>Prospective cohort, 803 SLE patients<sup>
<xref rid="bibr175-1759720X211073001" ref-type="bibr">175</xref>
</sup>
<break/>Longitudinal cohort, 345 lupus nephritis patients<sup>
<xref rid="bibr176-1759720X211073001" ref-type="bibr">176</xref>
</sup>
<break/>Prospective cohort, 914 SLE patients<sup>
<xref rid="bibr177-1759720X211073001" ref-type="bibr">177</xref>
</sup>
<break/>Retrospective study, 6241 patients<sup>
<xref rid="bibr178-1759720X211073001" ref-type="bibr">178</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup>
<break/>Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Delays the evolution to SLE</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Retrospective study, 130 military personal<sup>
<xref rid="bibr179-1759720X211073001" ref-type="bibr">179</xref>
</sup>
<break/>Nested case&#x2013;control study, GLADEL cohort, 265/530 patients<sup>
<xref rid="bibr94-1759720X211073001" ref-type="bibr">94</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Databases: Medline and Embase<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="table-fn2-1759720X211073001">
              <p>CC, case-control; CLE, cutaneous lupus erythematosus; CS, cross-sectional; DLE, discoid lupus erythematosus; DS, descriptive studies; GLADEL, Grupo Latino Americano de Estudio del Lupus; HCQ, hydroxychloroquine; LAC, lupus anticoagulant; LN, lupus nephritis; LUMINA, Lupus in Minorities: Nature vs Nurture; PC, prospective cohort; RA, retrospective analysis; RC, retrospective cohort; RCT, randomized controlled trial; SCLE, subacute cutaneous lupus erythematosus; SLICC, Systemic Lupus International Collaborating Clinics.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Antimalarials: chloroquine diphosphate (CDP) or hydroxychloroquine sulfate (HCQ).The most significant HCQ effect is the control of SLE disease activity itself, which implies amelioration of active clinical involvements, decrease in serum markers, decrease in activity scores, prevention of disease flares, and sustained remission on long-term use.</p>
        <p>Therefore, decrease in disease activity,<sup><xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref>,<xref rid="bibr85-1759720X211073001" ref-type="bibr">85</xref>,<xref rid="bibr95-1759720X211073001" ref-type="bibr">95</xref><xref rid="bibr96-1759720X211073001" ref-type="bibr"/><xref rid="bibr97-1759720X211073001" ref-type="bibr"/><xref rid="bibr98-1759720X211073001" ref-type="bibr"/><xref rid="bibr99-1759720X211073001" ref-type="bibr"/><xref rid="bibr100-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr101-1759720X211073001" ref-type="bibr">101</xref></sup> prevention of disease flares,<sup><xref rid="bibr78-1759720X211073001" ref-type="bibr">78</xref>,<xref rid="bibr100-1759720X211073001" ref-type="bibr">100</xref>,<xref rid="bibr103-1759720X211073001" ref-type="bibr">103</xref><xref rid="bibr104-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr105-1759720X211073001" ref-type="bibr">105</xref></sup> and improvement of proinflammatory cytokine profiles<sup><xref rid="bibr85-1759720X211073001" ref-type="bibr">85</xref>,<xref rid="bibr95-1759720X211073001" ref-type="bibr">95</xref>,<xref rid="bibr97-1759720X211073001" ref-type="bibr">97</xref>,<xref rid="bibr104-1759720X211073001" ref-type="bibr">104</xref>,<xref rid="bibr180-1759720X211073001" ref-type="bibr">180</xref>,<xref rid="bibr181-1759720X211073001" ref-type="bibr">181</xref></sup> have been highlighted with HCQ.</p>
        <p>Moreover, delay of the immune clinical spectrum to overt SLE was described in antinuclear antibodies (ANA)-positive patients.<sup><xref rid="bibr94-1759720X211073001" ref-type="bibr">94</xref>,<xref rid="bibr179-1759720X211073001" ref-type="bibr">179</xref></sup> A recent study showed that HCQ might suppress early mediators like the B cell activating factor (BAFF) and interferon (IFN), lowering the IFN-&#x3B3;-induced protein 10 (IP-10) levels in incomplete or new-onset SLE, supporting the hypothesis that HCQ could influence disease progression.<sup>
<xref rid="bibr182-1759720X211073001" ref-type="bibr">182</xref>
</sup></p>
        <p>In observational studies, HCQ has been shown beneficial for cutaneous lupus,<sup><xref rid="bibr95-1759720X211073001" ref-type="bibr">95</xref>,<xref rid="bibr102-1759720X211073001" ref-type="bibr">102</xref>,<xref rid="bibr106-1759720X211073001" ref-type="bibr">106</xref><xref rid="bibr107-1759720X211073001" ref-type="bibr"/><xref rid="bibr108-1759720X211073001" ref-type="bibr"/><xref rid="bibr109-1759720X211073001" ref-type="bibr"/><xref rid="bibr110-1759720X211073001" ref-type="bibr"/><xref rid="bibr111-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr112-1759720X211073001" ref-type="bibr">112</xref></sup> musculoskeletal involvement,<sup>
<xref rid="bibr99-1759720X211073001" ref-type="bibr">99</xref>
</sup> and various other key manifestations of SLE. The management of lupus nephritis (LN) remains suboptimal<sup>
<xref rid="bibr183-1759720X211073001" ref-type="bibr">183</xref>
</sup> and HCQ is adjuvant therapy to the immunosuppressive regimens in obtaining remission.<sup><xref rid="bibr79-1759720X211073001" ref-type="bibr">79</xref>,<xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref>,<xref rid="bibr115-1759720X211073001" ref-type="bibr">115</xref><xref rid="bibr116-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr117-1759720X211073001" ref-type="bibr">117</xref></sup></p>
        <p>HCQ decreases disease activity and prevents SLE flare during pregnancy,<sup><xref rid="bibr80-1759720X211073001" ref-type="bibr">80</xref>,<xref rid="bibr118-1759720X211073001" ref-type="bibr">118</xref>,<xref rid="bibr119-1759720X211073001" ref-type="bibr">119</xref>,<xref rid="bibr122-1759720X211073001" ref-type="bibr">122</xref></sup> and furthermore, there are reports sustaining a possible protective role for preeclampsia,<sup><xref rid="bibr120-1759720X211073001" ref-type="bibr">120</xref><xref rid="bibr121-1759720X211073001" ref-type="bibr"/><xref rid="bibr122-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr123-1759720X211073001" ref-type="bibr">123</xref></sup> fetal growth restriction, and prematurity.<sup>
<xref rid="bibr98-1759720X211073001" ref-type="bibr">98</xref>
</sup> Current data regarding HCQ efficacy during pregnancy are conclusive, however for other outcomes the results are contradictory. Thus, there are reports that did not found the impact of HCQ on pregnancy loss, preterm delivery or intrauterine growth retardation,<sup>
<xref rid="bibr119-1759720X211073001" ref-type="bibr">119</xref>
</sup> or upon miscarriage, stillbirth, pregnancy loss, or congenital abnormality rates.<sup>
<xref rid="bibr80-1759720X211073001" ref-type="bibr">80</xref>
</sup></p>
        <p>For neonatal lupus, one retrospective study that analyzed data of a historical cohort counting more than 200 pregnancies in SLE patients with positive anti-Ro/SS-A antibodies found HCQ benefits over recurrence and outcome of the neonatal lupus.<sup>
<xref rid="bibr184-1759720X211073001" ref-type="bibr">184</xref>
</sup> In another research, HCQ was not identified as independent protective factor for neonatal lupus after adjusting for confounders like age, race, antibodies status, corticosteroids, and prior cardiac-neonatal lupus risk, even if the neonatal lupus cases were less frequent in pregnancies treated by HCQ (14% <italic toggle="yes">versus</italic> 37%).<sup>
<xref rid="bibr185-1759720X211073001" ref-type="bibr">185</xref>
</sup></p>
        <p>Despite potential benefits of HCQ during pregnancy, adherence seems to be low. A population-based registry identified 376 pregnancies in which discontinuation of antimalarials occurred in 16.7% of cases in the year prior to pregnancy, 29.8% in the first trimester, 9.7% in the second, and 26.0% in the third.<sup>
<xref rid="bibr186-1759720X211073001" ref-type="bibr">186</xref>
</sup></p>
        <p>Importantly, HCQ passes the placenta and has fetal serum concentrations equal to those measured in the maternal blood. However, HCQ use during pregnancy<sup><xref rid="bibr80-1759720X211073001" ref-type="bibr">80</xref>,<xref rid="bibr119-1759720X211073001" ref-type="bibr">119</xref>,<xref rid="bibr120-1759720X211073001" ref-type="bibr">120</xref>,<xref rid="bibr123-1759720X211073001" ref-type="bibr">123</xref>,<xref rid="bibr187-1759720X211073001" ref-type="bibr">187</xref><xref rid="bibr188-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr189-1759720X211073001" ref-type="bibr">189</xref></sup> and breastfeeding is considered safe.<sup><xref rid="bibr5-1759720X211073001" ref-type="bibr">5</xref>,<xref rid="bibr190-1759720X211073001" ref-type="bibr">190</xref></sup> During lactation, HCQ passes in the maternal milk, but with lower concentrations than in maternal blood, estimated to be 0.2&#x2009;mg/kg/day.<sup>
<xref rid="bibr5-1759720X211073001" ref-type="bibr">5</xref>
</sup></p>
        <p>There are reports of CQ overdose in children and, by parallel, cautions are related to HCQ. Antimalarials might be toxic in children in relatively small doses and patients should be counseled to keep these drugs out of children.<sup>
<xref rid="bibr5-1759720X211073001" ref-type="bibr">5</xref>
</sup></p>
        <p>SLE disease itself is a risk factor for thrombosis. Also, about 20% of patients with SLE have antiphospholipid syndrome (APS).<sup>
<xref rid="bibr191-1759720X211073001" ref-type="bibr">191</xref>
</sup> Antimalarials might reduce the antiphospholipid antibodies titers<sup>
<xref rid="bibr124-1759720X211073001" ref-type="bibr">124</xref>
</sup> and the risk of thrombosis,<sup><xref rid="bibr116-1759720X211073001" ref-type="bibr">116</xref>,<xref rid="bibr125-1759720X211073001" ref-type="bibr">125</xref><xref rid="bibr126-1759720X211073001" ref-type="bibr"/><xref rid="bibr127-1759720X211073001" ref-type="bibr"/><xref rid="bibr128-1759720X211073001" ref-type="bibr"/><xref rid="bibr129-1759720X211073001" ref-type="bibr"/><xref rid="bibr130-1759720X211073001" ref-type="bibr"/><xref rid="bibr131-1759720X211073001" ref-type="bibr"/><xref rid="bibr132-1759720X211073001" ref-type="bibr"/><xref rid="bibr133-1759720X211073001" ref-type="bibr"/><xref rid="bibr134-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr135-1759720X211073001" ref-type="bibr">135</xref></sup> but not all published studies reported a protective effect over thrombosis.<sup><xref rid="bibr192-1759720X211073001" ref-type="bibr">192</xref><xref rid="bibr193-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr194-1759720X211073001" ref-type="bibr">194</xref></sup></p>
        <p>HCQ has also some metabolic effects by lowering fasting glucose,<sup>
<xref rid="bibr136-1759720X211073001" ref-type="bibr">136</xref>
</sup> yielding protection against diabetes,<sup>
<xref rid="bibr137-1759720X211073001" ref-type="bibr">137</xref>
</sup> and improvement of the lipids profile in most<sup><xref rid="bibr81-1759720X211073001" ref-type="bibr">81</xref>,<xref rid="bibr90-1759720X211073001" ref-type="bibr">90</xref>,<xref rid="bibr138-1759720X211073001" ref-type="bibr">138</xref><xref rid="bibr139-1759720X211073001" ref-type="bibr"/><xref rid="bibr140-1759720X211073001" ref-type="bibr"/><xref rid="bibr141-1759720X211073001" ref-type="bibr"/><xref rid="bibr142-1759720X211073001" ref-type="bibr"/><xref rid="bibr143-1759720X211073001" ref-type="bibr"/><xref rid="bibr144-1759720X211073001" ref-type="bibr"/><xref rid="bibr145-1759720X211073001" ref-type="bibr"/><xref rid="bibr146-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr147-1759720X211073001" ref-type="bibr">147</xref></sup> but not all<sup><xref rid="bibr195-1759720X211073001" ref-type="bibr">195</xref>,<xref rid="bibr196-1759720X211073001" ref-type="bibr">196</xref></sup> studies. However, the efficacy of HCQ upon atherosclerosis is more controversial.<sup><xref rid="bibr151-1759720X211073001" ref-type="bibr">151</xref>,<xref rid="bibr152-1759720X211073001" ref-type="bibr">152</xref>,<xref rid="bibr197-1759720X211073001" ref-type="bibr">197</xref>,<xref rid="bibr198-1759720X211073001" ref-type="bibr">198</xref></sup></p>
        <p>It is to remember that smoking might inhibit HCQ effects<sup><xref rid="bibr7-1759720X211073001" ref-type="bibr">7</xref>,<xref rid="bibr109-1759720X211073001" ref-type="bibr">109</xref>,<xref rid="bibr110-1759720X211073001" ref-type="bibr">110</xref>,<xref rid="bibr112-1759720X211073001" ref-type="bibr">112</xref></sup> and determine a twofold lower response of cutaneous involvement under HCQ;<sup>
<xref rid="bibr199-1759720X211073001" ref-type="bibr">199</xref>
</sup> counseling for smoking cessation is therefore important. Possible anti-neoplastic properties of HCQ have been poorly assessed in SLE.<sup>
<xref rid="bibr168-1759720X211073001" ref-type="bibr">168</xref>
</sup></p>
        <p>HCQ might inhibit the conversion of 25-(OH)-vitamin D to 1,25-(OH)2-vitamin D.<sup>
<xref rid="bibr200-1759720X211073001" ref-type="bibr">200</xref>
</sup> However, data regarding the impact of HCQ on bone metabolism in SLE remain controversial.<sup><xref rid="bibr86-1759720X211073001" ref-type="bibr">86</xref>,<xref rid="bibr162-1759720X211073001" ref-type="bibr">162</xref>,<xref rid="bibr163-1759720X211073001" ref-type="bibr">163</xref>,<xref rid="bibr201-1759720X211073001" ref-type="bibr">201</xref>,<xref rid="bibr202-1759720X211073001" ref-type="bibr">202</xref></sup> Many data suggest that HCQ has a protective role against infections<sup><xref rid="bibr92-1759720X211073001" ref-type="bibr">92</xref>,<xref rid="bibr116-1759720X211073001" ref-type="bibr">116</xref>,<xref rid="bibr154-1759720X211073001" ref-type="bibr">154</xref><xref rid="bibr155-1759720X211073001" ref-type="bibr"/><xref rid="bibr156-1759720X211073001" ref-type="bibr"/><xref rid="bibr157-1759720X211073001" ref-type="bibr"/><xref rid="bibr158-1759720X211073001" ref-type="bibr"/><xref rid="bibr159-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr160-1759720X211073001" ref-type="bibr">160</xref></sup> and severe events included<sup><xref rid="bibr92-1759720X211073001" ref-type="bibr">92</xref>,<xref rid="bibr154-1759720X211073001" ref-type="bibr">154</xref><xref rid="bibr155-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr156-1759720X211073001" ref-type="bibr">156</xref></sup> in SLE.</p>
        <p>Corticosteroids are widely prescribed, but also important determinants of cardiovascular, gastrointestinal, and metabolic comorbidities as well as of accrual damage and impaired quality of life in SLE. Thus, another important role for HCQ in SLE is that of corticosteroid-sparing agent.<sup><xref rid="bibr80-1759720X211073001" ref-type="bibr">80</xref>,<xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref>,<xref rid="bibr103-1759720X211073001" ref-type="bibr">103</xref></sup> However, as for other outcomes, there are also studies with negative results.<sup>
<xref rid="bibr102-1759720X211073001" ref-type="bibr">102</xref>
</sup></p>
        <p>SLE is a severe disease with survival rates at 5&#x2009;years of only 50% in early studies, which now exceed 90%.<sup>
<xref rid="bibr203-1759720X211073001" ref-type="bibr">203</xref>
</sup> While mortality in early stages is usually related to severe organ involvement and SLE disease activity itself, in late, long-standing SLE, accrual damage, and cardiovascular risk are the main determinants. In spite of some contrary results,<sup>
<xref rid="bibr204-1759720X211073001" ref-type="bibr">204</xref>
</sup> many studies reported HCQ protective effects for accrual damage<sup><xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>,<xref rid="bibr83-1759720X211073001" ref-type="bibr">83</xref>,<xref rid="bibr84-1759720X211073001" ref-type="bibr">84</xref>,<xref rid="bibr87-1759720X211073001" ref-type="bibr">87</xref><xref rid="bibr88-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr89-1759720X211073001" ref-type="bibr">89</xref>,<xref rid="bibr164-1759720X211073001" ref-type="bibr">164</xref><xref rid="bibr165-1759720X211073001" ref-type="bibr"/><xref rid="bibr166-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr167-1759720X211073001" ref-type="bibr">167</xref></sup> and HCQ has also been associated with shorter SLE-related hospitalization length.<sup><xref rid="bibr159-1759720X211073001" ref-type="bibr">159</xref>,<xref rid="bibr169-1759720X211073001" ref-type="bibr">169</xref>,<xref rid="bibr170-1759720X211073001" ref-type="bibr">170</xref></sup> And last, but not least, HCQ is one of the few treatments that has been shown to improve survival rates in SLE.<sup><xref rid="bibr87-1759720X211073001" ref-type="bibr">87</xref>,<xref rid="bibr91-1759720X211073001" ref-type="bibr">91</xref>,<xref rid="bibr93-1759720X211073001" ref-type="bibr">93</xref>,<xref rid="bibr116-1759720X211073001" ref-type="bibr">116</xref>,<xref rid="bibr127-1759720X211073001" ref-type="bibr">127</xref>,<xref rid="bibr171-1759720X211073001" ref-type="bibr">171</xref><xref rid="bibr172-1759720X211073001" ref-type="bibr"/><xref rid="bibr173-1759720X211073001" ref-type="bibr"/><xref rid="bibr174-1759720X211073001" ref-type="bibr"/><xref rid="bibr175-1759720X211073001" ref-type="bibr"/><xref rid="bibr176-1759720X211073001" ref-type="bibr"/><xref rid="bibr177-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr178-1759720X211073001" ref-type="bibr">178</xref></sup></p>
        <p>Therefore, based on its wide spectrum of effects, HCQ should probably be considered a possible confounder in all research involving patients with SLE.</p>
      </sec>
      <sec id="section9-1759720X211073001">
        <title>Systematic reviews and meta-analyses on hydroxychloroquine use in systemic lupus erythematosus</title>
        <p>The first systematic review regarding HCQ in SLE included a total of 95 studies published between 1982 and 2007.<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> All studies which considered disease activity as the main outcome (11 articles) found positive results, with more than 50% reduction in disease activity in most reports and a decrease in corticosteroid needs in three studies;<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> however, the risk of severe SLE flare was reduced only with borderline significance.<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> Also, the HCQ benefits as adjuvant therapy for LN was also confirmed.<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> The potential benefits upon accrual damage and survival were reported in a limited number of studies.<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> This systematic review was continued by another one using a similar methodology for the 2007&#x2013;2012&#x2009;period.<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup> The authors reported further evidence thrombosis prevention, increased survival, control of disease activity, lipid profile improvement, and prevention of damage accrual<sup>
<xref rid="bibr3-1759720X211073001" ref-type="bibr">3</xref>
</sup> (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental Table 4</ext-link>).</p>
        <table-wrap position="float" id="table4-1759720X211073001">
          <label>Table 4.</label>
          <caption>
            <p>Side effects of hydroxychloroquine.</p>
          </caption>
          <alternatives>
            <graphic xlink:href="10.1177_1759720X211073001-table4" position="float"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">System</th>
                  <th colspan="2" rowspan="1">HCQ&#x2019;s side effects</th>
                  <th rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <th rowspan="1" colspan="1"/>
                  <th align="left" rowspan="1" colspan="1">Short term</th>
                  <th align="left" rowspan="1" colspan="1">Long term</th>
                  <th align="left" rowspan="1" colspan="1">References</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">Cardiovascular</td>
                  <td rowspan="1" colspan="1">Hours-days: prolonged QT <sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup>(attention to the association with other drugs that affect the QT interval)<break/>Overdose: cardiovascular shock, collapse</td>
                  <td rowspan="1" colspan="1">Weeks-months: Conduction troubles, cardiomyopathy, vacuolar myopathy, valvular disorders<sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Costedoat-Chalumeau <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr4-1759720X211073001" ref-type="bibr">4</xref>
</sup> Doyno <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr216-1759720X211073001" ref-type="bibr">216</xref>
</sup> Nishiyama <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr217-1759720X211073001" ref-type="bibr">217</xref>
</sup> Ruiz-Irastorza <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Zhao <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr219-1759720X211073001" ref-type="bibr">219</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Dermatologic</td>
                  <td rowspan="1" colspan="1">Days-weeks: pruritus, rashes, urticaria, exanthematous pustulosis, toxic epidermal necrolysis, Stevens&#x2013;Johnson syndrome<sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Years: hyperpigmentation</td>
                  <td rowspan="1" colspan="1">Costedoat-Chalumeau <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr4-1759720X211073001" ref-type="bibr">4</xref>
</sup> Ruiz-Irastorza <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Digestive intolerance</td>
                  <td rowspan="1" colspan="1">Days: nausea, vomiting, diarrhea, bloating</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Costedoat-Chalumeau <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr4-1759720X211073001" ref-type="bibr">4</xref>
</sup> Ruiz-Irastorza <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Hematological</td>
                  <td rowspan="1" colspan="1">Days to weeks: bone marrow toxicity, cytopenia (neutropenia)<sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Weeks-months: bone marrow toxicity, cytopenia (neutropenia)<sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Sames <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr220-1759720X211073001" ref-type="bibr">220</xref>
</sup> Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Metabolic</td>
                  <td rowspan="1" colspan="1">Days: hypoglycemia<sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">El-Solia <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr221-1759720X211073001" ref-type="bibr">221</xref>
</sup> Cansu and Korkmaz;<sup>
<xref rid="bibr222-1759720X211073001" ref-type="bibr">222</xref>
</sup> Ruiz-Irastorza <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Neuropsychiatric</td>
                  <td rowspan="1" colspan="1">One-two days: confusion, disorientation, hallucination<break/>Overdose: psychosis, seizure<sup><xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>,<xref rid="table-fn6-1759720X211073001" ref-type="table-fn">b</xref></sup></td>
                  <td rowspan="1" colspan="1">Weeks-months: agitation, bradyphrenia, delirium, disorientation, drowsiness, confusion, pseudo-parkinsonism<sup>a,b</sup></td>
                  <td rowspan="1" colspan="1">Mascolo <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr225-1759720X211073001" ref-type="bibr">225</xref>
</sup> Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Neuromuscular</td>
                  <td rowspan="1" colspan="1">Days: increase of creatine kinase<sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Months: myositis, muscle weakness<sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup></td>
                  <td rowspan="1" colspan="1">Ruiz-Irastorza <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Stein <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr223-1759720X211073001" ref-type="bibr">223</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup> Siddiqui <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr224-1759720X211073001" ref-type="bibr">224</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Ophthalmologic</td>
                  <td rowspan="1" colspan="1">Days-weeks: eye accommodation troubles</td>
                  <td rowspan="1" colspan="1">Months&#x2013;years (5&#x2013;20&#x2009;years): retinopathy (maculopathy)</td>
                  <td rowspan="1" colspan="1">Marmor <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>
</sup> Rosenbaum <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr31-1759720X211073001" ref-type="bibr">31</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup> Petri <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr226-1759720X211073001" ref-type="bibr">226</xref>
</sup> Xie and Zhang;<sup>
<xref rid="bibr227-1759720X211073001" ref-type="bibr">227</xref>
</sup> Marmor <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>
</sup> Melles and Marmor;<sup>
<xref rid="bibr32-1759720X211073001" ref-type="bibr">32</xref>
</sup> Wolfe and Marmor;<sup>
<xref rid="bibr228-1759720X211073001" ref-type="bibr">228</xref>
</sup> Ruiz-Irastorza <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Otorhinolaryngology</td>
                  <td rowspan="1" colspan="1">Days-weeks: ototoxicity, tinnitus<sup>
<xref rid="table-fn5-1759720X211073001" ref-type="table-fn">a</xref>
</sup></td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Fiehn <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup></td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Only case reports</td>
                  <td rowspan="1" colspan="1">Fulminant hepatic failure; toxic myopathy with respiratory failure; podocytopathy mimicking Fabry disease; rare cutaneous side effects (erythroderma, dark rash, gray skin, erythema multiforme)</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">Chatre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> Makin <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr229-1759720X211073001" ref-type="bibr">229</xref>
</sup> Abou Assalie <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr239-1759720X211073001" ref-type="bibr">239</xref>
</sup> Koumaki <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr230-1759720X211073001" ref-type="bibr">230</xref>
</sup> Pai <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr231-1759720X211073001" ref-type="bibr">231</xref>
</sup> Pelechas and Drosos;<sup>
<xref rid="bibr232-1759720X211073001" ref-type="bibr">232</xref>
</sup> Ivo <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr233-1759720X211073001" ref-type="bibr">233</xref>
</sup> Serre <italic toggle="yes">et al.</italic>;<sup>
<xref rid="bibr234-1759720X211073001" ref-type="bibr">234</xref>
</sup> Wu <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr235-1759720X211073001" ref-type="bibr">235</xref>
</sup></td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="table-fn3-1759720X211073001">
              <p>HCQ, hydroxychloroquine.</p>
            </fn>
            <fn id="table-fn4-1759720X211073001">
              <p>The HCQ-related side effects, in terms of frequency and severity, are related to daily posology, treatment duration, concomitant therapies, and associated comorbidities.</p>
            </fn>
            <fn id="table-fn5-1759720X211073001">
              <label>a</label>
              <p>Only rare reported.</p>
            </fn>
            <fn id="table-fn6-1759720X211073001">
              <label>b</label>
              <p>Association not confirmed yet.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The protective effect of HCQ against infections was further confirmed in two systematic reviews and meta-analysis.<sup><xref rid="bibr153-1759720X211073001" ref-type="bibr">153</xref>,<xref rid="bibr161-1759720X211073001" ref-type="bibr">161</xref></sup> Also, two meta-analyses reported improvement of the lipid profile under HCQ in SLE.<sup><xref rid="bibr149-1759720X211073001" ref-type="bibr">149</xref>,<xref rid="bibr150-1759720X211073001" ref-type="bibr">150</xref></sup> For cutaneous involvement, Fairley <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr114-1759720X211073001" ref-type="bibr">114</xref>
</sup> reported in one systematic review only moderate HCQ efficacy.</p>
        <p>A 2018 meta-analysis of observational data failed to identify any significant beneficial effect of HCQ over fetal growth restriction and prematurity. However, the authors mentioned that these results should be regarded with caution due to lack of RCTs, high heterogeneity among reported data, and of numerous missing data like those on the antiphospholipid antibodies status.<sup>
<xref rid="bibr205-1759720X211073001" ref-type="bibr">205</xref>
</sup></p>
      </sec>
      <sec id="section10-1759720X211073001">
        <title>Overview of guidelines</title>
        <p>We reviewed here systematically the European League against Rheumatism (EULAR) recommendations referring to the use of HCQ. We identified all EULAR guidelines (<ext-link xlink:href="https://www.eular.org" ext-link-type="uri">www.eular.org</ext-link>) for the last 5&#x2009;years and searched for HCQ-related paragraphs using the terms &#x2018;Hydroxychloroquine&#x2019; and the respective abbreviation &#x2018;HCQ&#x2019;. All paragraphs found were extracted (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental Table 5</ext-link>) and data were further analyzed and summarized (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental Figure 2</ext-link>).</p>
        <p>From the total 30 EULAR management guidelines published since 2016, 10 referring to HCQ were identified, and main indications were noted (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1759720X211073001" ext-link-type="uri">Supplemental Table 6</ext-link>). Recommendations addressing specifically to HCQ were found in seven guidelines<sup><xref rid="bibr8-1759720X211073001" ref-type="bibr">8</xref>,<xref rid="bibr34-1759720X211073001" ref-type="bibr">34</xref>,<xref rid="bibr206-1759720X211073001" ref-type="bibr">206</xref><xref rid="bibr207-1759720X211073001" ref-type="bibr"/><xref rid="bibr208-1759720X211073001" ref-type="bibr"/><xref rid="bibr209-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr210-1759720X211073001" ref-type="bibr">210</xref></sup> while in others, HCQ was included as part of Disease Modifying AntiRheumatic Drugs (DMARDs).<sup><xref rid="bibr211-1759720X211073001" ref-type="bibr">211</xref><xref rid="bibr212-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr213-1759720X211073001" ref-type="bibr">213</xref></sup> The EULAR Guidelines recommendations referring mainly to SLE and related conditions are summarized in <xref rid="fig2-1759720X211073001" ref-type="fig">Figure 2</xref>.</p>
        <fig position="float" id="fig2-1759720X211073001">
          <label>Figure 2.</label>
          <caption>
            <p>Recommendations for hydroxychloroquine (HCQ) use according to the European League against Rheumatism (EULAR) guidelines.</p>
          </caption>
          <graphic xlink:href="10.1177_1759720X211073001-fig2" position="float"/>
        </fig>
        <p>Tunnincliffe <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr214-1759720X211073001" ref-type="bibr">214</xref>
</sup> and Tamirou <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr215-1759720X211073001" ref-type="bibr">215</xref>
</sup> reviewed SLE recommendations published up to 2014 and between 2004 and 2017, respectively, and identified not least than 14 and 23, respectively, original clinical guidelines or original statements with focus on SLE.</p>
        <p>The 2020 American College of Rheumatology (ACR) Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases<sup>
<xref rid="bibr190-1759720X211073001" ref-type="bibr">190</xref>
</sup> advise for HCQ use during pregnancy and breastfeeding, in cases with positive anti-Ro/SS-A and anti-La/SS-B antibodies as well as additional or alternative therapy in SLE women with refractory obstetric APS. HCQ continuation is strongly recommended in men who are planning to father a pregnancy.<sup>
<xref rid="bibr190-1759720X211073001" ref-type="bibr">190</xref>
</sup> The 2012 ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis specifies that all SLE patients with nephritis should be treated with HCQ as background therapy.<sup>
<xref rid="bibr9-1759720X211073001" ref-type="bibr">9</xref>
</sup></p>
        <p>The 2018 British Society for Rheumatology guideline for the management of SLE in adults<sup>
<xref rid="bibr10-1759720X211073001" ref-type="bibr">10</xref>
</sup> identified 45 studies to sustain the recommendation of antimalarial use (&lt;6.5&#x2009;mg/kg/day) for mild disease, prevention of flare in all patients, prevention of damage, and as steroid-sparing agent (overall SIGN level of evidence 1+++ and grade A of recommendation).<sup>
<xref rid="bibr10-1759720X211073001" ref-type="bibr">10</xref>
</sup></p>
        <p>Finally, the Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)&#x2013;Pan-American League of Associations of Rheumatology (PANLAR) stated also that antimalarials should be used in all SLE patients with exception of those who refuse or who have absolute contraindications, as first line for musculoskeletal or cutaneous involvement as well as associated with immunosuppressive treatments for other SLE organ involvements.<sup>
<xref rid="bibr11-1759720X211073001" ref-type="bibr">11</xref>
</sup></p>
      </sec>
    </sec>
    <sec id="section11-1759720X211073001">
      <title>Hydroxychloroquine safety profile</title>
      <p>A wide range of side effects such as cardiovascular, dermatological, digestive, hematological, metabolic, ophthalmologic, as well as other rare side effects were reported to be associated with HCQ use.<sup><xref rid="bibr4-1759720X211073001" ref-type="bibr">4</xref>,<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>,<xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>,<xref rid="bibr31-1759720X211073001" ref-type="bibr">31</xref>,<xref rid="bibr32-1759720X211073001" ref-type="bibr">32</xref>,<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>,<xref rid="bibr216-1759720X211073001" ref-type="bibr">216</xref><xref rid="bibr217-1759720X211073001" ref-type="bibr"/><xref rid="bibr218-1759720X211073001" ref-type="bibr"/><xref rid="bibr219-1759720X211073001" ref-type="bibr"/><xref rid="bibr220-1759720X211073001" ref-type="bibr"/><xref rid="bibr221-1759720X211073001" ref-type="bibr"/><xref rid="bibr222-1759720X211073001" ref-type="bibr"/><xref rid="bibr223-1759720X211073001" ref-type="bibr"/><xref rid="bibr224-1759720X211073001" ref-type="bibr"/><xref rid="bibr225-1759720X211073001" ref-type="bibr"/><xref rid="bibr226-1759720X211073001" ref-type="bibr"/><xref rid="bibr227-1759720X211073001" ref-type="bibr"/><xref rid="bibr228-1759720X211073001" ref-type="bibr"/><xref rid="bibr229-1759720X211073001" ref-type="bibr"/><xref rid="bibr230-1759720X211073001" ref-type="bibr"/><xref rid="bibr231-1759720X211073001" ref-type="bibr"/><xref rid="bibr232-1759720X211073001" ref-type="bibr"/><xref rid="bibr233-1759720X211073001" ref-type="bibr"/><xref rid="bibr234-1759720X211073001" ref-type="bibr"/><xref rid="bibr235-1759720X211073001" ref-type="bibr"/><xref rid="bibr236-1759720X211073001" ref-type="bibr"/><xref rid="bibr237-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr238-1759720X211073001" ref-type="bibr">238</xref></sup> The main side effects of HCQ are summarized in <xref rid="table4-1759720X211073001" ref-type="table">Table 4</xref>.</p>
      <p>Reviewing the antimalarials&#x2019; safety profile in SLE, Ruiz-Irastorza <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> noted low prevalence of antimalarials&#x2019; toxicity, mainly mild gastrointestinal and cutaneous side effects. These were significantly more frequent under CQ when compared with HCQ, results parallel by higher discontinuation rates for CQ. Overall, the HCQ global safety was rated as high.<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> Eljaaly <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr236-1759720X211073001" ref-type="bibr">236</xref>
</sup> published recently a meta-analysis for the HCQ safety when administrated for different pathologies (chronic urticaria, RA, SLE, osteoarthritis, IgA nephropathy, asymptomatic HIV infection, Alzheimer disease, cutaneous lupus) in daily doses of 200&#x2013;400&#x2009;mg and presented also encouraging results. Besides significant more frequent occurrence of skin pigmentation under HCQ, no other side effect reached a significant difference (rash, gastrointestinal complaints, headache, fatigue, visual troubles) and also no cardiac toxicity was reported.<sup>
<xref rid="bibr236-1759720X211073001" ref-type="bibr">236</xref>
</sup></p>
      <p>Thus, for long-term HCQ use, medium uptake duration of 32&#x2009;months,<sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup> the skin hyperpigmentation is not rarely reported and might be favored by factors like ecchymosis, bruising, platelet antiaggregant, and oral anticoagulants. Beside hyperpigmentation, all other HCQ-related side effects are only rarely encountered.</p>
      <p>On short-term use, the digestive intolerance is the most frequently encountered side effect, with occurrence possible since first HCQ administration.<sup><xref rid="bibr237-1759720X211073001" ref-type="bibr">237</xref>,<xref rid="bibr238-1759720X211073001" ref-type="bibr">238</xref></sup></p>
      <p>A wide range of mild neuropsychiatric manifestations, but also psychosis, was reported in relation to HCQ use, especially in elderly. However, this relation remains controversial as other concomitant factors like concomitant drugs, alcohol intake, use of glucocorticoids, or background disease itself could originate the neuropsychiatric manifestations occurrence in patients with SLE under HCQ.<sup>
<xref rid="bibr225-1759720X211073001" ref-type="bibr">225</xref>
</sup></p>
      <p>Retinopathy occurrence remains the most discussed and studied HCQ&#x2019;s side effect in SLE. The main risk factors for HCQ-related retinopathy are the treatment duration, daily and cumulative dose, chronic kidney disease, as well as pre-existent retinal disease.<sup>
<xref rid="bibr34-1759720X211073001" ref-type="bibr">34</xref>
</sup> Ophthalmologic screening is mandatory, yearly from baseline if there are known risk factors or at baseline, after 5&#x2009;years on HCQ, and yearly therefore in patients without retinopathy risk factors.<sup><xref rid="bibr8-1759720X211073001" ref-type="bibr">8</xref>,<xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>,<xref rid="bibr31-1759720X211073001" ref-type="bibr">31</xref>,<xref rid="bibr34-1759720X211073001" ref-type="bibr">34</xref></sup> The current 2020 Joint Statement on HCQ<sup>
<xref rid="bibr31-1759720X211073001" ref-type="bibr">31</xref>
</sup> reinforced the old recommendations<sup><xref rid="bibr8-1759720X211073001" ref-type="bibr">8</xref>,<xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>,<xref rid="bibr34-1759720X211073001" ref-type="bibr">34</xref>,<xref rid="bibr32-1759720X211073001" ref-type="bibr">32</xref></sup> of the need of sensitive testing modalities such as optical coherence tomography (OCT) and automated visual fields that could detect early toxicity.<sup>
<xref rid="bibr31-1759720X211073001" ref-type="bibr">31</xref>
</sup> When available, quinacrine (mepacrine) might be considered as an alternative in SLE patients with HCQ-related ocular or cutaneous side effects.</p>
      <p>As the eye side effects are dose-related, not only the duration of use but also the blood levels are predictors of retinopathy development with a statistical association in patients with [HCQ] blood levels &gt;1200&#x2009;ng/ml.<sup><xref rid="bibr226-1759720X211073001" ref-type="bibr">226</xref>,<xref rid="bibr227-1759720X211073001" ref-type="bibr">227</xref></sup> However, association between HCQ blood concentration and retinopathy has not been confirmed in another study.<sup>
<xref rid="bibr240-1759720X211073001" ref-type="bibr">240</xref>
</sup> For non-rheumatic diseases, doses of up to 1000&#x2009;mg daily (up to 20&#x2009;mg/kg daily) showed eye toxicity within 2&#x2009;years in 25&#x2013;40% of the patients exposed,<sup>
<xref rid="bibr30-1759720X211073001" ref-type="bibr">30</xref>
</sup> while for the doses up to 5&#x2009;mg/kg of real body weight, the risk of retinopathy within 10&#x2009;years was 2%.<sup>
<xref rid="bibr32-1759720X211073001" ref-type="bibr">32</xref>
</sup> For lifetime HCQ users, definite or probable toxicity was documented in only 0.65% even if 6.5% patients discontinued therapy because of eye-related side effects.<sup>
<xref rid="bibr228-1759720X211073001" ref-type="bibr">228</xref>
</sup> One longitudinal study showed ophthalmological alterations confirmed by ophthalmological examination in 5.5% of cases.<sup>
<xref rid="bibr241-1759720X211073001" ref-type="bibr">241</xref>
</sup></p>
      <p>When compared with HCQ, the risk of retinopathy related to CQ seems to be much higher, hence CQ is not recommended as the first-line antimalarial for the SLE treatment. One systematic review including four studies for CQ <italic toggle="yes">versus</italic> six studies for HCQ found definite retinal toxicity in 2.5% <italic toggle="yes">versus</italic> 0.1% and probable retinopathy in 2.6% <italic toggle="yes">versus</italic> 0.3% patients.<sup>
<xref rid="bibr13-1759720X211073001" ref-type="bibr">13</xref>
</sup> A recent report from the Hopkins cohort showed a higher overall frequency of retinopathy of 4.3%, but the risk increased significantly after 15&#x2009;years of HCQ use,<sup>
<xref rid="bibr226-1759720X211073001" ref-type="bibr">226</xref>
</sup> namely 1% in the first 5&#x2009;years, 1.8% for 6&#x2013;10&#x2009;years, 3.3% for 11&#x2013;15&#x2009;years, and 11.5% for 16&#x2013;20&#x2009;years.<sup>
<xref rid="bibr226-1759720X211073001" ref-type="bibr">226</xref>
</sup></p>
      <p>For antimalarials cardiac toxicity, the results of 86 articles were systematically reviewed and a total of 127 patients (65.4% female) were identified, of which about 60% had taken CQ, while the rest HCQ.<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup> The most frequent cardiac side effects reported were conduction disorders (85%), followed by cardiac hypertrophy (22%), hypokinesia (9.4%), cardiac failure (26.8%), pulmonary arterial hypertension (3.9%), and valvular dysfunction (7.1%). Less than half of the patients (44.9%) recovered normal heart function after the antimalarial drug withdrawal.<sup>
<xref rid="bibr218-1759720X211073001" ref-type="bibr">218</xref>
</sup></p>
      <p>Disparate cases of HCQ-related neuromyopathy, particularly manifested as insidious onset of proximal myopathy that may be later associated with peripheral neuropathy and cardiac myotoxicity, are reported. The frequency of HCQ-related myopathies is not known, but is probably extremely rare.<sup>
<xref rid="bibr35-1759720X211073001" ref-type="bibr">35</xref>
</sup> Early recognition is important as the recovery after the drug withdrawal might be incomplete.<sup>
<xref rid="bibr223-1759720X211073001" ref-type="bibr">223</xref>
</sup></p>
      <p>Different case reports presented rare and very rare sides effects attributable to HCQ in the absence of other identifiable causes, like early fulminant hepatic failure,<sup>
<xref rid="bibr229-1759720X211073001" ref-type="bibr">229</xref>
</sup> toxic myopathy with respiratory failure,<sup>
<xref rid="bibr224-1759720X211073001" ref-type="bibr">224</xref>
</sup> and rare cutaneous lesions.<sup><xref rid="bibr230-1759720X211073001" ref-type="bibr">230</xref><xref rid="bibr231-1759720X211073001" ref-type="bibr"/><xref rid="bibr232-1759720X211073001" ref-type="bibr"/><xref rid="bibr233-1759720X211073001" ref-type="bibr"/><xref rid="bibr234-1759720X211073001" ref-type="bibr"/>&#x2013;<xref rid="bibr235-1759720X211073001" ref-type="bibr">235</xref>,<xref rid="bibr239-1759720X211073001" ref-type="bibr">239</xref></sup></p>
    </sec>
    <sec id="section12-1759720X211073001">
      <title>Hydroxychloroquine blood level monitoring and withdrawal</title>
      <p>Even if the HCQ role in SLE is acknowledged, less than half of the patients are taking HCQ as prescribed.<sup>
<xref rid="bibr242-1759720X211073001" ref-type="bibr">242</xref>
</sup> Measurement of HCQ in whole blood was proposed to monitor both response and adherence to treatment, but an appropriate cut-off for defining efficient HCQ&#x2019;s blood levels remains under debate. For CLE, one prospective multicenter study found significantly higher median blood [HCQ] levels in patients with complete remission (910&#x2009;ng/ml in remission <italic toggle="yes">versus</italic> 692&#x2009;ng/ml when partial remission and 569&#x2009;ng/ml in treatment failure, <italic toggle="yes">p</italic>&#x2009;=&#x2009;0.007).<sup>
<xref rid="bibr107-1759720X211073001" ref-type="bibr">107</xref>
</sup> In a prospective study, improvement of cutaneous lesions was observed when [HCQ] blood levels higher than 750&#x2009;ng/ml were reached.<sup>
<xref rid="bibr113-1759720X211073001" ref-type="bibr">113</xref>
</sup> Also, one study defined subtherapeutic [HCQ] levels, associated with trend of more disease flares, as less than 500&#x2009;ng/ml.<sup>
<xref rid="bibr243-1759720X211073001" ref-type="bibr">243</xref>
</sup> A recent report showed that low [HCQ] blood levels are associated with thrombotic events (720&#x2009;ng/ml <italic toggle="yes">versus</italic> 935&#x2009;ng/ml; <italic toggle="yes">p</italic>&#x2009;=&#x2009;0.025).<sup>
<xref rid="bibr135-1759720X211073001" ref-type="bibr">135</xref>
</sup></p>
      <p>On one hand, a decrease in the flare rate was not observed when [HCQ] level was maintained over 1000&#x2009;ng/ml.<sup>
<xref rid="bibr72-1759720X211073001" ref-type="bibr">72</xref>
</sup> On the other hand, decrease to 2&#x2013;3&#x2009;mg/kg/day did not modify serum [HCQ] levels significantly at 3 and 6&#x2009;months, but only at 12&#x2009;months.<sup>
<xref rid="bibr73-1759720X211073001" ref-type="bibr">73</xref>
</sup></p>
      <p>One of the main reasons for using [HCQ] blood levels in daily practice is the great interindividual variability, of which determinants are not completely characterized.<sup>
<xref rid="bibr5-1759720X211073001" ref-type="bibr">5</xref>
</sup> [HCQ] levels were found to be related to its major metabolite, N-desethylhydroxychloroquine (DHCQ), to HCQ weight-adjusted oral dose and also to the time since last dose taken.<sup><xref rid="bibr243-1759720X211073001" ref-type="bibr">243</xref>,<xref rid="bibr244-1759720X211073001" ref-type="bibr">244</xref></sup></p>
      <p>Analyzing a longitudinal cohort, Mok <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr243-1759720X211073001" ref-type="bibr">243</xref>
</sup> found that the majority of SLE patients screened had mainly [HCQ] subtherapeutic levels: &lt;10&#x2009;ng/ml (defined as total non-adherence) in 11%, 10&#x2013;500&#x2009;ng/ml (subtherapeutic levels) in 77%, and &gt;500&#x2009;ng/ml (therapeutic levels) in only 12% patients. Levels correlated with the dose prescribed<sup>
<xref rid="bibr243-1759720X211073001" ref-type="bibr">243</xref>
</sup> and, importantly, higher [HCQ] levels were associated with less SLE flare occurrence over time.<sup>
<xref rid="bibr243-1759720X211073001" ref-type="bibr">243</xref>
</sup></p>
      <p>Monitoring HCQ levels might allow identification of early nonadherence<sup>
<xref rid="bibr243-1759720X211073001" ref-type="bibr">243</xref>
</sup> and improve nonadherence.<sup>
<xref rid="bibr72-1759720X211073001" ref-type="bibr">72</xref>
</sup> HCQ levels measurement might help in counseling before the treatment change in regard to lack of adherence <italic toggle="yes">versus</italic> lack of treatment efficacy.<sup>
<xref rid="bibr5-1759720X211073001" ref-type="bibr">5</xref>
</sup></p>
      <p>Finally, considering the HCQ&#x2019;s side effects related to long-term use, one important question is how to identify the appropriate moment for stopping the treatment. The first RCT designed for HCQ<sup><xref rid="bibr66-1759720X211073001" ref-type="bibr">66</xref>,<xref rid="bibr67-1759720X211073001" ref-type="bibr">67</xref></sup> showed efficacy of long-term HCQ use in sustaining remission. In this RCT, the average HCQ total treatment duration before withdrawal was about 3&#x2009;years.<sup><xref rid="bibr66-1759720X211073001" ref-type="bibr">66</xref>,<xref rid="bibr67-1759720X211073001" ref-type="bibr">67</xref></sup> A more recent retrospective study showed that HCQ discontinuation in patients older than 55&#x2009;years with quiescent SLE and more than 5&#x2009;years treatment, due to retinal toxicity, patient&#x2019;s preference, cardiac toxicity, or other suspected adverse effects, did not result in significant increase in flare occurrence.<sup>
<xref rid="bibr245-1759720X211073001" ref-type="bibr">245</xref>
</sup> Finally, a recent survey across large international sample of physicians has shown that in case of sustained remission, 49.7% maintained the same dose indefinitely, 48.3% reduced the dose, while only 2.0% discontinued antimalarials.<sup>
<xref rid="bibr37-1759720X211073001" ref-type="bibr">37</xref>
</sup></p>
    </sec>
    <sec id="section13-1759720X211073001">
      <title>Conclusion</title>
      <p>In summary, HCQ is indicated in all patients with SLE in the absence of any contraindications or side effects, with high grade evidence in case of LN, cutaneous involvement, or during pregnancy and breastfeeding. However, there is a relatively small effect size for the prevention of severe flares in SLE. Monitoring HCQ blood levels might help to overcome adherence issues, which are quite common in SLE and adjust the daily dosage based on individual pharmacokinetic variability. Still, there is a need for additional research focused on defining the optimal conditions for HCQ withdrawal.</p>
    </sec>
    <sec sec-type="supplementary-material" id="section14-1759720X211073001" specific-use="figshare">
      <title>Supplemental Material</title>
      <supplementary-material id="suppl1-1759720X211073001" position="float" content-type="local-data">
        <caption>
          <title>sj-docx-1-tab-10.1177_1759720X211073001 &#x2013; Supplemental material for Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge</title>
        </caption>
        <media xlink:href="sj-docx-1-tab-10.1177_1759720X211073001.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
        <p>Supplemental material, sj-docx-1-tab-10.1177_1759720X211073001 for Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge by Alina Dima, Ciprian Jurcut, Fran&#xE7;ois Chasset, Renaud Felten and Laurent Arnaud in Therapeutic Advances in Musculoskeletal Disease</p>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="con">
        <p><bold>Author contributions:</bold>
<bold>Alina Dima:</bold> Conceptualization; Methodology; Writing &#x2013; original draft.</p>
        <p><bold>Ciprian Jurcut:</bold> Conceptualization; Writing &#x2013; original draft.</p>
        <p><bold>Francois Chasset:</bold> Conceptualization; Writing &#x2013; original draft.</p>
        <p><bold>Renaud Felten:</bold> Conceptualization; Writing &#x2013; original draft.</p>
        <p><bold>Laurent Arnaud:</bold> Conceptualization; Methodology; Supervision; Writing &#x2013; review &amp; editing.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p><bold>Conflict of interest statement:</bold> The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding:</bold> The authors received no financial support for the research, authorship, and/or publication of this article.</p>
      </fn>
      <fn fn-type="supplementary-material">
        <p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>ORCID iDs:</bold> Alina Dima <inline-graphic xlink:href="10.1177_1759720X211073001-img4.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0001-8743-3236" ext-link-type="uri">https://orcid.org/0000-0001-8743-3236</ext-link></p>
        <p>Renaud Felten <inline-graphic xlink:href="10.1177_1759720X211073001-img4.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-4951-4032" ext-link-type="uri">https://orcid.org/0000-0002-4951-4032</ext-link></p>
        <p>Laurent Arnaud <inline-graphic xlink:href="10.1177_1759720X211073001-img4.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-8077-8394" ext-link-type="uri">https://orcid.org/0000-0002-8077-8394</ext-link></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1759720X211073001">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Olsen</surname><given-names>NJ</given-names></name>
<name><surname>Schleich</surname><given-names>MA</given-names></name>
<name><surname>Karp</surname><given-names>DR.</given-names></name>
</person-group>
<article-title>Multifaceted effects of hydroxychloroquine in human disease</article-title>. <source>Semin Arthritis Rheum</source>
<year>2013</year>; <volume>43</volume>: <fpage>264</fpage>&#x2013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">23481418</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1759720X211073001">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dima</surname><given-names>A</given-names></name>
<name><surname>Jurcut</surname><given-names>C</given-names></name>
<name><surname>Arnaud</surname><given-names>L.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine in systemic and auto-immune diseases: where are we now?</article-title>
<source>Jt Bone Spine</source>
<year>2021</year>; <volume>88</volume>: <fpage>105143</fpage>.</mixed-citation>
      </ref>
      <ref id="bibr3-1759720X211073001">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Akhavan</surname><given-names>PS</given-names></name>
<name><surname>Su</surname><given-names>J</given-names></name>
<name><surname>Lou</surname><given-names>W</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>
<year>2013</year>; <volume>40</volume>: <fpage>831</fpage>&#x2013;<lpage>841</lpage>.<pub-id pub-id-type="pmid">23588942</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1759720X211073001">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
<name><surname>Leroux</surname><given-names>G</given-names></name>
<name><surname>Piette</surname><given-names>JC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment</article-title>. <source>Joint Bone Spine</source>
<year>2010</year>; <volume>77</volume>: <fpage>4</fpage>&#x2013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">20022788</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1759720X211073001">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
<name><surname>Dunogu&#xE9;</surname><given-names>B</given-names></name>
<name><surname>Morel</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine: a multifaceted treatment in lupus</article-title>. <source>Press M&#xE9;dicale</source>
<year>2014</year>; <volume>43</volume>: <fpage>e167</fpage>&#x2013;<lpage>e180</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr6-1759720X211073001">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine: past, present, future</article-title>. <source>Lupus</source>
<year>1998</year>; <volume>7</volume>: <fpage>65</fpage>&#x2013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">9541087</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-1759720X211073001">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Stojan</surname><given-names>G</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
</person-group>
<article-title>Atherosclerosis in systemic lupus erythematosus</article-title>. <source>J Cardiovasc Pharmacol</source>
<year>2013</year>; <volume>62</volume>: <fpage>255</fpage>&#x2013;<lpage>262</lpage>.<pub-id pub-id-type="pmid">23792700</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1759720X211073001">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fanouriakis</surname><given-names>A</given-names></name>
<name><surname>Kostopoulou</surname><given-names>M</given-names></name>
<name><surname>Alunno</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>2019 update of the EULAR recommendations for the management of systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source>
<year>2019</year>; <volume>78</volume>: <fpage>736</fpage>&#x2013;<lpage>745</lpage>.<pub-id pub-id-type="pmid">30926722</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1759720X211073001">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>BH</given-names></name>
<name><surname>McMahon</surname><given-names>MA</given-names></name>
<name><surname>Wilkinson</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis</article-title>. <source>Arthritis Care Res</source>
<year>2012</year>; <volume>64</volume>: <fpage>797</fpage>&#x2013;<lpage>808</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr10-1759720X211073001">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>C</given-names></name>
<name><surname>Amissah-Arthur</surname><given-names>M-B</given-names></name>
<name><surname>Gayed</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults</article-title>. <source>Rheumatology</source>
<year>2017</year>; <volume>57</volume>: <fpage>e1</fpage>&#x2013;<lpage>45</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr11-1759720X211073001">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pons-Estel</surname><given-names>BA</given-names></name>
<name><surname>Bonfa</surname><given-names>E</given-names></name>
<name><surname>Soriano</surname><given-names>ER</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)</article-title>. <source>Ann Rheum Dis</source>
<year>2018</year>; <volume>77</volume>: <fpage>1549</fpage>&#x2013;<lpage>1557</lpage>.<pub-id pub-id-type="pmid">30045853</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1759720X211073001">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Felten</surname><given-names>R</given-names></name>
<name><surname>Lipsker</surname><given-names>D</given-names></name>
<name><surname>Sibilia</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The history of lupus throughout the ages</article-title>. <source>J Am Acad Dermatol.</source> Epub ahead of print <day>4</day>
<month>May</month>
<year>2020</year>. DOI: <pub-id pub-id-type="doi">10.1016/j.jaad.2020.04.150.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1759720X211073001">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name>
<name><surname>Ramos-Casals</surname><given-names>M</given-names></name>
<name><surname>Brito-Zeron</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review</article-title>. <source>Ann Rheum Dis</source>
<year>2010</year>; <volume>69</volume>: <fpage>20</fpage>&#x2013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">19103632</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1759720X211073001">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Meinao</surname><given-names>IM</given-names></name>
<name><surname>Sato</surname><given-names>EI</given-names></name>
<name><surname>Andrade</surname><given-names>LE</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Controlled trial with chloroquine diphosphate in systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>1996</year>; <volume>5</volume>: <fpage>237</fpage>&#x2013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">8803897</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1759720X211073001">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dubois</surname><given-names>EL.</given-names></name>
</person-group>
<article-title>Antimalarials in the management of discoid and systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source>
<year>1978</year>; <volume>8</volume>: <fpage>33</fpage>&#x2013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">358397</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1759720X211073001">
        <label>16</label>
        <mixed-citation publication-type="gov">
<collab>Lupus therapies continue to evolve</collab>. <article-title>FDA</article-title>, <ext-link xlink:href="https://www.fda.gov/consumers/consumer-updates/lupus-therapies-continue-evolve" ext-link-type="uri">https://www.fda.gov/consumers/consumer-updates/lupus-therapies-continue-evolve</ext-link> (<comment>accessed 27 February 2021</comment>).</mixed-citation>
      </ref>
      <ref id="bibr17-1759720X211073001">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>HS</given-names></name>
<name><surname>Im</surname><given-names>JS</given-names></name>
<name><surname>Cho</surname><given-names>JY</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by</article-title>
<source>Plasmodium vivax. Antimicrob Agents Chemother</source>
<year>2009</year>; <volume>53</volume>: <fpage>1468</fpage>&#x2013;<lpage>1475</lpage>.<pub-id pub-id-type="pmid">19188392</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1759720X211073001">
        <label>18</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Browning</surname><given-names>DJ.</given-names></name>
</person-group>
<source>Hydroxychloroquine and chloroquine retinopathy</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2014</year>.</mixed-citation>
      </ref>
      <ref id="bibr19-1759720X211073001">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ducharme</surname><given-names>J</given-names></name>
<name><surname>Farinotti</surname><given-names>R.</given-names></name>
</person-group>
<article-title>Clinical pharmacokinetics and metabolism of chloroquine</article-title>. <source>Clin Pharmacokinet</source>
<year>1996</year>; <volume>31</volume>: <fpage>257</fpage>&#x2013;<lpage>274</lpage>.<pub-id pub-id-type="pmid">8896943</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1759720X211073001">
        <label>20</label>
        <mixed-citation publication-type="journal">
<collab>Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases</collab>. <source>Lupus</source>
<year>1996</year>; <volume>5</volume>: S11&#x2013;S15, <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/8803904/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/8803904/</ext-link> (<comment>accessed 4 March 2021</comment>).</mixed-citation>
      </ref>
      <ref id="bibr21-1759720X211073001">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Walker</surname><given-names>O</given-names></name>
<name><surname>Birkett</surname><given-names>D</given-names></name>
<name><surname>Alvan</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Characterization of chloroquine plasma protein binding in man</article-title>. <source>Br J Clin Pharmacol</source>
<year>1983</year>; <volume>15</volume>: <fpage>375</fpage>&#x2013;<lpage>377</lpage>.<pub-id pub-id-type="pmid">6849768</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1759720X211073001">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shannon</surname><given-names>JA</given-names></name>
<name><surname>Earle</surname><given-names>DP</given-names></name>
<name><surname>Brodie</surname><given-names>BB</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The pharmacological basis for the rational use of Abatrine in the treatment of malaria</article-title>. <source>J Pharmacol Exp Ther</source>
<year>1944</year>; <volume>81</volume>: <fpage>304</fpage>&#x2013;<lpage>330</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr23-1759720X211073001">
        <label>23</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tett</surname><given-names>S</given-names></name>
<name><surname>Cutler</surname><given-names>D</given-names></name>
<name><surname>Day</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Bioavailability of hydroxychloroquine tablets in healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source>
<year>1989</year>; <volume>27</volume>: <fpage>771</fpage>&#x2013;<lpage>779</lpage>.<pub-id pub-id-type="pmid">2757893</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-1759720X211073001">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Frisk-Holmberg</surname><given-names>M</given-names></name>
<name><surname>Bergqvist</surname><given-names>Y</given-names></name>
<name><surname>Termond</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects</article-title>. <source>Eur J Clin Pharmacol</source>
<year>1984</year>; <volume>26</volume>: <fpage>521</fpage>&#x2013;<lpage>530</lpage>.<pub-id pub-id-type="pmid">6610555</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-1759720X211073001">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zahr</surname><given-names>N</given-names></name>
<name><surname>Urien</surname><given-names>S</given-names></name>
<name><surname>Llopis</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19</article-title>. <source>Therapie</source>
<year>2021</year>; <volume>76</volume>: <fpage>285</fpage>&#x2013;<lpage>295</lpage>.<pub-id pub-id-type="pmid">33558079</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-1759720X211073001">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Munster</surname><given-names>T</given-names></name>
<name><surname>Gibbs</surname><given-names>JP</given-names></name>
<name><surname>Shen</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source>
<year>2002</year>; <volume>46</volume>: <fpage>1460</fpage>&#x2013;<lpage>1469</lpage>.<pub-id pub-id-type="pmid">12115175</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1759720X211073001">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tett</surname><given-names>S</given-names></name>
<name><surname>Cutler</surname><given-names>D</given-names></name>
<name><surname>Day</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>A dose-ranging study of the pharmacokinetics of hydroxyl-chloroquine following intravenous administration to healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source>
<year>1988</year>; <volume>26</volume>: <fpage>303</fpage>&#x2013;<lpage>313</lpage>.<pub-id pub-id-type="pmid">3179169</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-1759720X211073001">
        <label>28</label>
        <mixed-citation publication-type="journal">
<collab>Plasma quinacrine concentration as a function of dosage and environment: joint report of the Armored Medical Research Laboratory, Fort Knox, Ky</collab>. <article-title>and the Commission on Tropical Diseases, Army Epidemiological Board, Preventive Medicine Service, Office of the Surgeon General, United States Army</article-title>. <source>Arch Intern Med</source>
<year>1946</year>; <volume>78</volume>: <fpage>64</fpage>&#x2013;<lpage>107</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr29-1759720X211073001">
        <label>29</label>
        <mixed-citation publication-type="webpage">
<collab>Plaquenil (hydroxychloroquine sulfate) dosing, indications, interactions, adverse effects, and more</collab>, <ext-link xlink:href="https://reference.medscape.com/drug/plaquenil-hydroxychloroquine-sulfate-343205" ext-link-type="uri">https://reference.medscape.com/drug/plaquenil-hydroxychloroquine-sulfate-343205</ext-link> (<comment>accessed 17 June 2020</comment>).</mixed-citation>
      </ref>
      <ref id="bibr30-1759720X211073001">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Marmor</surname><given-names>MF</given-names></name>
<name><surname>Kellner</surname><given-names>U</given-names></name>
<name><surname>Lai</surname><given-names>TYY</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)</article-title>. <source>Ophthalmology</source>
<year>2016</year>; <volume>123</volume>: <fpage>1386</fpage>&#x2013;<lpage>1394</lpage>.<pub-id pub-id-type="pmid">26992838</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1759720X211073001">
        <label>31</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenbaum</surname><given-names>JT</given-names></name>
<name><surname>Costenbader</surname><given-names>KH</given-names></name>
<name><surname>Desmarais</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>ACR, AAD, RDS, and AAO 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity</article-title>. <source>Arthritis Rheumatol</source>
<year>2021</year>; <volume>73</volume>: <fpage>908</fpage>&#x2013;<lpage>911</lpage>.<pub-id pub-id-type="pmid">33559327</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-1759720X211073001">
        <label>32</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Melles</surname><given-names>RB</given-names></name>
<name><surname>Marmor</surname><given-names>MF.</given-names></name>
</person-group>
<article-title>The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy</article-title>. <source>JAMA Ophthalmol</source>
<year>2014</year>; <volume>132</volume>: <fpage>1453</fpage>&#x2013;<lpage>1460</lpage>.<pub-id pub-id-type="pmid">25275721</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1759720X211073001">
        <label>33</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
<name><surname>Isenberg</surname><given-names>D</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
</person-group>
<article-title>Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis</article-title>
<source>et al. Ann Rheum Dis</source>
<year>2020</year>; <volume>79</volume>: <fpage>e90</fpage>.</mixed-citation>
      </ref>
      <ref id="bibr34-1759720X211073001">
        <label>34</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fanouriakis</surname><given-names>A</given-names></name>
<name><surname>Kostopoulou</surname><given-names>M</given-names></name>
<name><surname>Cheema</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis</article-title>. <source>Ann Rheum Dis</source>
<year>2020</year>; <volume>79</volume>: <fpage>713</fpage>&#x2013;<lpage>723</lpage>.<pub-id pub-id-type="pmid">32220834</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-1759720X211073001">
        <label>35</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fiehn</surname><given-names>C</given-names></name>
<name><surname>Ness</surname><given-names>T</given-names></name>
<name><surname>Weseloh</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review</article-title>. <source>Z Rheumatol</source>
<year>2021</year>; <volume>80</volume>: <fpage>1</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr36-1759720X211073001">
        <label>36</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rainsford</surname><given-names>KD</given-names></name>
<name><surname>Parke</surname><given-names>AL</given-names></name>
<name><surname>Clifford-Rashotte</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases</article-title>. <source>Inflammopharmacology</source>
<year>2015</year>; <volume>23</volume>: <fpage>231</fpage>&#x2013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">26246395</pub-id></mixed-citation>
      </ref>
      <ref id="bibr37-1759720X211073001">
        <label>37</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Petitdemange</surname><given-names>A</given-names></name>
<name><surname>Felten</surname><given-names>R</given-names></name>
<name><surname>Sibilia</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey</article-title>. <source>Ther Adv Musculoskelet Dis</source>
<year>2021</year>; <volume>13</volume>: <fpage>1</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr38-1759720X211073001">
        <label>38</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wallace</surname><given-names>DJ</given-names></name>
<name><surname>Tse</surname><given-names>K</given-names></name>
<name><surname>Hanrahan</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America</article-title>. <source>Lupus Sci Med</source>
<year>2019</year>; <volume>6</volume>: <fpage>e000317</fpage>.<pub-id pub-id-type="pmid">31168400</pub-id></mixed-citation>
      </ref>
      <ref id="bibr39-1759720X211073001">
        <label>39</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Schrezenmeier</surname><given-names>E</given-names></name>
<name><surname>D&#xF6;rner</surname><given-names>T.</given-names></name>
</person-group>
<article-title>Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology</article-title>. <source>Nat Rev Rheumatol</source>
<year>2020</year>; <volume>16</volume>: <fpage>155</fpage>&#x2013;<lpage>166</lpage>.<pub-id pub-id-type="pmid">32034323</pub-id></mixed-citation>
      </ref>
      <ref id="bibr40-1759720X211073001">
        <label>40</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ponticelli</surname><given-names>C</given-names></name>
<name><surname>Moroni</surname><given-names>G.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine in systemic lupus erythematosus (SLE)</article-title>. <source>Expert Opin Drug Saf</source>
<year>2017</year>; <volume>16</volume>: <fpage>411</fpage>&#x2013;<lpage>419</lpage>.<pub-id pub-id-type="pmid">27927040</pub-id></mixed-citation>
      </ref>
      <ref id="bibr41-1759720X211073001">
        <label>41</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lamphier</surname><given-names>M</given-names></name>
<name><surname>Zheng</surname><given-names>W</given-names></name>
<name><surname>Latz</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Novel small molecule inhibitors of tlr7 and tlr9: mechanism of action and efficacy in vivo</article-title>. <source>Mol Pharmacol</source>
<year>2014</year>; <volume>85</volume>: <fpage>429</fpage>&#x2013;<lpage>440</lpage>.<pub-id pub-id-type="pmid">24342772</pub-id></mixed-citation>
      </ref>
      <ref id="bibr42-1759720X211073001">
        <label>42</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ku&#x17E;nik</surname><given-names>A</given-names></name>
<name><surname>Benc&#x2C7;ina</surname><given-names>M</given-names></name>
<name><surname>&#x160;vajger</surname><given-names>U</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines</article-title>. <source>J Immunol</source>
<year>2011</year>; <volume>186</volume>: <fpage>4794</fpage>&#x2013;<lpage>4804</lpage>.<pub-id pub-id-type="pmid">21398612</pub-id></mixed-citation>
      </ref>
      <ref id="bibr43-1759720X211073001">
        <label>43</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gardet</surname><given-names>A</given-names></name>
<name><surname>Pellerin</surname><given-names>A</given-names></name>
<name><surname>McCarl</surname><given-names>C-A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb treatment on pDC IFN&#x3B1; production from patients affected with cutaneous lupus erythematosus</article-title>. <source>Front Immunol</source>
<year>2019</year>; <volume>10</volume>: <fpage>275</fpage>.<pub-id pub-id-type="pmid">30846987</pub-id></mixed-citation>
      </ref>
      <ref id="bibr44-1759720X211073001">
        <label>44</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>An</surname><given-names>J</given-names></name>
<name><surname>Woodward</surname><given-names>JJ</given-names></name>
<name><surname>Lai</surname><given-names>W</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Inhibition of cyclic GMP-AMP synthase using a novel antimalarial drug derivative in trex1-deficient mice</article-title>. <source>Arthritis Rheumatol</source>
<year>2018</year>; <volume>70</volume>: <fpage>1807</fpage>&#x2013;<lpage>1819</lpage>.<pub-id pub-id-type="pmid">29781188</pub-id></mixed-citation>
      </ref>
      <ref id="bibr45-1759720X211073001">
        <label>45</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wozniacka</surname><given-names>A</given-names></name>
<name><surname>Lesiak</surname><given-names>A</given-names></name>
<name><surname>Boncela</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The influence of antimalarial treatment on IL-1&#x3B2;, IL-6 and TNF-&#x3B1; mRNA expression on UVB-irradiated skin in systemic lupus erythematosus</article-title>. <source>Br J Dermatol</source>
<year>2008</year>; <volume>159</volume>: <fpage>1124</fpage>&#x2013;<lpage>1130</lpage>.<pub-id pub-id-type="pmid">18764842</pub-id></mixed-citation>
      </ref>
      <ref id="bibr46-1759720X211073001">
        <label>46</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lesiak</surname><given-names>A</given-names></name>
<name><surname>Narbutt</surname><given-names>J</given-names></name>
<name><surname>Kobos</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis</article-title>. <source>Clin Exp Dermatol</source>
<year>2009</year>; <volume>34</volume>: <fpage>570</fpage>&#x2013;<lpage>575</lpage>.<pub-id pub-id-type="pmid">19077101</pub-id></mixed-citation>
      </ref>
      <ref id="bibr47-1759720X211073001">
        <label>47</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zeidi</surname><given-names>M</given-names></name>
<name><surname>Kim</surname><given-names>HJ</given-names></name>
<name><surname>Werth</surname><given-names>VP.</given-names></name>
</person-group>
<article-title>Increased myeloid dendritic cells and TNF-&#x3B1; expression predicts poor response to hydroxychloroquine in cutaneous lupus erythematosus</article-title>. <source>J Invest Dermatol</source>
<year>2019</year>; <volume>139</volume>: <fpage>324</fpage>&#x2013;<lpage>332</lpage>.<pub-id pub-id-type="pmid">30227141</pub-id></mixed-citation>
      </ref>
      <ref id="bibr48-1759720X211073001">
        <label>48</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>CK</given-names></name>
<name><surname>Vivekanandan-Giri</surname><given-names>A</given-names></name>
<name><surname>Tang</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus</article-title>. <source>Arthritis Rheumatol</source>
<year>2014</year>; <volume>66</volume>: <fpage>2532</fpage>&#x2013;<lpage>2544</lpage>.<pub-id pub-id-type="pmid">24838349</pub-id></mixed-citation>
      </ref>
      <ref id="bibr49-1759720X211073001">
        <label>49</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>CK</given-names></name>
<name><surname>Kaplan</surname><given-names>MJ.</given-names></name>
</person-group>
<article-title>The role of neutrophils in the pathogenesis of systemic lupus erythematosus</article-title>. <source>Curr Opin Rheumatol</source>
<year>2015</year>; <volume>27</volume>: <fpage>448</fpage>&#x2013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">26125102</pub-id></mixed-citation>
      </ref>
      <ref id="bibr50-1759720X211073001">
        <label>50</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cepika</surname><given-names>AM</given-names></name>
<name><surname>Soldo Jure&#x161;a</surname><given-names>D</given-names></name>
<name><surname>Morovic Vergles</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Decrease in circulating DNA, IL-10 and BAFF levels in newly-diagnosed SLE patients after corticosteroid and chloroquine treatment</article-title>. <source>Cell Immunol</source>
<year>2012</year>; <volume>276</volume>: <fpage>196</fpage>&#x2013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">22703694</pub-id></mixed-citation>
      </ref>
      <ref id="bibr51-1759720X211073001">
        <label>51</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Levy</surname><given-names>JMM</given-names></name>
<name><surname>Towers</surname><given-names>CG</given-names></name>
<name><surname>Thorburn</surname><given-names>A.</given-names></name>
</person-group>
<article-title>Targeting autophagy in cancer</article-title>. <source>Nat Rev Cancer</source>
<year>2017</year>; <volume>17</volume>: <fpage>528</fpage>&#x2013;<lpage>542</lpage>.<pub-id pub-id-type="pmid">28751651</pub-id></mixed-citation>
      </ref>
      <ref id="bibr52-1759720X211073001">
        <label>52</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Humbert</surname><given-names>M</given-names></name>
<name><surname>Bertolino</surname><given-names>P</given-names></name>
<name><surname>Forquet</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Major histocompatibility complex class II-restricted presentation of secreted and endoplasmic reticulum resident antigens requires the invariant chains and is sensitive to lysosomotropic agents</article-title>. <source>Eur J Immunol</source>
<year>1993</year>; <volume>23</volume>: <fpage>3167</fpage>&#x2013;<lpage>3172</lpage>.<pub-id pub-id-type="pmid">8258331</pub-id></mixed-citation>
      </ref>
      <ref id="bibr53-1759720X211073001">
        <label>53</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Silva</surname><given-names>JC</given-names></name>
<name><surname>Mariz</surname><given-names>HA</given-names></name>
<name><surname>Rocha</surname><given-names>LF</given-names><suffix>Jr</suffix></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients</article-title>. <source>Clinics (Sao Paulo)</source>
<year>2013</year>; <volume>68</volume>: <fpage>766</fpage>&#x2013;<lpage>771</lpage>.<pub-id pub-id-type="pmid">23778483</pub-id></mixed-citation>
      </ref>
      <ref id="bibr54-1759720X211073001">
        <label>54</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L</given-names></name>
<name><surname>Ma</surname><given-names>H</given-names></name>
<name><surname>Jiang</surname><given-names>Z</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Immunoregulation therapy changes the frequency of interleukin (IL)-22&#x2004;+&#x2004;CD4&#x2004;+&#x2004;T cells in systemic lupus erythematosus patients</article-title>. <source>Clin Exp Immunol</source>
<year>2014</year>; <volume>177</volume>: <fpage>212</fpage>&#x2013;<lpage>218</lpage>.<pub-id pub-id-type="pmid">24635166</pub-id></mixed-citation>
      </ref>
      <ref id="bibr55-1759720X211073001">
        <label>55</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shin</surname><given-names>MS</given-names></name>
<name><surname>Lee</surname><given-names>N</given-names></name>
<name><surname>Kang</surname><given-names>I.</given-names></name>
</person-group>
<article-title>Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells</article-title>. <source>Curr Opin Rheumatol</source>
<year>2011</year>; <volume>23</volume>: <fpage>444</fpage>&#x2013;<lpage>448</lpage>.<pub-id pub-id-type="pmid">21720245</pub-id></mixed-citation>
      </ref>
      <ref id="bibr56-1759720X211073001">
        <label>56</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sailler</surname><given-names>L</given-names></name>
<name><surname>Puissant</surname><given-names>B</given-names></name>
<name><surname>M&#xE9;liani</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients</article-title>. <source>Ann NY Acad Sci</source>
<year>2007</year>; <volume>1108</volume>: <fpage>41</fpage>&#x2013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">17893969</pub-id></mixed-citation>
      </ref>
      <ref id="bibr57-1759720X211073001">
        <label>57</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Spada</surname><given-names>R</given-names></name>
<name><surname>Rojas</surname><given-names>JM</given-names></name>
<name><surname>Barber</surname><given-names>DF.</given-names></name>
</person-group>
<article-title>Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus</article-title>. <source>J Leukoc Biol</source>
<year>2015</year>; <volume>98</volume>: <fpage>479</fpage>&#x2013;<lpage>487</lpage>.<pub-id pub-id-type="pmid">26216938</pub-id></mixed-citation>
      </ref>
      <ref id="bibr58-1759720X211073001">
        <label>58</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fox</surname><given-names>RI.</given-names></name>
</person-group>
<article-title>Mechanism of action of hydroxychloroquine as an antirheumatic drug</article-title>. <source>Semin Arthritis Rheum</source>
<year>1993</year>; <volume>23</volume>: <fpage>82</fpage>&#x2013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">8278823</pub-id></mixed-citation>
      </ref>
      <ref id="bibr59-1759720X211073001">
        <label>59</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sjolin-Forsberg</surname><given-names>G</given-names></name>
<name><surname>Berne</surname><given-names>B</given-names></name>
<name><surname>Eggelte</surname><given-names>TA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients</article-title>. <source>Acta Derm Venereol</source>
<year>1995</year>; <volume>75</volume>: <fpage>228</fpage>&#x2013;<lpage>231</lpage>.<pub-id pub-id-type="pmid">7653184</pub-id></mixed-citation>
      </ref>
      <ref id="bibr60-1759720X211073001">
        <label>60</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wozniacka</surname><given-names>A</given-names></name>
<name><surname>Lesiak</surname><given-names>A</given-names></name>
<name><surname>Narbutt</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>2007</year>; <volume>16</volume>: <fpage>89</fpage>&#x2013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">17402364</pub-id></mixed-citation>
      </ref>
      <ref id="bibr61-1759720X211073001">
        <label>61</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bondeson</surname><given-names>J</given-names></name>
<name><surname>Sundler</surname><given-names>R.</given-names></name>
</person-group>
<article-title>Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1&#x3B2; and tumor necrosis factor &#x3B1; in macrophages: implications for their mode of action in rheumatoid arthritis</article-title>. <source>Gen Pharmacol</source>
<year>1998</year>; <volume>30</volume>: <fpage>357</fpage>&#x2013;<lpage>366</lpage>.<pub-id pub-id-type="pmid">9510087</pub-id></mixed-citation>
      </ref>
      <ref id="bibr62-1759720X211073001">
        <label>62</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>el Tahir</surname><given-names>KE</given-names></name>
</person-group>. <article-title>Influence of niridazole and chloroquine on arterial and myometrial prostacyclin synthesis</article-title>. <source>Br J Pharmacol</source>
<year>1987</year>; <volume>92</volume>: <fpage>567</fpage>&#x2013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">3322461</pub-id></mixed-citation>
      </ref>
      <ref id="bibr63-1759720X211073001">
        <label>63</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Segal-Eiras</surname><given-names>A</given-names></name>
<name><surname>Segura</surname><given-names>GM</given-names></name>
<name><surname>Babini</surname><given-names>JC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis</article-title>. <source>J Rheumatol</source>
<year>1985</year>; <volume>12</volume>: <fpage>87</fpage>&#x2013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">3981522</pub-id></mixed-citation>
      </ref>
      <ref id="bibr64-1759720X211073001">
        <label>64</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wozniacka</surname><given-names>A</given-names></name>
<name><surname>Carter</surname><given-names>A</given-names></name>
<name><surname>McCauliffe</surname><given-names>DP.</given-names></name>
</person-group>
<article-title>Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit</article-title>. <source>Lupus</source>
<year>2002</year>; <volume>11</volume>: <fpage>71</fpage>&#x2013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">11958581</pub-id></mixed-citation>
      </ref>
      <ref id="bibr65-1759720X211073001">
        <label>65</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>TQ</given-names></name>
<name><surname>Capra</surname><given-names>JD</given-names></name>
<name><surname>Sontheimer</surname><given-names>RD.</given-names></name>
</person-group>
<article-title>4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation</article-title>. <source>Lupus</source>
<year>1998</year>; <volume>7</volume>: <fpage>148</fpage>&#x2013;<lpage>153</lpage>.<pub-id pub-id-type="pmid">9607637</pub-id></mixed-citation>
      </ref>
      <ref id="bibr66-1759720X211073001">
        <label>66</label>
        <mixed-citation publication-type="journal">
<collab>A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus</collab>. <source>N Engl J Med</source>
<year>1991</year>; <volume>324</volume>: <fpage>150</fpage>&#x2013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">1984192</pub-id></mixed-citation>
      </ref>
      <ref id="bibr67-1759720X211073001">
        <label>67</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tsakonas</surname><given-names>E</given-names></name>
<name><surname>Joseph</surname><given-names>L</given-names></name>
<name><surname>Esdaile</surname><given-names>JM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>1998</year>; <volume>7</volume>: <fpage>80</fpage>&#x2013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">9541091</pub-id></mixed-citation>
      </ref>
      <ref id="bibr68-1759720X211073001">
        <label>68</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>HJ</given-names></name>
<name><surname>Egger</surname><given-names>MJ</given-names></name>
<name><surname>Singer</surname><given-names>JZ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>
<year>1994</year>; <volume>21</volume>: <fpage>1457</fpage>&#x2013;<lpage>1462</lpage>.<pub-id pub-id-type="pmid">7983646</pub-id></mixed-citation>
      </ref>
      <ref id="bibr69-1759720X211073001">
        <label>69</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Meng</surname><given-names>J</given-names></name>
<name><surname>Lu</surname><given-names>Y</given-names></name>
<name><surname>Dong</surname><given-names>X</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Long-term effects of hydroxychloroquine on metabolism of serum lipids and left ventricular structure and function in patients of systemic lupus erythematosus</article-title>. <source>Natl Med J China</source>
<year>2014</year>; <volume>94</volume>: <fpage>965</fpage>&#x2013;<lpage>968</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr70-1759720X211073001">
        <label>70</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kavanaugh</surname><given-names>A</given-names></name>
<name><surname>Adams-Huet</surname><given-names>B</given-names></name>
<name><surname>Jain</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus</article-title>. <source>J Clin Rheumatol</source>
<year>1997</year>; <volume>3</volume>: <fpage>3</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19078110</pub-id></mixed-citation>
      </ref>
      <ref id="bibr71-1759720X211073001">
        <label>71</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Levy</surname><given-names>RA</given-names></name>
<name><surname>Vilela</surname><given-names>VS</given-names></name>
<name><surname>Cataldo</surname><given-names>MJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study</article-title>. <source>Lupus</source>
<year>2001</year>; <volume>10</volume>: <fpage>401</fpage>&#x2013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">11434574</pub-id></mixed-citation>
      </ref>
      <ref id="bibr72-1759720X211073001">
        <label>72</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
<name><surname>Galicier</surname><given-names>L</given-names></name>
<name><surname>Auma&#xEE;tre</surname><given-names>O</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)</article-title>. <source>Ann Rheum Dis</source>
<year>2013</year>; <volume>72</volume>: <fpage>1786</fpage>&#x2013;<lpage>1792</lpage>.<pub-id pub-id-type="pmid">23144449</pub-id></mixed-citation>
      </ref>
      <ref id="bibr73-1759720X211073001">
        <label>73</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zanetti</surname><given-names>CB</given-names></name>
<name><surname>Pedrosa</surname><given-names>T</given-names></name>
<name><surname>Kupa</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2&#x2013;3 mg/kg/day): 12-month prospective randomized controlled trial</article-title>. <source>Clin Rheumatol</source>
<year>2021</year>; <volume>40</volume>: <fpage>2745</fpage>&#x2013;<lpage>2751</lpage>.<pub-id pub-id-type="pmid">33486596</pub-id></mixed-citation>
      </ref>
      <ref id="bibr74-1759720X211073001">
        <label>74</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kraak</surname><given-names>JH</given-names></name>
<name><surname>Van Ketel</surname><given-names>W</given-names></name>
<name><surname>Prakken</surname><given-names>JR</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial</article-title>. <source>Dermatologica</source>
<year>1965</year>; <volume>130</volume>: <fpage>293</fpage>&#x2013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">14333636</pub-id></mixed-citation>
      </ref>
      <ref id="bibr75-1759720X211073001">
        <label>75</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yokogawa</surname><given-names>N</given-names></name>
<name><surname>Eto</surname><given-names>H</given-names></name>
<name><surname>Tanikawa</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial</article-title>. <source>Arthritis Rheumatol</source>
<year>2017</year>; <volume>69</volume>: <fpage>791</fpage>&#x2013;<lpage>799</lpage>.<pub-id pub-id-type="pmid">27992698</pub-id></mixed-citation>
      </ref>
      <ref id="bibr76-1759720X211073001">
        <label>76</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ruzicka</surname><given-names>T</given-names></name>
<name><surname>Sommerburg</surname><given-names>C</given-names></name>
<name><surname>Goerz</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine</article-title>. <source>Br J Dermatol</source>
<year>1992</year>; <volume>127</volume>: <fpage>513</fpage>&#x2013;<lpage>518</lpage>.<pub-id pub-id-type="pmid">1467292</pub-id></mixed-citation>
      </ref>
      <ref id="bibr77-1759720X211073001">
        <label>77</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bezerra</surname><given-names>EL</given-names></name>
<name><surname>Vilar</surname><given-names>MJ</given-names></name>
<name><surname>da Trindade Neto</surname><given-names>PB</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source>
<year>2005</year>; <volume>52</volume>: <fpage>3073</fpage>&#x2013;<lpage>3078</lpage>.<pub-id pub-id-type="pmid">16200586</pub-id></mixed-citation>
      </ref>
      <ref id="bibr78-1759720X211073001">
        <label>78</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Babaoglu</surname><given-names>H</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Goldman</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Time to lupus low disease activity state in the Hopkins lupus cohort: role of African American ethnicity</article-title>. <source>Arthritis Care Res (Hoboken)</source>
<year>2020</year>; <volume>72</volume>: <fpage>225</fpage>&#x2013;<lpage>232</lpage>.<pub-id pub-id-type="pmid">31507071</pub-id></mixed-citation>
      </ref>
      <ref id="bibr79-1759720X211073001">
        <label>79</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kasitanon</surname><given-names>N</given-names></name>
<name><surname>Fine</surname><given-names>DM</given-names></name>
<name><surname>Haas</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis</article-title>. <source>Lupus</source>
<year>2006</year>; <volume>15</volume>: <fpage>366</fpage>&#x2013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">16830883</pub-id></mixed-citation>
      </ref>
      <ref id="bibr80-1759720X211073001">
        <label>80</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Clowse</surname><given-names>MEB</given-names></name>
<name><surname>Magder</surname><given-names>L</given-names></name>
<name><surname>Witter</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine in lupus pregnancy</article-title>. <source>Arthritis Rheum</source>
<year>2006</year>; <volume>54</volume>: <fpage>3640</fpage>&#x2013;<lpage>3647</lpage>.<pub-id pub-id-type="pmid">17075810</pub-id></mixed-citation>
      </ref>
      <ref id="bibr81-1759720X211073001">
        <label>81</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M</given-names></name>
<name><surname>Lakatta</surname><given-names>C</given-names></name>
<name><surname>Magder</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis</article-title>. <source>Am J Med</source>
<year>1994</year>; <volume>96</volume>: <fpage>254</fpage>&#x2013;<lpage>259</lpage>.<pub-id pub-id-type="pmid">8154514</pub-id></mixed-citation>
      </ref>
      <ref id="bibr82-1759720X211073001">
        <label>82</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Durcan</surname><given-names>L</given-names></name>
<name><surname>Winegar</surname><given-names>DA</given-names></name>
<name><surname>Connelly</surname><given-names>MA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Longitudinal evaluation of lipoprotein variables in Systemic Lupus Erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy</article-title>. <source>J Rheumatol</source>
<year>2016</year>; <volume>43</volume>: <fpage>745</fpage>&#x2013;<lpage>750</lpage>.<pub-id pub-id-type="pmid">26834214</pub-id></mixed-citation>
      </ref>
      <ref id="bibr83-1759720X211073001">
        <label>83</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>MMPH</given-names></name>
<name><surname>Purvey</surname><given-names>S</given-names></name>
<name><surname>Fang</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Predictors of organ damage in Systemic Lupus Erythematosus: the Hopkins&#x2019; Lupus cohort</article-title>. <source>Arthritis Rheum</source>
<year>2012</year>; <volume>64</volume>: <fpage>4021</fpage>&#x2013;<lpage>4028</lpage>.<pub-id pub-id-type="pmid">22932985</pub-id></mixed-citation>
      </ref>
      <ref id="bibr84-1759720X211073001">
        <label>84</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pons-Estel</surname><given-names>GJ</given-names></name>
<name><surname>Alarc&#xF3;n</surname><given-names>GS</given-names></name>
<name><surname>Mcgwin</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: data from LUMINA, a multiethnic U.S. Cohort NIH Public Access</article-title>. <source>Arthritis Rheum</source>
<year>2009</year>; <volume>61</volume>: <fpage>830</fpage>&#x2013;<lpage>839</lpage>.<pub-id pub-id-type="pmid">19479701</pub-id></mixed-citation>
      </ref>
      <ref id="bibr85-1759720X211073001">
        <label>85</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Willis</surname><given-names>R</given-names></name>
<name><surname>Seif</surname><given-names>AM</given-names></name>
<name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort</article-title>. <source>Lupus</source>
<year>2012</year>; <volume>21</volume>: <fpage>830</fpage>&#x2013;<lpage>835</lpage>.<pub-id pub-id-type="pmid">22343096</pub-id></mixed-citation>
      </ref>
      <ref id="bibr86-1759720X211073001">
        <label>86</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Calvo-Al&#xE9;n</surname><given-names>J</given-names></name>
<name><surname>McGwin</surname><given-names>G</given-names></name>
<name><surname>Toloza</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study</article-title>. <source>Ann Rheum Dis</source>
<year>2006</year>; <volume>65</volume>: <fpage>785</fpage>&#x2013;<lpage>790</lpage>.<pub-id pub-id-type="pmid">16269429</pub-id></mixed-citation>
      </ref>
      <ref id="bibr87-1759720X211073001">
        <label>87</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Alarc&#xF3;n</surname><given-names>GS</given-names></name>
<name><surname>McGwin</surname><given-names>G</given-names></name>
<name><surname>Bertoli</surname><given-names>AM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)</article-title>. <source>Ann Rheum Dis</source>
<year>2007</year>; <volume>66</volume>: <fpage>1168</fpage>&#x2013;<lpage>1172</lpage>.<pub-id pub-id-type="pmid">17389655</pub-id></mixed-citation>
      </ref>
      <ref id="bibr88-1759720X211073001">
        <label>88</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gonz&#xE1;lez</surname><given-names>LA</given-names></name>
<name><surname>Pons-Estel</surname><given-names>GJ</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort</article-title>. <source>Lupus</source>
<year>2009</year>; <volume>18</volume>: <fpage>822</fpage>&#x2013;<lpage>830</lpage>.<pub-id pub-id-type="pmid">19578107</pub-id></mixed-citation>
      </ref>
      <ref id="bibr89-1759720X211073001">
        <label>89</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pons-Estel</surname><given-names>GJ</given-names></name>
<name><surname>Alarc&#xF3;n</surname><given-names>GS</given-names></name>
<name><surname>Gonz&#xE1;lez</surname><given-names>LA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort</article-title>. <source>Arthritis Care Res</source>
<year>2010</year>; <volume>62</volume>: <fpage>393</fpage>&#x2013;<lpage>400</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr90-1759720X211073001">
        <label>90</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nikpour</surname><given-names>M</given-names></name>
<name><surname>Gladman</surname><given-names>DD</given-names></name>
<name><surname>Ibanez</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study</article-title>. <source>Arthritis Res Ther</source>
<year>2010</year>; <volume>12</volume>: <fpage>R125</fpage>.<pub-id pub-id-type="pmid">20591138</pub-id></mixed-citation>
      </ref>
      <ref id="bibr91-1759720X211073001">
        <label>91</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Urowitz</surname><given-names>MB</given-names></name>
<name><surname>Gladman</surname><given-names>DD</given-names></name>
<name><surname>Tom</surname><given-names>BDM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>
<year>2008</year>; <volume>35</volume>: <fpage>2152</fpage>&#x2013;<lpage>2158</lpage>.<pub-id pub-id-type="pmid">18793004</pub-id></mixed-citation>
      </ref>
      <ref id="bibr92-1759720X211073001">
        <label>92</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pimentel-Quiroz</surname><given-names>VR</given-names></name>
<name><surname>Ugarte-Gil</surname><given-names>MF</given-names></name>
<name><surname>Harvey</surname><given-names>GB</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort</article-title>. <source>Lupus</source>
<year>2019</year>; <volume>28</volume>: <fpage>1101</fpage>&#x2013;<lpage>1110</lpage>.<pub-id pub-id-type="pmid">31291843</pub-id></mixed-citation>
      </ref>
      <ref id="bibr93-1759720X211073001">
        <label>93</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shinjo</surname><given-names>SK</given-names></name>
<name><surname>Bonf&#xE1;</surname><given-names>E</given-names></name>
<name><surname>Wojdyla</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort</article-title>. <source>Arthritis Rheum</source>
<year>2010</year>; <volume>62</volume>: <fpage>855</fpage>&#x2013;<lpage>862</lpage>.<pub-id pub-id-type="pmid">20131238</pub-id></mixed-citation>
      </ref>
      <ref id="bibr94-1759720X211073001">
        <label>94</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pons-Estel</surname><given-names>GJ</given-names></name>
<name><surname>Alarc&#xF3;n</surname><given-names>GS</given-names></name>
<name><surname>Hachuel</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Anti-malarials exert a protective effect while mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort</article-title>. <source>Rheumatology</source>
<year>2012</year>; <volume>51</volume>: <fpage>1293</fpage>&#x2013;<lpage>1298</lpage>.<pub-id pub-id-type="pmid">22389125</pub-id></mixed-citation>
      </ref>
      <ref id="bibr95-1759720X211073001">
        <label>95</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wozniacka</surname><given-names>A</given-names></name>
<name><surname>Lesiak</surname><given-names>A</given-names></name>
<name><surname>Narbutt</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients</article-title>. <source>Lupus</source>
<year>2006</year>; <volume>15</volume>: <fpage>268</fpage>&#x2013;<lpage>275</lpage>.<pub-id pub-id-type="pmid">16761500</pub-id></mixed-citation>
      </ref>
      <ref id="bibr96-1759720X211073001">
        <label>96</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shinjo</surname><given-names>SK.</given-names></name>
</person-group>
<article-title>Systemic lupus erythematosus in the elderly: antimalarials in disease remission</article-title>. <source>Rheumatol Int</source>
<year>2009</year>; <volume>29</volume>: <fpage>1087</fpage>&#x2013;<lpage>1090</lpage>.<pub-id pub-id-type="pmid">19352682</pub-id></mixed-citation>
      </ref>
      <ref id="bibr97-1759720X211073001">
        <label>97</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Monzavi</surname><given-names>SM</given-names></name>
<name><surname>Alirezaei</surname><given-names>A</given-names></name>
<name><surname>Shariati-Sarabi</surname><given-names>Z</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers</article-title>. <source>Inflammopharmacology</source>
<year>2018</year>; <volume>26</volume>: <fpage>1175</fpage>&#x2013;<lpage>1182</lpage>.<pub-id pub-id-type="pmid">29987550</pub-id></mixed-citation>
      </ref>
      <ref id="bibr98-1759720X211073001">
        <label>98</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Balevic</surname><given-names>SJ</given-names></name>
<name><surname>Cohen-Wolkowiez</surname><given-names>M</given-names></name>
<name><surname>Eudy</surname><given-names>AM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine levels throughout pregnancies complicated by rheumatic disease: implications for maternal and neonatal outcomes</article-title>. <source>J Rheumatol</source>
<year>2019</year>; <volume>46</volume>: <fpage>57</fpage>&#x2013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">30275257</pub-id></mixed-citation>
      </ref>
      <ref id="bibr99-1759720X211073001">
        <label>99</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hanaoka</surname><given-names>H</given-names></name>
<name><surname>Iida</surname><given-names>H</given-names></name>
<name><surname>Kiyokawa</surname><given-names>T</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine improves the disease activity and allows the reduction of the corticosteroid dose regardless of background treatment in Japanese patients with systemic lupus erythematosus</article-title>. <source>Intern Med</source>
<year>2019</year>; <volume>58</volume>: <fpage>1257</fpage>&#x2013;<lpage>1262</lpage>.<pub-id pub-id-type="pmid">30626831</pub-id></mixed-citation>
      </ref>
      <ref id="bibr100-1759720X211073001">
        <label>100</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Miyagawa</surname><given-names>I</given-names></name>
<name><surname>Nakano</surname><given-names>K</given-names></name>
<name><surname>Nakayamada</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus</article-title>. <source>Int J Rheum Dis</source>
<year>2020</year>; <volume>23</volume>: <fpage>549</fpage>&#x2013;<lpage>558</lpage>.<pub-id pub-id-type="pmid">32020727</pub-id></mixed-citation>
      </ref>
      <ref id="bibr101-1759720X211073001">
        <label>101</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Giannakou</surname><given-names>I</given-names></name>
<name><surname>Chatzidionysiou</surname><given-names>K</given-names></name>
<name><surname>Magder</surname><given-names>LS</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort</article-title>. <source>Lupus Sci Med</source>
<year>2018</year>; <volume>5</volume>: <fpage>e000287</fpage>.<pub-id pub-id-type="pmid">30538818</pub-id></mixed-citation>
      </ref>
      <ref id="bibr102-1759720X211073001">
        <label>102</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rudnicki</surname><given-names>GEG</given-names></name>
</person-group>. <article-title>The efficacy of antimalarials in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>
<year>1975</year>; <volume>2</volume>: <fpage>323</fpage>&#x2013;<lpage>330</lpage>.<pub-id pub-id-type="pmid">1102684</pub-id></mixed-citation>
      </ref>
      <ref id="bibr103-1759720X211073001">
        <label>103</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rothfield</surname><given-names>N.</given-names></name>
</person-group>
<article-title>Efficacy of antimalarials in systemic lupus erythematosus</article-title>. <source>Am J Med</source>
<year>1988</year>; <volume>85</volume>: <fpage>53</fpage>&#x2013;<lpage>56</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr104-1759720X211073001">
        <label>104</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zen</surname><given-names>M</given-names></name>
<name><surname>Saccon</surname><given-names>F</given-names></name>
<name><surname>Gatto</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission</article-title>. <source>Rheumatology</source>
<year>2020</year>; <volume>59</volume>: <fpage>1591</fpage>&#x2013;<lpage>1598</lpage>.<pub-id pub-id-type="pmid">31642908</pub-id></mixed-citation>
      </ref>
      <ref id="bibr105-1759720X211073001">
        <label>105</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
<name><surname>Amoura</surname><given-names>Z</given-names></name>
<name><surname>Hulot</surname><given-names>J-S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with Systemic Lupus Erythematosus</article-title>. <source>Arthritis Rheum</source>
<year>2006</year>; <volume>54</volume>: <fpage>3284</fpage>&#x2013;<lpage>3290</lpage>.<pub-id pub-id-type="pmid">17009263</pub-id></mixed-citation>
      </ref>
      <ref id="bibr106-1759720X211073001">
        <label>106</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yokogawa</surname><given-names>N</given-names></name>
<name><surname>Tanikawa</surname><given-names>A</given-names></name>
<name><surname>Amagai</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)</article-title>. <source>Mod Rheumatol</source>
<year>2013</year>; <volume>23</volume>: <fpage>318</fpage>&#x2013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">22581095</pub-id></mixed-citation>
      </ref>
      <ref id="bibr107-1759720X211073001">
        <label>107</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Franc&#xE8;s</surname><given-names>C</given-names></name>
<name><surname>Cosnes</surname><given-names>A</given-names></name>
<name><surname>Duhaut</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study</article-title>. <source>Arch Dermatol</source>
<year>2012</year>; <volume>148</volume>: <fpage>479</fpage>&#x2013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">22508872</pub-id></mixed-citation>
      </ref>
      <ref id="bibr108-1759720X211073001">
        <label>108</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wahie</surname><given-names>S</given-names></name>
<name><surname>Daly</surname><given-names>AK</given-names></name>
<name><surname>Cordell</surname><given-names>HJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study</article-title>. <source>J Invest Dermatol</source>
<year>2011</year>; <volume>131</volume>: <fpage>1981</fpage>&#x2013;<lpage>1986</lpage>.<pub-id pub-id-type="pmid">21734714</pub-id></mixed-citation>
      </ref>
      <ref id="bibr109-1759720X211073001">
        <label>109</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kuhn</surname><given-names>A</given-names></name>
<name><surname>Sigges</surname><given-names>J</given-names></name>
<name><surname>Biazar</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database</article-title>. <source>Br J Dermatol</source>
<year>2014</year>; <volume>171</volume>: <fpage>571</fpage>&#x2013;<lpage>579</lpage>.<pub-id pub-id-type="pmid">24673427</pub-id></mixed-citation>
      </ref>
      <ref id="bibr110-1759720X211073001">
        <label>110</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Piette</surname><given-names>EW</given-names></name>
<name><surname>Foering</surname><given-names>KP</given-names></name>
<name><surname>Chang</surname><given-names>AY</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Impact of smoking in cutaneous lupus erythematosus</article-title>. <source>Arch Dermatol</source>
<year>2012</year>; <volume>148</volume>: <fpage>317</fpage>&#x2013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">22105815</pub-id></mixed-citation>
      </ref>
      <ref id="bibr111-1759720X211073001">
        <label>111</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kreuter</surname><given-names>A</given-names></name>
<name><surname>Gaifullina</surname><given-names>R</given-names></name>
<name><surname>Tigges</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Lupus erythematosus tumidus response to antimalarial treatment in 36 patients with emphasis on smoking</article-title>. <source>Arch Dermatol</source>
<year>2009</year>; <volume>145</volume>: <fpage>244</fpage>&#x2013;<lpage>248</lpage>.<pub-id pub-id-type="pmid">19289751</pub-id></mixed-citation>
      </ref>
      <ref id="bibr112-1759720X211073001">
        <label>112</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jewell</surname><given-names>ML</given-names></name>
<name><surname>McCauliffe</surname><given-names>DE.</given-names></name>
</person-group>
<article-title>Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment</article-title>. <source>J Am Acad Dermatol</source>
<year>2000</year>; <volume>42</volume>: <fpage>983</fpage>&#x2013;<lpage>987</lpage>.<pub-id pub-id-type="pmid">10827400</pub-id></mixed-citation>
      </ref>
      <ref id="bibr113-1759720X211073001">
        <label>113</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chasset</surname><given-names>F</given-names></name>
<name><surname>Arnaud</surname><given-names>L</given-names></name>
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study</article-title>. <source>J Am Acad Dermatol</source>
<year>2016</year>; <volume>74</volume>: <fpage>693</fpage>&#x2013;<lpage>699</lpage>.<pub-id pub-id-type="pmid">26850655</pub-id></mixed-citation>
      </ref>
      <ref id="bibr114-1759720X211073001">
        <label>114</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fairley</surname><given-names>JL</given-names></name>
<name><surname>Oon</surname><given-names>S</given-names></name>
<name><surname>Saracino</surname><given-names>AM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Management of cutaneous manifestations of lupus erythematosus: a systematic review</article-title>. <source>Semin Arthritis Rheum</source>
<year>2020</year>; <volume>50</volume>: <fpage>95</fpage>&#x2013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">31526594</pub-id></mixed-citation>
      </ref>
      <ref id="bibr115-1759720X211073001">
        <label>115</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Barber</surname><given-names>CEH</given-names></name>
<name><surname>Geldenhuys</surname><given-names>L</given-names></name>
<name><surname>Hanly</surname><given-names>JG.</given-names></name>
</person-group>
<article-title>Sustained remission of lupus nephritis</article-title>. <source>Lupus</source>
<year>2006</year>; <volume>15</volume>: <fpage>94</fpage>&#x2013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">16539280</pub-id></mixed-citation>
      </ref>
      <ref id="bibr116-1759720X211073001">
        <label>116</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sis&#xF3;</surname><given-names>A</given-names></name>
<name><surname>Ramos-Casals</surname><given-names>M</given-names></name>
<name><surname>Bov&#xE9;</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival</article-title>. <source>Lupus</source>
<year>2008</year>; <volume>17</volume>: <fpage>281</fpage>&#x2013;<lpage>288</lpage>.<pub-id pub-id-type="pmid">18413408</pub-id></mixed-citation>
      </ref>
      <ref id="bibr117-1759720X211073001">
        <label>117</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JS</given-names></name>
<name><surname>Oh</surname><given-names>JS</given-names></name>
<name><surname>Kim</surname><given-names>YG</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine</article-title>. <source>Lupus</source>
<year>2020</year>; <volume>29</volume>: <fpage>52</fpage>&#x2013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">31793379</pub-id></mixed-citation>
      </ref>
      <ref id="bibr118-1759720X211073001">
        <label>118</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cort&#xE9;s-Hern&#xE1;ndez</surname><given-names>J</given-names></name>
<name><surname>Ordi-Ros</surname><given-names>J</given-names></name>
<name><surname>Paredes</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies</article-title>. <source>Rheumatology</source>
<year>2002</year>; <volume>41</volume>: <fpage>643</fpage>&#x2013;<lpage>650</lpage>.<pub-id pub-id-type="pmid">12048290</pub-id></mixed-citation>
      </ref>
      <ref id="bibr119-1759720X211073001">
        <label>119</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Al Arfaj</surname><given-names>AS</given-names></name>
<name><surname>Khalil</surname><given-names>N</given-names></name>
</person-group>. <article-title>Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia</article-title>. <source>Lupus</source>
<year>2010</year>; <volume>19</volume>: <fpage>1665</fpage>&#x2013;<lpage>1673</lpage>.<pub-id pub-id-type="pmid">20947541</pub-id></mixed-citation>
      </ref>
      <ref id="bibr120-1759720X211073001">
        <label>120</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Koh</surname><given-names>JH</given-names></name>
<name><surname>Ko</surname><given-names>HS</given-names></name>
<name><surname>Kwok</surname><given-names>SK</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>2015</year>; <volume>24</volume>: <fpage>210</fpage>&#x2013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">25305214</pub-id></mixed-citation>
      </ref>
      <ref id="bibr121-1759720X211073001">
        <label>121</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Seo</surname><given-names>MR</given-names></name>
<name><surname>Chae</surname><given-names>J</given-names></name>
<name><surname>Kim</surname><given-names>YM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia</article-title>. <source>Lupus</source>
<year>2019</year>; <volume>28</volume>: <fpage>722</fpage>&#x2013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">30971164</pub-id></mixed-citation>
      </ref>
      <ref id="bibr122-1759720X211073001">
        <label>122</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Saavedra</surname><given-names>M&#xC1;</given-names></name>
<name><surname>Miranda-Hern&#xE1;ndez</surname><given-names>D</given-names></name>
<name><surname>Lara-Mej&#xED;a</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: a prospective cohort study</article-title>. <source>Int J Rheum Dis</source>
<year>2020</year>; <volume>23</volume>: <fpage>633</fpage>&#x2013;<lpage>640</lpage>.<pub-id pub-id-type="pmid">32227576</pub-id></mixed-citation>
      </ref>
      <ref id="bibr123-1759720X211073001">
        <label>123</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Diav-Citrin</surname><given-names>O</given-names></name>
<name><surname>Blyakhman</surname><given-names>S</given-names></name>
<name><surname>Shechtman</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study</article-title>. <source>Reprod Toxicol</source>
<year>2013</year>; <volume>39</volume>: <fpage>58</fpage>&#x2013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">23602891</pub-id></mixed-citation>
      </ref>
      <ref id="bibr124-1759720X211073001">
        <label>124</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Broder</surname><given-names>A</given-names></name>
<name><surname>Putterman</surname><given-names>C.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in SLE</article-title>. <source>J Rheumatol</source>
<year>2013</year>; <volume>40</volume>: <fpage>30</fpage>&#x2013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">22859353</pub-id></mixed-citation>
      </ref>
      <ref id="bibr125-1759720X211073001">
        <label>125</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wallace</surname><given-names>DJ.</given-names></name>
</person-group>
<article-title>Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source>
<year>1987</year>; <volume>30</volume>: <fpage>1435</fpage>&#x2013;<lpage>1436</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr126-1759720X211073001">
        <label>126</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>MY</given-names></name>
<name><surname>Chan</surname><given-names>EY</given-names></name>
<name><surname>Fong</surname><given-names>DY</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>
<year>2005</year>; <volume>32</volume>: <fpage>622</fpage>&#x2013;<lpage>628</lpage>, <ext-link xlink:href="https://europepmc.org/article/med/15801016" ext-link-type="uri">https://europepmc.org/article/med/15801016</ext-link> (<comment>accessed 22 February 2021</comment>).<pub-id pub-id-type="pmid">15801016</pub-id></mixed-citation>
      </ref>
      <ref id="bibr127-1759720X211073001">
        <label>127</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name>
<name><surname>Egurbide</surname><given-names>MV</given-names></name>
<name><surname>Pijoan</surname><given-names>JI</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>2006</year>; <volume>15</volume>: <fpage>577</fpage>&#x2013;<lpage>583</lpage>.<pub-id pub-id-type="pmid">17080912</pub-id></mixed-citation>
      </ref>
      <ref id="bibr128-1759720X211073001">
        <label>128</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Choojitarom</surname><given-names>K</given-names></name>
<name><surname>Verasertniyom</surname><given-names>O</given-names></name>
<name><surname>Totemchokchyakarn</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Lupus nephritis and Raynaud&#x2019;s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies</article-title>. <source>Clin Rheumatol</source>
<year>2008</year>; <volume>27</volume>: <fpage>345</fpage>&#x2013;<lpage>351</lpage>.<pub-id pub-id-type="pmid">17805483</pub-id></mixed-citation>
      </ref>
      <ref id="bibr129-1759720X211073001">
        <label>129</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tektonidou</surname><given-names>MG</given-names></name>
<name><surname>Laskari</surname><given-names>K</given-names></name>
<name><surname>Panagiotakos</surname><given-names>DB</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies</article-title>. <source>Arthritis Care Res</source>
<year>2009</year>; <volume>61</volume>: <fpage>29</fpage>&#x2013;<lpage>36</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr130-1759720X211073001">
        <label>130</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Becker-Merok</surname><given-names>A</given-names></name>
<name><surname>Nossent</surname><given-names>JC.</given-names></name>
</person-group>
<article-title>Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>2009</year>; <volume>18</volume>: <fpage>508</fpage>&#x2013;<lpage>515</lpage>.<pub-id pub-id-type="pmid">19395452</pub-id></mixed-citation>
      </ref>
      <ref id="bibr131-1759720X211073001">
        <label>131</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kaiser</surname><given-names>R</given-names></name>
<name><surname>Cleveland</surname><given-names>CM</given-names></name>
<name><surname>Criswell</surname><given-names>LA.</given-names></name>
</person-group>
<article-title>Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort</article-title>. <source>Ann Rheum Dis</source>
<year>2009</year>; <volume>68</volume>: <fpage>238</fpage>&#x2013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">18782792</pub-id></mixed-citation>
      </ref>
      <ref id="bibr132-1759720X211073001">
        <label>132</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jung</surname><given-names>H</given-names></name>
<name><surname>Bobba</surname><given-names>R</given-names></name>
<name><surname>Su</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source>
<year>2010</year>; <volume>62</volume>: <fpage>863</fpage>&#x2013;<lpage>868</lpage>.<pub-id pub-id-type="pmid">20131232</pub-id></mixed-citation>
      </ref>
      <ref id="bibr133-1759720X211073001">
        <label>133</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Law</surname><given-names>G</given-names></name>
<name><surname>Magder</surname><given-names>L</given-names></name>
<name><surname>Fang</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>SAT0222 hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive patients</article-title>. <source>Ann Rheum Dis</source>
<year>2013</year>; <volume>71</volume>: <fpage>5471</fpage>&#x2013;<lpage>5547</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr134-1759720X211073001">
        <label>134</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fasano</surname><given-names>S</given-names></name>
<name><surname>Pierro</surname><given-names>L</given-names></name>
<name><surname>Pantano</surname><given-names>I</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>
<year>2017</year>; <volume>44</volume>: <fpage>1032</fpage>&#x2013;<lpage>1038</lpage>.<pub-id pub-id-type="pmid">28507183</pub-id></mixed-citation>
      </ref>
      <ref id="bibr135-1759720X211073001">
        <label>135</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M</given-names></name>
<name><surname>Konig</surname><given-names>MF</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Higher hydroxychloroquine blood levels are associated with reduced thrombosis risk in systemic lupus erythematosus</article-title>. <source>Arthritis Rheumatol</source>
<year>2021</year>; <volume>73</volume>: <fpage>997</fpage>&#x2013;<lpage>1004</lpage>.<pub-id pub-id-type="pmid">33403833</pub-id></mixed-citation>
      </ref>
      <ref id="bibr136-1759720X211073001">
        <label>136</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kaprove Penn</surname><given-names>S</given-names></name>
<name><surname>Kao</surname><given-names>AH</given-names></name>
<name><surname>Schott</surname><given-names>LL</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus NIH public access</article-title>. <source>J Rheumatol</source>
<year>2010</year>; <volume>37</volume>: <fpage>1136</fpage>&#x2013;<lpage>1142</lpage>.<pub-id pub-id-type="pmid">20436082</pub-id></mixed-citation>
      </ref>
      <ref id="bibr137-1759720X211073001">
        <label>137</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y-M</given-names></name>
<name><surname>Lin</surname><given-names>C-H</given-names></name>
<name><surname>Lan</surname><given-names>T-H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study</article-title>. <source>Rheumatology</source>
<year>2015</year>; <volume>54</volume>: <fpage>1244</fpage>&#x2013;<lpage>1249</lpage>.<pub-id pub-id-type="pmid">25587177</pub-id></mixed-citation>
      </ref>
      <ref id="bibr138-1759720X211073001">
        <label>138</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wallace</surname><given-names>DJ</given-names></name>
<name><surname>Metzger</surname><given-names>AL</given-names></name>
<name><surname>Stecher</surname><given-names>VJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids</article-title>. <source>Am J Med</source>
<year>1990</year>; <volume>89</volume>: <fpage>322</fpage>&#x2013;<lpage>326</lpage>.<pub-id pub-id-type="pmid">2393036</pub-id></mixed-citation>
      </ref>
      <ref id="bibr139-1759720X211073001">
        <label>139</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hodis</surname><given-names>HN</given-names></name>
<name><surname>Quismorio</surname><given-names>FP</given-names><suffix>Jr</suffix></name>
<name><surname>Wickham</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>
<year>1993</year>; <volume>20</volume>: <fpage>661</fpage>&#x2013;<lpage>665</lpage>, <ext-link xlink:href="http://europepmc.org/article/med/8496861" ext-link-type="uri">http://europepmc.org/article/med/8496861</ext-link> (<comment>accessed 15 February 2021</comment>).<pub-id pub-id-type="pmid">8496861</pub-id></mixed-citation>
      </ref>
      <ref id="bibr140-1759720X211073001">
        <label>140</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>P</given-names></name>
<name><surname>Gladman</surname><given-names>DD</given-names></name>
<name><surname>Urowitz</surname><given-names>MB</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs</article-title>. <source>J Rheumatol</source>
<year>1999</year>; <volume>26</volume>: <fpage>325</fpage>&#x2013;<lpage>330</lpage>, <ext-link xlink:href="http://europepmc.org/article/med/9972966" ext-link-type="uri">http://europepmc.org/article/med/9972966</ext-link> (<comment>accessed 15 February 2021</comment>).<pub-id pub-id-type="pmid">9972966</pub-id></mixed-citation>
      </ref>
      <ref id="bibr141-1759720X211073001">
        <label>141</label>
        <mixed-citation publication-type="journal">
<collab>Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus</collab>. <source>J Rheumatol</source>
<year>2000</year>; <volume>27</volume>: <fpage>2142</fpage>&#x2013;<lpage>2145</lpage>. <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/10990225/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/10990225/</ext-link> (<comment>accessed 15 February 2021</comment>).<pub-id pub-id-type="pmid">10990225</pub-id></mixed-citation>
      </ref>
      <ref id="bibr142-1759720X211073001">
        <label>142</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Borba</surname><given-names>EF</given-names></name>
<name><surname>Bonf&#xE1;</surname><given-names>E.</given-names></name>
</person-group>
<article-title>Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy</article-title>. <source>J Rheumatol</source>
<year>2001</year>; <volume>28</volume>: <fpage>780</fpage>&#x2013;<lpage>785</lpage>.<pub-id pub-id-type="pmid">11327250</pub-id></mixed-citation>
      </ref>
      <ref id="bibr143-1759720X211073001">
        <label>143</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Karimifar</surname><given-names>M</given-names></name>
<name><surname>Gharibdoost</surname><given-names>F</given-names></name>
<name><surname>Akbarian</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Triglyceride and high-density lipoprotein levels as the markers of disease activity and their association with TNF-? and TNF receptor system in systemic lupus erythematosus</article-title>. <source>APLAR J Rheumatol</source>
<year>2007</year>; <volume>10</volume>: <fpage>221</fpage>&#x2013;<lpage>226</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr144-1759720X211073001">
        <label>144</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sachet</surname><given-names>JC</given-names></name>
<name><surname>Borba</surname><given-names>EF</given-names></name>
<name><surname>Bonf&#xE1;</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients</article-title>. <source>Lupus</source>
<year>2007</year>; <volume>16</volume>: <fpage>273</fpage>&#x2013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">17439934</pub-id></mixed-citation>
      </ref>
      <ref id="bibr145-1759720X211073001">
        <label>145</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cardoso</surname><given-names>CRL</given-names></name>
<name><surname>Signorelli</surname><given-names>FV</given-names></name>
<name><surname>Papi</surname><given-names>JA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients</article-title>. <source>Rheumatol Int</source>
<year>2008</year>; <volume>28</volume>: <fpage>323</fpage>&#x2013;<lpage>327</lpage>.<pub-id pub-id-type="pmid">17786449</pub-id></mixed-citation>
      </ref>
      <ref id="bibr146-1759720X211073001">
        <label>146</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chong</surname><given-names>YB</given-names></name>
<name><surname>Yap</surname><given-names>DY</given-names></name>
<name><surname>Tang</surname><given-names>CS</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Dyslipidaemia in patients with lupus nephritis</article-title>. <source>Nephrology</source>
<year>2011</year>; <volume>16</volume>: <fpage>511</fpage>&#x2013;<lpage>517</lpage>.<pub-id pub-id-type="pmid">21355950</pub-id></mixed-citation>
      </ref>
      <ref id="bibr147-1759720X211073001">
        <label>147</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cairoli</surname><given-names>E</given-names></name>
<name><surname>Rebella</surname><given-names>M</given-names></name>
<name><surname>Danese</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect</article-title>. <source>Lupus</source>
<year>2012</year>; <volume>21</volume>: <fpage>1178</fpage>&#x2013;<lpage>1182</lpage>.<pub-id pub-id-type="pmid">22641182</pub-id></mixed-citation>
      </ref>
      <ref id="bibr148-1759720X211073001">
        <label>148</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ali Abdalla</surname><given-names>M</given-names></name>
<name><surname>Mostafa El Desouky</surname><given-names>S</given-names></name>
<name><surname>Sayed Ahmed</surname><given-names>A</given-names></name>
</person-group>. <article-title>Clinical significance of lipid profile in systemic lupus erythematosus patients: relation to disease activity and therapeutic potential of drugs</article-title>. <source>Egypt Rheumatol</source>
<year>2017</year>; <volume>39</volume>: <fpage>93</fpage>&#x2013;<lpage>98</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr149-1759720X211073001">
        <label>149</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tao</surname><given-names>CY</given-names></name>
<name><surname>Shang</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>T</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis</article-title>. <source>Medicine</source>
<year>2019</year>; <volume>98</volume>: <fpage>e15030</fpage>.<pub-id pub-id-type="pmid">30946340</pub-id></mixed-citation>
      </ref>
      <ref id="bibr150-1759720X211073001">
        <label>150</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Babary</surname><given-names>H</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Ayatollahi</surname><given-names>Y</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis</article-title>. <source>Int J Rheum Dis</source>
<year>2018</year>; <volume>21</volume>: <fpage>84</fpage>&#x2013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">28884965</pub-id></mixed-citation>
      </ref>
      <ref id="bibr151-1759720X211073001">
        <label>151</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Selzer</surname><given-names>F</given-names></name>
<name><surname>Sutton-Tyrrell</surname><given-names>K</given-names></name>
<name><surname>Fitzgerald</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Vascular stiffness in women with systemic lupus erythematosus</article-title>. <source>Hypertension</source>
<year>2001</year>; <volume>37</volume>: 1075&#x2013;<year>1082</year>, <ext-link xlink:href="http://www.hypertensionaha.org" ext-link-type="uri">http://www.hypertensionaha.org</ext-link></mixed-citation>
      </ref>
      <ref id="bibr152-1759720X211073001">
        <label>152</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tanay</surname><given-names>A</given-names></name>
<name><surname>Leibovitz</surname><given-names>E</given-names></name>
<name><surname>Frayman</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment</article-title>. <source>Ann NY Acad Sci</source>
<year>2007</year>; <volume>1108</volume>: <fpage>24</fpage>&#x2013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">17893967</pub-id></mixed-citation>
      </ref>
      <ref id="bibr153-1759720X211073001">
        <label>153</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pego-Reigosa</surname><given-names>JM</given-names></name>
<name><surname>Nicholson</surname><given-names>L</given-names></name>
<name><surname>Pooley</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis</article-title>. <source>Rheumatology</source>
<year>2021</year>; <volume>60</volume>: <fpage>60</fpage>&#x2013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">33099651</pub-id></mixed-citation>
      </ref>
      <ref id="bibr154-1759720X211073001">
        <label>154</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name>
<name><surname>Olivares</surname><given-names>N</given-names></name>
<name><surname>Ruiz-Arruza</surname><given-names>I</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Open Access Predictors of major infections in systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source>
<year>2009</year>; <volume>11</volume>: <fpage>109</fpage>.<pub-id pub-id-type="pmid">19439057</pub-id></mixed-citation>
      </ref>
      <ref id="bibr155-1759720X211073001">
        <label>155</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Herrinton</surname><given-names>LJ</given-names></name>
<name><surname>Liu</surname><given-names>L</given-names></name>
<name><surname>Goldfien</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials</article-title>. <source>J Rheumatol</source>
<year>2016</year>; <volume>43</volume>: <fpage>1503</fpage>&#x2013;<lpage>1509</lpage>.<pub-id pub-id-type="pmid">27370880</pub-id></mixed-citation>
      </ref>
      <ref id="bibr156-1759720X211073001">
        <label>156</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>R&#xFA;a-Figueroa</surname><given-names>&#xCD;</given-names></name>
<name><surname>L&#xF3;pez-Longo</surname><given-names>J</given-names></name>
<name><surname>Galindo-Izquierdo</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source>
<year>2017</year>; <volume>47</volume>: <fpage>38</fpage>&#x2013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">28259425</pub-id></mixed-citation>
      </ref>
      <ref id="bibr157-1759720X211073001">
        <label>157</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zamora</surname><given-names>LD</given-names></name>
<name><surname>Collante</surname><given-names>MTM</given-names></name>
<name><surname>Navarra</surname><given-names>S.</given-names></name>
</person-group>
<article-title>Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus</article-title>. <source>Int J Rheum Dis</source>
<year>2020</year>; <volume>23</volume>: <fpage>197</fpage>&#x2013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">31692250</pub-id></mixed-citation>
      </ref>
      <ref id="bibr158-1759720X211073001">
        <label>158</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gonz&#xE1;lez-Echavarri</surname><given-names>C</given-names></name>
<name><surname>Capdevila</surname><given-names>O</given-names></name>
<name><surname>Espinosa</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort</article-title>. <source>Lupus</source>
<year>2018</year>; <volume>27</volume>: <fpage>2253</fpage>&#x2013;<lpage>2261</lpage>.<pub-id pub-id-type="pmid">30451641</pub-id></mixed-citation>
      </ref>
      <ref id="bibr159-1759720X211073001">
        <label>159</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rosa</surname><given-names>GPD</given-names></name>
<name><surname>Ortega</surname><given-names>MF</given-names></name>
<name><surname>Teixeira</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Causes and factors related to hospitalizations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995&#x2013;2015) from a single referral centre in Catalonia</article-title>. <source>Lupus</source>
<year>2019</year>; <volume>28</volume>: <fpage>1158</fpage>&#x2013;<lpage>1166</lpage>.<pub-id pub-id-type="pmid">31299879</pub-id></mixed-citation>
      </ref>
      <ref id="bibr160-1759720X211073001">
        <label>160</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yeo</surname><given-names>KJ</given-names></name>
<name><surname>Chen</surname><given-names>HH</given-names></name>
<name><surname>Chen</surname><given-names>YM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine may reduce risk of pneumocystis pneumonia in lupus patients: a nationwide, population-based case-control study</article-title>. <source>BMC Infect Dis</source>
<year>2020</year>; <volume>20</volume>: <fpage>1</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr161-1759720X211073001">
        <label>161</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>Q</given-names></name>
<name><surname>Xing</surname><given-names>X</given-names></name>
<name><surname>Lu</surname><given-names>Z</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis of observational studies</article-title>. <source>Semin Arthritis Rheum</source>
<year>2020</year>; <volume>50</volume>: <fpage>1022</fpage>&#x2013;<lpage>1039</lpage>.<pub-id pub-id-type="pmid">32911280</pub-id></mixed-citation>
      </ref>
      <ref id="bibr162-1759720X211073001">
        <label>162</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lakshminarayanan</surname><given-names>S</given-names></name>
<name><surname>Walsh</surname><given-names>S</given-names></name>
<name><surname>Mohanraj</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Factors associated with low bone mineral density in female patients with Systemic Lupus Erythematosus</article-title>. <source>J Rheumatol</source>
<year>2001</year>; <volume>28</volume>: 102&#x2013;108, <ext-link xlink:href="http://www.jrheum.org" ext-link-type="uri">www.jrheum.org</ext-link> (<comment>accessed 15 February 2021</comment>).</mixed-citation>
      </ref>
      <ref id="bibr163-1759720X211073001">
        <label>163</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>CC</given-names></name>
<name><surname>Mak</surname><given-names>A</given-names></name>
<name><surname>Ma</surname><given-names>KM.</given-names></name>
</person-group>
<article-title>Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>2005</year>; <volume>14</volume>: <fpage>106</fpage>&#x2013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">15751814</pub-id></mixed-citation>
      </ref>
      <ref id="bibr164-1759720X211073001">
        <label>164</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Molad</surname><given-names>Y</given-names></name>
<name><surname>Gorshtein</surname><given-names>A</given-names></name>
<name><surname>Wysenbeek</surname><given-names>AJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort</article-title>. <source>Lupus</source>
<year>2002</year>; <volume>11</volume>: <fpage>356</fpage>&#x2013;<lpage>361</lpage>.<pub-id pub-id-type="pmid">12139373</pub-id></mixed-citation>
      </ref>
      <ref id="bibr165-1759720X211073001">
        <label>165</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bruce</surname><given-names>IN</given-names></name>
<name><surname>O&#x2019;Keeffe</surname><given-names>AG</given-names></name>
<name><surname>Farewell</surname><given-names>V</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort</article-title>. <source>Ann Rheum Dis</source>
<year>2015</year>; <volume>74</volume>: <fpage>1706</fpage>&#x2013;<lpage>1713</lpage>.<pub-id pub-id-type="pmid">24834926</pub-id></mixed-citation>
      </ref>
      <ref id="bibr166-1759720X211073001">
        <label>166</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>LSH</given-names></name>
<name><surname>Pullenayegum</surname><given-names>E</given-names></name>
<name><surname>Lim</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>From childhood to adulthood: the trajectory of damage in patients with juvenile-onset Systemic Lupus Erythematosus</article-title>. <source>Arthritis Care Res</source>
<year>2017</year>; <volume>69</volume>: <fpage>1627</fpage>&#x2013;<lpage>1635</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr167-1759720X211073001">
        <label>167</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Piga</surname><given-names>M</given-names></name>
<name><surname>Floris</surname><given-names>A</given-names></name>
<name><surname>Sebastiani</surname><given-names>GD</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort</article-title>. <source>Rheumatology</source>
<year>2020</year>; <volume>59</volume>: <fpage>2272</fpage>&#x2013;<lpage>2281</lpage>.<pub-id pub-id-type="pmid">31840179</pub-id></mixed-citation>
      </ref>
      <ref id="bibr168-1759720X211073001">
        <label>168</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name>
<name><surname>Ugarte</surname><given-names>A</given-names></name>
<name><surname>Egurbide</surname><given-names>MV</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Antimalarials may influence the risk of malignancy in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source>
<year>2007</year>; <volume>66</volume>: <fpage>815</fpage>&#x2013;<lpage>817</lpage>.<pub-id pub-id-type="pmid">17204564</pub-id></mixed-citation>
      </ref>
      <ref id="bibr169-1759720X211073001">
        <label>169</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liang</surname><given-names>H</given-names></name>
<name><surname>Pan</surname><given-names>HF</given-names></name>
<name><surname>Tao</surname><given-names>JH</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Causes and factors associated with frequent hospitalization in Chinese patients with systemic lupus erythematosus: an ambispective cohort study</article-title>. <source>Med Sci Monit</source>
<year>2019</year>; <volume>25</volume>: <fpage>8061</fpage>&#x2013;<lpage>8068</lpage>.<pub-id pub-id-type="pmid">31655846</pub-id></mixed-citation>
      </ref>
      <ref id="bibr170-1759720X211073001">
        <label>170</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Feldman</surname><given-names>CH</given-names></name>
<name><surname>Xu</surname><given-names>C</given-names></name>
<name><surname>Williams</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Patterns and predictors of recurrent acute care use among Medicaid beneficiaries with systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source>
<year>2020</year>; <volume>50</volume>: <fpage>1428</fpage>&#x2013;<lpage>1436</lpage>.<pub-id pub-id-type="pmid">32252975</pub-id></mixed-citation>
      </ref>
      <ref id="bibr171-1759720X211073001">
        <label>171</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hern&#xE1;ndez-Cruz</surname><given-names>B</given-names></name>
<name><surname>Tapia</surname><given-names>N</given-names></name>
<name><surname>Villa-Romero</surname><given-names>AR</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Risk factors associated with mortality in systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source>
<year>2001</year>; <volume>19</volume>: <fpage>395</fpage>&#x2013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">11491494</pub-id></mixed-citation>
      </ref>
      <ref id="bibr172-1759720X211073001">
        <label>172</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Feng</surname><given-names>X</given-names></name>
<name><surname>Zou</surname><given-names>Y</given-names></name>
<name><surname>Pan</surname><given-names>W</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China</article-title>. <source>J Rheumatol</source>
<year>2011</year>; <volume>38</volume>: <fpage>1289</fpage>&#x2013;<lpage>1295</lpage>.<pub-id pub-id-type="pmid">21459949</pub-id></mixed-citation>
      </ref>
      <ref id="bibr173-1759720X211073001">
        <label>173</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Okpechi</surname><given-names>IG</given-names></name>
<name><surname>Ayodele</surname><given-names>OE</given-names></name>
<name><surname>Jones</surname><given-names>ESW</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Outcome of patients with membranous lupus nephritis in Cape Town South Africa</article-title>. <source>Nephrol Dial Transplant</source>
<year>2012</year>; <volume>27</volume>: <fpage>3509</fpage>&#x2013;<lpage>3515</lpage>.<pub-id pub-id-type="pmid">22610989</pub-id></mixed-citation>
      </ref>
      <ref id="bibr174-1759720X211073001">
        <label>174</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>ZH</given-names></name>
<name><surname>Zhang</surname><given-names>LJ</given-names></name>
<name><surname>Liu</surname><given-names>WX</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Predictors of survival in Chinese patients with lupus nephritis</article-title>. <source>Lupus</source>
<year>2012</year>; <volume>21</volume>: <fpage>1049</fpage>&#x2013;<lpage>1056</lpage>.<pub-id pub-id-type="pmid">22513365</pub-id></mixed-citation>
      </ref>
      <ref id="bibr175-1759720X211073001">
        <label>175</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>CC</given-names></name>
<name><surname>Tse</surname><given-names>SM</given-names></name>
<name><surname>Chan</surname><given-names>KL</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort</article-title>. <source>Lupus</source>
<year>2018</year>; <volume>27</volume>: <fpage>722</fpage>&#x2013;<lpage>727</lpage>.<pub-id pub-id-type="pmid">29087260</pub-id></mixed-citation>
      </ref>
      <ref id="bibr176-1759720X211073001">
        <label>176</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pakchotanon</surname><given-names>R</given-names></name>
<name><surname>Gladman</surname><given-names>DD</given-names></name>
<name><surname>Su</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis</article-title>. <source>Lupus</source>
<year>2018</year>; <volume>27</volume>: <fpage>468</fpage>&#x2013;<lpage>474</lpage>.<pub-id pub-id-type="pmid">28857717</pub-id></mixed-citation>
      </ref>
      <ref id="bibr177-1759720X211073001">
        <label>177</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>CC</given-names></name>
<name><surname>Ho</surname><given-names>LY</given-names></name>
<name><surname>Chan</surname><given-names>KL</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Trend of survival of a cohort of Chinese patients with Systemic Lupus Erythematosus over 25 years</article-title>. <source>Front Med</source>
<year>2020</year>; <volume>7</volume>: <fpage>552</fpage>&#x2013;<lpage>557</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr178-1759720X211073001">
        <label>178</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jorge</surname><given-names>A</given-names></name>
<name><surname>McCormick</surname><given-names>N</given-names></name>
<name><surname>Lu</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine and mortality among patients with Systemic Lupus Erythematosus in the general population</article-title>. <source>Arthritis Care Res</source>
<year>2021</year>; <volume>73</volume>: <fpage>1219</fpage>&#x2013;<lpage>1223</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr179-1759720X211073001">
        <label>179</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>James</surname><given-names>JA</given-names></name>
<name><surname>Kim-Howard</surname><given-names>XR</given-names></name>
<name><surname>Bruner</surname><given-names>BF</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>2007</year>; <volume>16</volume>: <fpage>401</fpage>&#x2013;<lpage>409</lpage>.<pub-id pub-id-type="pmid">17664230</pub-id></mixed-citation>
      </ref>
      <ref id="bibr180-1759720X211073001">
        <label>180</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>L&#xF3;pez</surname><given-names>P</given-names></name>
<name><surname>G&#xF3;mez</surname><given-names>J</given-names></name>
<name><surname>Mozo</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs</article-title>. <source>Arthritis Res Ther</source>
<year>2006</year>; <volume>8</volume>: <fpage>R42</fpage>.<pub-id pub-id-type="pmid">16507146</pub-id></mixed-citation>
      </ref>
      <ref id="bibr181-1759720X211073001">
        <label>181</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dima</surname><given-names>A</given-names></name>
<name><surname>Jurcut</surname><given-names>C</given-names></name>
<name><surname>Balanescu</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients</article-title>. <source>Egypt Rheumatol</source>
<year>2016</year>; <volume>39</volume>: <fpage>1</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr182-1759720X211073001">
        <label>182</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lambers</surname><given-names>WM</given-names></name>
<name><surname>Westra</surname><given-names>J</given-names></name>
<name><surname>Bootsma</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset Systemic Lupus Erythematosus</article-title>. <source>J Rheumatol</source>
<year>2021</year>; <volume>48</volume>: <fpage>847</fpage>&#x2013;<lpage>851</lpage>.<pub-id pub-id-type="pmid">33191279</pub-id></mixed-citation>
      </ref>
      <ref id="bibr183-1759720X211073001">
        <label>183</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fanouriakis</surname><given-names>A</given-names></name>
<name><surname>Bertsias</surname><given-names>G.</given-names></name>
</person-group>
<article-title>Changing paradigms in the treatment of systemic lupus erythematosus</article-title>. <source>Lupus Sci Med</source>
<year>2019</year>; <volume>6</volume>: <fpage>e000310</fpage>.<pub-id pub-id-type="pmid">31168398</pub-id></mixed-citation>
      </ref>
      <ref id="bibr184-1759720X211073001">
        <label>184</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Izmirly</surname><given-names>PM</given-names></name>
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
<name><surname>Pisoni</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro associated cardiac manifestations of neonatal lupus</article-title>. <source>Circ July</source>
<year>2012</year>; <volume>3</volume>: <fpage>76</fpage>&#x2013;<lpage>82</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr185-1759720X211073001">
        <label>185</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Izmirly</surname><given-names>PM</given-names></name>
<name><surname>Kim</surname><given-names>MY</given-names></name>
<name><surname>Llanos</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine</article-title>. <source>Ann Rheum Dis</source>
<year>2010</year>; <volume>69</volume>: <fpage>1827</fpage>&#x2013;<lpage>1830</lpage>.<pub-id pub-id-type="pmid">20447951</pub-id></mixed-citation>
      </ref>
      <ref id="bibr186-1759720X211073001">
        <label>186</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zusman</surname><given-names>EZ</given-names></name>
<name><surname>Sayre</surname><given-names>EC</given-names></name>
<name><surname>Avi&#xF1;a-Zubieta</surname><given-names>JA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Patterns of medication use before, during and after pregnancy in women with systemic lupus erythematosus: a population-based cohort study</article-title>. <source>Lupus</source>
<year>2019</year>; <volume>28</volume>: <fpage>1205</fpage>&#x2013;<lpage>1213</lpage>.<pub-id pub-id-type="pmid">31311418</pub-id></mixed-citation>
      </ref>
      <ref id="bibr187-1759720X211073001">
        <label>187</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Smyth</surname><given-names>A</given-names></name>
<name><surname>Oliveira</surname><given-names>GHM</given-names></name>
<name><surname>Lahr</surname><given-names>BD</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>A systematic review and meta-analysis of pregnancy outcomes in patients with Systemic Lupus Erythematosus and Lupus Nephritis</article-title>. <source>Clin J Am Soc Nephrol</source>
<year>2010</year>; <volume>5</volume>: <fpage>2060</fpage>&#x2013;<lpage>2068</lpage>.<pub-id pub-id-type="pmid">20688887</pub-id></mixed-citation>
      </ref>
      <ref id="bibr188-1759720X211073001">
        <label>188</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Buchanan</surname><given-names>NMM</given-names></name>
<name><surname>Toubi</surname><given-names>E</given-names></name>
<name><surname>Khamashta</surname><given-names>MA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases</article-title>. <source>Ann Rheum Dis</source>
<year>1996</year>; <volume>55</volume>: <fpage>486</fpage>&#x2013;<lpage>488</lpage>.<pub-id pub-id-type="pmid">8774170</pub-id></mixed-citation>
      </ref>
      <ref id="bibr189-1759720X211073001">
        <label>189</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
<name><surname>Amoura</surname><given-names>Z</given-names></name>
<name><surname>Duhaut</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Safety of hydroxychloroquine in pregnant patients with connective tissue diseases a study of one hundred thirty-three cases compared with a control group</article-title>. <source>Arthritis Rheum</source>
<year>2003</year>; <volume>48</volume>: <fpage>3207</fpage>&#x2013;<lpage>3211</lpage>.<pub-id pub-id-type="pmid">14613284</pub-id></mixed-citation>
      </ref>
      <ref id="bibr190-1759720X211073001">
        <label>190</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sammaritano</surname><given-names>LR</given-names></name>
<name><surname>Bermas</surname><given-names>BL</given-names></name>
<name><surname>Chakravarty</surname><given-names>EE</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases</article-title>. <source>Arthritis Rheumatol</source>
<year>2020</year>; <volume>72</volume>: <fpage>529</fpage>&#x2013;<lpage>556</lpage>.<pub-id pub-id-type="pmid">32090480</pub-id></mixed-citation>
      </ref>
      <ref id="bibr191-1759720X211073001">
        <label>191</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>CC</given-names></name>
<name><surname>Tong</surname><given-names>KH</given-names></name>
<name><surname>To</surname><given-names>CH</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis</article-title>. <source>Medicine</source>
<year>2007</year>; <volume>86</volume>: <fpage>203</fpage>&#x2013;<lpage>209</lpage>.<pub-id pub-id-type="pmid">17632261</pub-id></mixed-citation>
      </ref>
      <ref id="bibr192-1759720X211073001">
        <label>192</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Toloza</surname><given-names>SMA</given-names></name>
<name><surname>Uribe</surname><given-names>AG</given-names></name>
<name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name>
</person-group>, <etal>et al</etal>. <article-title>Systemic Lupus Erythematosus in a multiethnic US Cohort (LUMINA) XXIII. Baseline predictors of vascular events</article-title>. <source>Arthritis Rheum</source>
<year>2004</year>; <volume>50</volume>: <fpage>3947</fpage>&#x2013;<lpage>3957</lpage>.<pub-id pub-id-type="pmid">15593203</pub-id></mixed-citation>
      </ref>
      <ref id="bibr193-1759720X211073001">
        <label>193</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>CC</given-names></name>
<name><surname>Tang</surname><given-names>SS</given-names></name>
<name><surname>To</surname><given-names>CH</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Incidence and risk factors of thromboembolism in Systemic Lupus Erythematosus a comparison of three ethnic groups</article-title>. <source>Arthritis Rheum</source>
<year>2005</year>; <volume>52</volume>: <fpage>2774</fpage>&#x2013;<lpage>2782</lpage>.<pub-id pub-id-type="pmid">16142761</pub-id></mixed-citation>
      </ref>
      <ref id="bibr194-1759720X211073001">
        <label>194</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>KT</given-names></name>
<name><surname>Ahn</surname><given-names>CW</given-names></name>
<name><surname>Alarcon</surname><given-names>GS</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events</article-title>. <source>Rheumatology</source>
<year>2005</year>; <volume>44</volume>: <fpage>1303</fpage>&#x2013;<lpage>1307</lpage>.<pub-id pub-id-type="pmid">16030085</pub-id></mixed-citation>
      </ref>
      <ref id="bibr195-1759720X211073001">
        <label>195</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tam</surname><given-names>LS</given-names></name>
<name><surname>Li</surname><given-names>EK</given-names></name>
<name><surname>Lam</surname><given-names>CWK</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease</article-title>. <source>Lupus</source>
<year>2000</year>; <volume>9</volume>: <fpage>413</fpage>&#x2013;<lpage>416</lpage>.<pub-id pub-id-type="pmid">10981644</pub-id></mixed-citation>
      </ref>
      <ref id="bibr196-1759720X211073001">
        <label>196</label>
        <mixed-citation publication-type="journal">
<collab>Antimalarials cholesterol profile of patients with systemic lupus erythematosus</collab>. <source>Rev Bras Reumatol</source>
<year>2011</year>; <volume>51</volume>: 383&#x2013;384, 386&#x2013;387, <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/21779713/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/21779713/</ext-link> (<comment>accessed 25 February 2021</comment>).</mixed-citation>
      </ref>
      <ref id="bibr197-1759720X211073001">
        <label>197</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Manzi</surname><given-names>S</given-names></name>
<name><surname>Selzer</surname><given-names>F</given-names></name>
<name><surname>Sutton-Tyrrell</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source>
<year>1999</year>; <volume>42</volume>: <fpage>51</fpage>&#x2013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">9920014</pub-id></mixed-citation>
      </ref>
      <ref id="bibr198-1759720X211073001">
        <label>198</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Roman</surname><given-names>MJ</given-names></name>
<name><surname>Shanker</surname><given-names>B-A</given-names></name>
<name><surname>Davis</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prevalence and correlates of accelerated atherosclerosis in Systemic Lupus Erythematosus</article-title>. <source>N Engl J Med</source>
<year>2003</year>; <volume>349</volume>: <fpage>2399</fpage>&#x2013;<lpage>2406</lpage>.<pub-id pub-id-type="pmid">14681505</pub-id></mixed-citation>
      </ref>
      <ref id="bibr199-1759720X211073001">
        <label>199</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chasset</surname><given-names>F</given-names></name>
<name><surname>Franc&#xE8;s</surname><given-names>C</given-names></name>
<name><surname>Barete</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature</article-title>. <source>J Am Acad Dermatol</source>
<year>2015</year>; <volume>72</volume>: <fpage>634</fpage>&#x2013;<lpage>639</lpage>.<pub-id pub-id-type="pmid">25648824</pub-id></mixed-citation>
      </ref>
      <ref id="bibr200-1759720X211073001">
        <label>200</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Huisman</surname><given-names>A</given-names></name>
<name><surname>White</surname><given-names>KP</given-names></name>
<name><surname>Algra</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Vitamin D levels in women with Systemic Lupus Erythematosus and fibromyalgia</article-title>. <source>J Rheumatol</source>
<year>2001</year>; <volume>28</volume>: <fpage>2535</fpage>&#x2013;<lpage>2539</lpage>.<pub-id pub-id-type="pmid">11708429</pub-id></mixed-citation>
      </ref>
      <ref id="bibr201-1759720X211073001">
        <label>201</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobs</surname><given-names>J</given-names></name>
<name><surname>Korswagen</surname><given-names>LA</given-names></name>
<name><surname>Schilder</surname><given-names>AM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus</article-title>. <source>Osteoporos Int</source>
<year>2013</year>; <volume>24</volume>: <fpage>1827</fpage>&#x2013;<lpage>1833</lpage>.<pub-id pub-id-type="pmid">23052940</pub-id></mixed-citation>
      </ref>
      <ref id="bibr202-1759720X211073001">
        <label>202</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>R</given-names></name>
<name><surname>Ibanez</surname><given-names>D</given-names></name>
<name><surname>Gladman</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients</article-title>. <source>Lupus</source>
<year>2007</year>; <volume>16</volume>: <fpage>157</fpage>&#x2013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">17432099</pub-id></mixed-citation>
      </ref>
      <ref id="bibr203-1759720X211073001">
        <label>203</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Durcan</surname><given-names>L</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
</person-group>
<article-title>Why targeted therapies are necessary for systemic lupus erythematosus</article-title>. <source>Lupus</source>
<year>2016</year>; <volume>25</volume>: <fpage>1070</fpage>&#x2013;<lpage>1079</lpage>.<pub-id pub-id-type="pmid">27497251</pub-id></mixed-citation>
      </ref>
      <ref id="bibr204-1759720X211073001">
        <label>204</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lopez</surname><given-names>R</given-names></name>
<name><surname>Davidson</surname><given-names>JE</given-names></name>
<name><surname>Beeby</surname><given-names>MD</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort</article-title>. <source>Rheumatology</source>
<year>2012</year>; <volume>51</volume>: <fpage>491</fpage>&#x2013;<lpage>498</lpage>.<pub-id pub-id-type="pmid">22109798</pub-id></mixed-citation>
      </ref>
      <ref id="bibr205-1759720X211073001">
        <label>205</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Guillotin</surname><given-names>V</given-names></name>
<name><surname>Bouhet</surname><given-names>A</given-names></name>
<name><surname>Barnetche</surname><given-names>T</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: a systematic review and meta-analysis</article-title>. <source>Joint Bone Spine</source>
<year>2018</year>; <volume>85</volume>: <fpage>663</fpage>&#x2013;<lpage>668</lpage>.<pub-id pub-id-type="pmid">29631068</pub-id></mixed-citation>
      </ref>
      <ref id="bibr206-1759720X211073001">
        <label>206</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Andreoli</surname><given-names>L</given-names></name>
<name><surname>Bertsias</surname><given-names>GK</given-names></name>
<name><surname>Agmon-Levin</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>EULAR recommendations for women&#x2019;s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome</article-title>. <source>Ann Rheum Dis</source>
<year>2017</year>; <volume>76</volume>: <fpage>476</fpage>&#x2013;<lpage>485</lpage>.<pub-id pub-id-type="pmid">27457513</pub-id></mixed-citation>
      </ref>
      <ref id="bibr207-1759720X211073001">
        <label>207</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tektonidou</surname><given-names>MG</given-names></name>
<name><surname>Andreoli</surname><given-names>L</given-names></name>
<name><surname>Limper</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>EULAR recommendations for the management of antiphospholipid syndrome in adults</article-title>. <source>Ann Rheum Dis</source>
<year>2019</year>; <volume>78</volume>: <fpage>1296</fpage>&#x2013;<lpage>1304</lpage>.<pub-id pub-id-type="pmid">31092409</pub-id></mixed-citation>
      </ref>
      <ref id="bibr208-1759720X211073001">
        <label>208</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ramos-Casals</surname><given-names>M</given-names></name>
<name><surname>Brito-Zer&#xF3;n</surname><given-names>P</given-names></name>
<name><surname>Bombardieri</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>EULAR recommendations for the management of Sj&#xF6;gren&#x2019;s syndrome with topical and systemic therapies</article-title>. <source>Ann Rheum Dis</source>
<year>2020</year>; <volume>79</volume>: <fpage>3</fpage>&#x2013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">31672775</pub-id></mixed-citation>
      </ref>
      <ref id="bibr209-1759720X211073001">
        <label>209</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Landew&#xE9;</surname><given-names>RB</given-names></name>
<name><surname>Machado</surname><given-names>PM</given-names></name>
<name><surname>Kroon</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2</article-title>. <source>Ann Rheum Dis</source>
<year>2020</year>; <volume>79</volume>: <fpage>851</fpage>&#x2013;<lpage>858</lpage>.<pub-id pub-id-type="pmid">32503854</pub-id></mixed-citation>
      </ref>
      <ref id="bibr210-1759720X211073001">
        <label>210</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kostine</surname><given-names>M</given-names></name>
<name><surname>Finckh</surname><given-names>A</given-names></name>
<name><surname>Bingham</surname><given-names>CO</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors</article-title>. <source>Ann Rheum Dis</source>
<year>2021</year>; <volume>80</volume>: <fpage>36</fpage>&#x2013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">32327425</pub-id></mixed-citation>
      </ref>
      <ref id="bibr211-1759720X211073001">
        <label>211</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kloppenburg</surname><given-names>M</given-names></name>
<name><surname>Kroon</surname><given-names>FPB</given-names></name>
<name><surname>Blanco</surname><given-names>FJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>2018 update of the EULAR recommendations for the management of hand osteoarthritis</article-title>. <source>Ann Rheum Dis</source>
<year>2019</year>; <volume>78</volume>: <fpage>16</fpage>&#x2013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">30154087</pub-id></mixed-citation>
      </ref>
      <ref id="bibr212-1759720X211073001">
        <label>212</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Smolen</surname><given-names>JS</given-names></name>
<name><surname>Landew&#xE9;</surname><given-names>RBM</given-names></name>
<name><surname>Bijlsma</surname><given-names>JWJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update</article-title>. <source>Ann Rheum Dis</source>
<year>2020</year>; <volume>79</volume>: <fpage>685</fpage>&#x2013;<lpage>699</lpage>.<pub-id pub-id-type="pmid">31969328</pub-id></mixed-citation>
      </ref>
      <ref id="bibr213-1759720X211073001">
        <label>213</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Combe</surname><given-names>B</given-names></name>
<name><surname>Landewe</surname><given-names>R</given-names></name>
<name><surname>Daien</surname><given-names>CI</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>2016 update of the EULAR recommendations for the management of early arthritis</article-title>. <source>Ann Rheum Dis</source>
<year>2017</year>; <volume>76</volume>: <fpage>948</fpage>&#x2013;<lpage>959</lpage>.<pub-id pub-id-type="pmid">27979873</pub-id></mixed-citation>
      </ref>
      <ref id="bibr214-1759720X211073001">
        <label>214</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tunnicliffe</surname><given-names>DJ</given-names></name>
<name><surname>Singh-Grewal</surname><given-names>D</given-names></name>
<name><surname>Kim</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines</article-title>. <source>Arthritis Care Res</source>
<year>2015</year>; <volume>67</volume>: <fpage>1440</fpage>&#x2013;<lpage>1452</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr215-1759720X211073001">
        <label>215</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tamirou</surname><given-names>F</given-names></name>
<name><surname>Arnaud</surname><given-names>L</given-names></name>
<name><surname>Talarico</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Systemic lupus erythematosus: state of the art on clinical practice guidelines</article-title>. <source>RMD Open</source>
<year>2018</year>; <volume>4</volume>: <fpage>e000793</fpage>.<pub-id pub-id-type="pmid">30564454</pub-id></mixed-citation>
      </ref>
      <ref id="bibr216-1759720X211073001">
        <label>216</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Doyno</surname><given-names>C</given-names></name>
<name><surname>Sobieraj</surname><given-names>DM</given-names></name>
<name><surname>Baker</surname><given-names>WL.</given-names></name>
</person-group>
<article-title>Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose</article-title>. <source>Clin Toxicol</source>
<year>2020</year>; <volume>0</volume>: <fpage>1</fpage>&#x2013;<lpage>12</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr217-1759720X211073001">
        <label>217</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nishiyama</surname><given-names>T</given-names></name>
<name><surname>Kondo</surname><given-names>Y</given-names></name>
<name><surname>Tsuboi</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine</article-title>. <source>Mod Rheumatol</source>
<year>2021</year>; <volume>31</volume>: <fpage>1107</fpage>&#x2013;<lpage>1112</lpage>.<pub-id pub-id-type="pmid">33496215</pub-id></mixed-citation>
      </ref>
      <ref id="bibr218-1759720X211073001">
        <label>218</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chatre</surname><given-names>C</given-names></name>
<name><surname>Roubille</surname><given-names>F</given-names></name>
<name><surname>Vernhet</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature</article-title>. <source>Drug Saf</source>
<year>2018</year>; <volume>41</volume>: <fpage>919</fpage>&#x2013;<lpage>931</lpage>.<pub-id pub-id-type="pmid">29858838</pub-id></mixed-citation>
      </ref>
      <ref id="bibr219-1759720X211073001">
        <label>219</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H</given-names></name>
<name><surname>Wald</surname><given-names>J</given-names></name>
<name><surname>Palmer</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine-induced cardiomyopathy and heart failure in twins</article-title>. <source>J Thorac Dis</source>
<year>2018</year>; <volume>10</volume>: <fpage>E70</fpage>&#x2013;<lpage>E73</lpage>.<pub-id pub-id-type="pmid">29600108</pub-id></mixed-citation>
      </ref>
      <ref id="bibr220-1759720X211073001">
        <label>220</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sames</surname><given-names>E</given-names></name>
<name><surname>Paterson</surname><given-names>H</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis</article-title>. <source>Eur J Rheumatol</source>
<year>2016</year>; <volume>3</volume>: <fpage>91</fpage>&#x2013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">27708979</pub-id></mixed-citation>
      </ref>
      <ref id="bibr221-1759720X211073001">
        <label>221</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>El-Solia</surname><given-names>A</given-names></name>
<name><surname>Al-Otaibi</surname><given-names>K</given-names></name>
<name><surname>Ai-Hwiesh</surname><given-names>AK.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis</article-title>. <source>BMJ Case Rep</source>
<year>2018</year>; <volume>2018</volume>: <fpage>2017</fpage>&#x2013;<lpage>2019</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr222-1759720X211073001">
        <label>222</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cansu</surname><given-names>D&#xDC;</given-names></name>
<name><surname>Korkmaz</surname><given-names>C</given-names></name>
</person-group>. <article-title>Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA</article-title>. <source>Rheumatology</source>
<year>2008</year>; <volume>47</volume>: <fpage>378</fpage>&#x2013;<lpage>379</lpage>.<pub-id pub-id-type="pmid">18222983</pub-id></mixed-citation>
      </ref>
      <ref id="bibr223-1759720X211073001">
        <label>223</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Stein</surname><given-names>M</given-names></name>
<name><surname>Bell</surname><given-names>MJ</given-names></name>
<name><surname>Ang</surname><given-names>LC.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine neuromyotoxicity</article-title>. <source>J Rheumatol</source>
<year>2000</year>; <volume>27</volume>: <fpage>2927</fpage>&#x2013;<lpage>2931</lpage>.<pub-id pub-id-type="pmid">11128688</pub-id></mixed-citation>
      </ref>
      <ref id="bibr224-1759720X211073001">
        <label>224</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Siddiqui</surname><given-names>AK</given-names></name>
<name><surname>Huberfeld</surname><given-names>SI</given-names></name>
<name><surname>Weidenheim</surname><given-names>KM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine-induced toxic myopathy causing respiratory failure</article-title>. <source>Chest</source>
<year>2007</year>; <volume>131</volume>: <fpage>588</fpage>&#x2013;<lpage>590</lpage>.<pub-id pub-id-type="pmid">17296665</pub-id></mixed-citation>
      </ref>
      <ref id="bibr225-1759720X211073001">
        <label>225</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mascolo</surname><given-names>A</given-names></name>
<name><surname>Berrino</surname><given-names>PM</given-names></name>
<name><surname>Gareri</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article</article-title>. <source>Inflammopharmacology</source>
<year>2018</year>; <volume>26</volume>: <fpage>1141</fpage>&#x2013;<lpage>1149</lpage>.<pub-id pub-id-type="pmid">29948492</pub-id></mixed-citation>
      </ref>
      <ref id="bibr226-1759720X211073001">
        <label>226</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M</given-names></name>
<name><surname>Elkhalifa</surname><given-names>M</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy</article-title>. <source>Arthritis Rheumatol</source>
<year>2020</year>; <volume>72</volume>: <fpage>448</fpage>&#x2013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">31532077</pub-id></mixed-citation>
      </ref>
      <ref id="bibr227-1759720X211073001">
        <label>227</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xie</surname><given-names>W</given-names></name>
<name><surname>Zhang</surname><given-names>ZL.</given-names></name>
</person-group>
<article-title>Additional analyses to confirm relationship of hydroxychloroquine blood levels to retinopathy: comment on the article by Petri</article-title>
<source>et al. Arthritis Rheumatol</source>
<year>2020</year>; <volume>72</volume>: <fpage>694</fpage>.</mixed-citation>
      </ref>
      <ref id="bibr228-1759720X211073001">
        <label>228</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wolfe</surname><given-names>F</given-names></name>
<name><surname>Marmor</surname><given-names>MF.</given-names></name>
</person-group>
<article-title>Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus</article-title>. <source>Arthritis Care Res</source>
<year>2010</year>; <volume>62</volume>: <fpage>775</fpage>&#x2013;<lpage>784</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr229-1759720X211073001">
        <label>229</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Makin</surname><given-names>AJ</given-names></name>
<name><surname>Wendon</surname><given-names>J</given-names></name>
<name><surname>Fitt</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Fulminant hepatic failure secondary to hydroxychloroquine</article-title>. <source>Gut</source>
<year>1994</year>; <volume>35</volume>: <fpage>569</fpage>&#x2013;<lpage>570</lpage>.<pub-id pub-id-type="pmid">8175002</pub-id></mixed-citation>
      </ref>
      <ref id="bibr230-1759720X211073001">
        <label>230</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Koumaki</surname><given-names>D</given-names></name>
<name><surname>Koumaki</surname><given-names>V</given-names></name>
<name><surname>Bertsias</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine-induced erythema multiforme</article-title>. <source>Clin Case Reports</source>
<year>2020</year>; <volume>8</volume>: <fpage>578</fpage>&#x2013;<lpage>579</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr231-1759720X211073001">
        <label>231</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pai</surname><given-names>SB</given-names></name>
<name><surname>Sudershan</surname><given-names>B</given-names></name>
<name><surname>Kuruvilla</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine-induced erythroderma</article-title>. <source>Indian J Pharmacol</source>
<year>2017</year>; <volume>49</volume>: <fpage>132</fpage>&#x2013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">28458440</pub-id></mixed-citation>
      </ref>
      <ref id="bibr232-1759720X211073001">
        <label>232</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pelechas</surname><given-names>E</given-names></name>
<name><surname>Drosos</surname><given-names>AA.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine-induced dark butterfly rash in a rheumatoid arthritis patient</article-title>. <source>Rheumatology</source>
<year>2018</year>; <volume>57</volume>: <fpage>849</fpage>.<pub-id pub-id-type="pmid">29088445</pub-id></mixed-citation>
      </ref>
      <ref id="bibr233-1759720X211073001">
        <label>233</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ivo</surname><given-names>R</given-names></name>
<name><surname>Lopes</surname><given-names>CA</given-names></name>
<name><surname>Reis</surname><given-names>R.</given-names></name>
</person-group>
<article-title>Woman in grey: hydroxychloroquine-induced hyperpigmentation</article-title>. <source>BMJ Case Rep</source>
<year>2018</year>; <volume>11</volume>: <fpage>2017</fpage>&#x2013;<lpage>2018</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr234-1759720X211073001">
        <label>234</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Serre</surname><given-names>J</given-names></name>
<name><surname>Buob</surname><given-names>D</given-names></name>
<name><surname>Boffa</surname><given-names>JJ.</given-names></name>
</person-group>
<article-title>Hydroxychloroquine-induced podocytopathy mimicking Fabry disease</article-title>. <source>BMJ Case Rep</source>
<year>2019</year>; <volume>12</volume>: <fpage>2018</fpage>&#x2013;<lpage>2020</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr235-1759720X211073001">
        <label>235</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>SZ</given-names></name>
<name><surname>Liang</surname><given-names>X</given-names></name>
<name><surname>Geng</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine-induced renal phospholipidosis resembling fabry disease in undifferentiated connective tissue disease: a case report</article-title>. <source>World J Clin Cases</source>
<year>2019</year>; <volume>7</volume>: <fpage>4377</fpage>&#x2013;<lpage>4383</lpage>.<pub-id pub-id-type="pmid">31911921</pub-id></mixed-citation>
      </ref>
      <ref id="bibr236-1759720X211073001">
        <label>236</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Eljaaly</surname><given-names>K</given-names></name>
<name><surname>Alireza</surname><given-names>KH</given-names></name>
<name><surname>Alshehri</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine safety: a meta-analysis of randomized controlled trials</article-title>. <source>Travel Med Infect Dis</source>
<year>2020</year>; <volume>36</volume>: <fpage>101812</fpage>.<pub-id pub-id-type="pmid">32645478</pub-id></mixed-citation>
      </ref>
      <ref id="bibr237-1759720X211073001">
        <label>237</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bahloul</surname><given-names>E</given-names></name>
<name><surname>Jallouli</surname><given-names>M</given-names></name>
<name><surname>Garbaa</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases</article-title>. <source>Lupus</source>
<year>2017</year>; <volume>26</volume>: <fpage>1304</fpage>&#x2013;<lpage>1308</lpage>.<pub-id pub-id-type="pmid">28355984</pub-id></mixed-citation>
      </ref>
      <ref id="bibr238-1759720X211073001">
        <label>238</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jallouli</surname><given-names>M</given-names></name>
<name><surname>Franc&#xE8;s</surname><given-names>C</given-names></name>
<name><surname>Piette</surname><given-names>JC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus a case-control study</article-title>. <source>JAMA Dermatol</source>
<year>2013</year>; <volume>149</volume>: <fpage>935</fpage>&#x2013;<lpage>940</lpage>.<pub-id pub-id-type="pmid">23824340</pub-id></mixed-citation>
      </ref>
      <ref id="bibr239-1759720X211073001">
        <label>239</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Abou Assalie</surname><given-names>N</given-names></name>
<name><surname>Durcan</surname><given-names>R</given-names></name>
<name><surname>Durcan</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine-induced erythema multiforme</article-title>. <source>J Clin Rheumatol</source>
<year>2017</year>; <volume>23</volume>: <fpage>127</fpage>&#x2013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">28099213</pub-id></mixed-citation>
      </ref>
      <ref id="bibr240-1759720X211073001">
        <label>240</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lenfant</surname><given-names>T</given-names></name>
<name><surname>Salah</surname><given-names>S</given-names></name>
<name><surname>Leroux</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis</article-title>. <source>Revmatol</source>
<year>2020</year>; <volume>59</volume>: <fpage>3807</fpage>&#x2013;<lpage>3816</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr241-1759720X211073001">
        <label>241</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Spinelli</surname><given-names>FR</given-names></name>
<name><surname>Moscarelli</surname><given-names>E</given-names></name>
<name><surname>Ceccarelli</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort</article-title>. <source>Lupus</source>
<year>2018</year>; <volume>27</volume>: <fpage>1616</fpage>&#x2013;<lpage>1623</lpage>.<pub-id pub-id-type="pmid">29954281</pub-id></mixed-citation>
      </ref>
      <ref id="bibr242-1759720X211073001">
        <label>242</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Garg</surname><given-names>S</given-names></name>
<name><surname>Unnithan</surname><given-names>R</given-names></name>
<name><surname>Hansen</surname><given-names>KE</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis</article-title>. <source>Arthritis Care Res</source>
<year>2021</year>; <volume>73</volume>: <fpage>707</fpage>&#x2013;<lpage>716</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr243-1759720X211073001">
        <label>243</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>CC</given-names></name>
<name><surname>Penn</surname><given-names>HJ</given-names></name>
<name><surname>Chan</surname><given-names>KL</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis</article-title>. <source>Arthritis Care Res</source>
<year>2016</year>; <volume>68</volume>: <fpage>1295</fpage>&#x2013;<lpage>1302</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr244-1759720X211073001">
        <label>244</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JY</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Kwok</surname><given-names>SK</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Care Res</source>
<year>2017</year>; <volume>69</volume>: <fpage>536</fpage>&#x2013;<lpage>542</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr245-1759720X211073001">
        <label>245</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fernandez-Ruiz</surname><given-names>R</given-names></name>
<name><surname>Bornkamp</surname><given-names>N</given-names></name>
<name><surname>Kim</surname><given-names>MY</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study</article-title>. <source>Arthritis Res Ther</source>
<year>2020</year>; <volume>22</volume>: <fpage>191</fpage>.<pub-id pub-id-type="pmid">32807233</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>